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Abstract 
 
The work contained in this thesis is split into two sections.  
Each section covers a different biological pathway, its current importance as a potential 
drug target, and the syntheses towards a selection of natural products and analogues 
relevant to the pathway. 
 
 
In Section A, the novel approach towards a new class of   formyl amides is described. 
Furthermore, this new methodology is used to generate the imide intermediate A1. This 
imide is now considered a key intermediate in our synthesis of natural products CJ 15,801, 
Pantothenate, and the first generation of analogues based on CJ 15,801. 
 
 
 
 
 
This section also covers the potential scope for   formyl imides in chemical synthesis in 
general. 
 
Section B describes two novel approaches towards non mevalonate pathway (MEP) 
intermediates and inhibitors. The synthesis towards a previously unpublished 2,2 dimethyl 
MEP analogue, is described alongside the attempted generation MEP. The methodology 
described herein shows the use of Neighbouring Group Participation in intramolecular 
opening of epoxides, and how this can be applied to the generation of analogues. 
 
 
 
 
 
Above all, the aim of this thesis is to open up new synthetic strategies towards potential 
inhibitors for individual biosynthetic pathways. 
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2,2 DMEP  2,2 DiMethyl Erythritol Phosphate 
Ac     acetyl 
atm     atmosphere 
ATP     Adenosine Triphosphate 
Bn     benzyl 
BnBr     benzylbromide 
Bu     butyl 
oC     degrees Celsius 
Ca     calcium 
cat.     catalytic 
CoA     Coenzyme A 
Cu     copper 
DCC     dicyclohexylcarbodiimide 
DCE     1,2 dichloroethane 
DCM     dichloromethane 
DET     diethyl tartrate 
DIBAL   diisobutylaluminium hydride 
DIPT     diisopropyl tartrate  
DMAP   4 dimethylaminopyridine 
DMP     Dess Martin Periodinane 
DMSO   dimethylsulphoxide 
DOXP   1 deoxy D xylulose 5 phosphate 
e.e    enantiomeric excess 
ERG8    phosphomevalonate kinase;  
ERG10   acetoacetyl CoA ligase;  
ERG12   mevalonate kinase; 
ERG13   2 hydroxy 3 methylglutaryl CoA synthase (HMG CoA synthase);  
ERG20   farnesyl diphosphate synthase. 
Et     ethyl 
EtOAc   ethylacetate 
g    gram 
HMB PP  (E) 4 hydroxy 3 methyl but 2 enyl pyrophosphate 
HMG1    2 hydroxy 3 methylglutaryl CoA reductase 1 
HMG2   2 hydroxy 3 methylglutaryl CoA reductase 2  
hr    hour 
HRMS   high resolution mass spec 
IDI1     isopentenyl pyrophosphate, dimethylallyl diphosphate isomerase;  
IBX     2 iodoxybenzoic acid 
IPP     isopentenyl pyrophosphate;  
IR     infrared 
ISPC    DOXP reductase 
ISPD    4 diphosphocytidyl 2 C methyl D erythritol synthase 
ISPE    4 diphosphocytidyl 2 C methyl D erythritol kinase 
ISPF    2 C methyl D erythritol 2,4 cyclodiphosphate synthase 
ISPG    HMB PP synthase 
KHMDS   potassium (bistrimethylsilyl)amide 
L.A    lewis acid 
LAH     lithium aluminium hydride 
liq.     liquid 5 
mbar    millibar 
Me     methyl 
MeCN     acetonitrile 
MeOH   methanol 
MEP     2 C methyl D erythritol 4 phosphate 
mg     milligram 
MIC     Minimum Inhibitory Concentration  
mL     millilitre 
MVD1   diphosphomevalonate decarboxylase;  
m/z    mass to charge ratio 
n     normal 
NaH     sodium hydride 
n BuLi   n butyllithium 
NGP     neighbouring group participation 
NMO    4 methylmorpholine   oxide 
NMR     nuclear magnetic resonance 
nOe    nuclear Overhauser effect 
p     para 
PanK    pantothenate kinase 
PMB     p methoxybenzyl 
PPC    4’ phospho   pantothenoylcysteine 
p TsOH   p toluenesulphonic acid 
RDA     Recommended daily allowance 
RT     room temperature 
SAE     sharpless asymmetric epoxidation  
SAR     structure activity relationships 
TBAI    tert butylammoniumiodide 
TBS     t butyldimethylsilyl 
THF     tetrahydrofuran 
TPAP    Tetrapropylammonium perruthenate 
TMSOK  Potassium trimethylsilanolate 
w/v    weight per volume 
wt/wt    weight per weight 6 
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1  Malaria 
1.1 Malaria: Discovery and Review 
Malaria was first identified in 1880 by Alphonse Laveran, a French army surgeon working 
in Algeria. He documented the description of parasites in the red blood cells of a man 
showing symptoms of malaria. In 1886; Camillo Golgi established that there were at least 
two forms of the malaria. Within a decade further discoveries were documented. In 1898, 
Ronald Ross (a British officer in the Indian Medical Service), demonstrated that patients 
suffering from malaria could transmit the parasites to mosquitoes during a blood meal. All 
three were awarded the Nobel Prize for their discoveries in 1907, 1906, and 1902 
respectively. 
 
Since then malaria has continued to ravage third world countries. In addition to other 
threats such as the HIV/ AIDS virus, malaria has consistently contributed to the death toll 
in Africa and other endemic countries. 
1.2 The Malarial Cycle 
 
 
Figure 1.2.1 – The Malarial Cycle 
(1) 
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The cycle starts with sporozoites entering the bloodstream, and migrating to the liver. The 
sporozoites infect liver cells where they are undetected by the human immune system, and 
can multiply into merozoites. Merozoites then rupture the liver cells, and escape back into 
the bloodstream. Once in the bloodstream, the merozoites infect red blood cells and enter 
their erythrocytic stage. Whilst in the red blood cells they are again invisible to the human 
immune system, and develop into ring forms. From the ring form they transform into 
trophozoites to feed, then multinucleated schizonts to reproduce, then merozoites again. 
The merozoites rupture the blood cells and return to the bloodstream to infect more blood 
cells. Only the ring forms circulate in the bloodstream. The other red blood cells stick to 
the walls of small blood vessels using adhesive proteins on the infected cell surface, 
preventing them from being destroyed in the spleen.  
Some merozoites turn into male and female gametocytes. If an infected person is bitten by 
a mosquito, the mosquito can pick up these gametocytes within the blood. Fertilization and 
sexual recombination of the parasite then occurs in the mosquito's gut, where new 
sporozoites develop and travel to the mosquito's salivary gland, completing the cycle. 
 
There are 4 species of Plasmodia responsible for malaria. Plasmodium falciparum, ovale, 
vivax, and malariae. Plasmodia degrade the haemoglobin in red blood cells, to acquire the 
amino acids needed to construct its own protein. During this process, the parasite produces 
the toxic and soluble molecule haem, which it biocrystallizes to form haemozoin, a non 
toxic molecule. 
 
1.3 Malaria in Numbers 
In past years it was thought there were at least 100 million deaths and 500 million further 
cases of malaria every year, worldwide.    M.V.J. Villa - 2009    10 
Current estimates suggest that in 2002 the global burden of clinical malaria was in the area 
of 515 million cases. Approximately 60% of all cases of malaria occur among the poorest 
20% of the world's population 
(2), and it is estimated that more than one third of these cases 
occur in Asia, with around 3% occurring in the Americas. 
The estimated cost to effectively control malaria in the 82 countries (of which 20 are listed 
below) with the highest burden is about $3.2 billion annually. 
 
Figure 1.3.1- Population Density of Malaria cases 
 
Rank  Country  Number  Year    Rank  Country  Number  Year 
1  Uganda  12,343,411  2003    11  Burundi  1,808,588  2002 
2  Tanzania (United 
Rep. of) 
10,712,526  2003    12  India  1,781,336  2003 
3  Mozambique  5,087,865  2003    13  Burkina Faso  1,451,125  2002 
4  Congo (Dem. 
Republic of) 
4,386,638  2003    14  Angola  1,409,328  2002 
5  Ghana  3,552,869  2003    15  Zimbabwe  1,252,668  2002 
6  Sudan  3,084,320  2003    16  Senegal  1,120,094  2000 
7  Malawi  2,853,317  2002    17  Guinea  889,089  2000 
8  Nigeria  2,608,479  2003    18  Rwanda  856,233  2003 
9  Madagascar  2,114,400  2003    19  Mali  809,428  2003 
10  Zambia  2,010,185  2001    20  Benin  779,041  2001 
Table 1.3.1- Number of cases of malaria by country 
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Although most malaria cases occur among residents of countries where malaria is endemic 
(occurring on a constant basis), travellers to these countries can also be infected if bitten by 
an infected mosquito. This is one way in which malaria has appeared in non endemic 
countries. Malaria can also occur among non travelers in the form of congenital malaria 
(malaria passed from an infected mother to her child during pregnancy or birth), introduced 
malaria (malaria introduced in a non endemic malaria region by an infected host), or 
transfusion related malaria (malaria acquired during blood transfusions). 
In the badly affected areas, children are the most threatened. The first two years of their 
life are the most dangerous, as they have not yet developed sufficient immunity.  Malaria 
accounted for one in 10 deaths among children in developing countries in 2002.  
The second most badly affected are pregnant women. Usual “western” problems associated 
with pregnancy (illness, anaemia) can be magnified due to malarial infection, and in some/ 
most cases cause death.  
1.4 Diagnosis 
The biggest fear is that current estimates of the scale of malaria are underestimated due to 
some people being infected and never finding a doctor. When these people do find a 
doctor, the list of diagnosis tools is limited. The most important diagnostic method is the 
recognition of malaria symptoms. These include: 
•  Fever 
•  Chills 
•  Headaches 
•  Nausea 
•  Profuse Sweating 
•  Muscle pain 
•  Fatigue 
 M.V.J. Villa - 2009    12 
The only form of definitive diagnosis is through observation of parasites in the red blood 
cells under a microscope. 
 
More advanced diagnostic tools include fluorescent staining, genetic probes and antigen 
detection in the form of a dip stick, but these methods are not widely used. 
 
Malaria accounts for 10% of Africa's disease burden, and is thought to cost the African 
continent more than $12 billion annually. Therefore, due to the financial and sociological 
issues malaria gives rise to, the quest for an effective cure is an ongoing one. 
 
1.5 Current Treatments 
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Figure 1.5.1 
 
As malaria has been a problem as long as modern medicine has been practiced, a number 
of different treatments have been developed over the years.  
These include: Quinine, Chloroquine, Malarone and Artemisinin (Fig 1.5.1). M.V.J. Villa - 2009    13 
1.6 Quinine 
Quinine (1) was extracted, isolated, and named in 1817 by French researchers Pierre 
Joseph Pelletier and Joseph Bienaimé Caventouin. It was extracted from the bark of the 
South American cinchona tree, and to this day Cinchona trees remain the only practical 
source of quinine. It contains two major fused ring systems: The aromatic isoquinoline and 
the bicyclic quinuclidine. 
 
Quinine inhibits haemozoin biocrystallization, increasing the levels of toxic haem in the 
parasites; resulting in parasite death. 
 
The first formal synthesis was reported by Woodward 
(3) in 1944, and was later 
corroborated by modern techniques recently by Smith 
(4). 
   
 
Scheme 1.6.1 
 
However, no synthetic methods can compete with isolation of the alkaloid from natural 
sources with respect to economic efficiency. 
 
The use of quinine does have its drawbacks. The FDA classes quinine as a Category X 
teratogen, as it is known to act as an abortifacient and cause birth defects in large doses. In 
the UK, the risks to the pregnancy are considered small, in comparison to the risk of death 
from P. falciparum malaria. M.V.J. Villa - 2009    14 
1.7 Chloroquine 
Chloroquine (2) is a 4 aminoquinoline drug used in the treatment or prevention of malaria.  
The lysosomotropic character of chloroquine is believed to account for much of its anti 
malarial activity; the drug concentrates in the acidic food vacuole of the parasite and 
interferes with essential processes. 
 
Upon the production of haemozoin in the food vacuole, Chloroquine binds to haem (or FP) 
to form what is known as the FP Chloroquine complex, this complex prevents further 
biocrystallization of haem and is highly toxic to the cell. The FP Chloroquine complex 
disrupts membrane function, resulting in cell lysis. The parasite is then effectively flooded 
by its own metabolic products. 
 
Chloroquine and related quinines have been associated with cases of retinal toxicity, 
particularly when provided at higher doses for longer time frames. Other side effects 
include stomach aches, itching, headaches and blurred vision. Increased doses can be fatal. 
 
1.8 Malarone 
Malarone (3) is a fixed preparation available from GSK. It is a mixture of Atovaquone ( a 
hydroxy 1,4 naphthoquinone) and proguanil. Malarone has fewer side effects than other 
available treatments.  
The dose is one tablet daily, starting one or two days before traveling into a malaria 
endemic area. It is continued throughout the stay, and for another 7 days after returning 
from the malarious area. For this reason, the drug is considered expensive to use, and is 
generally only available to wealthier Westerners, travelling for short periods of time. 
 
With such large amounts of treatments being made available, and their overly 
inappropriate use, the widespread resistance to conventional anti malarial drugs has M.V.J. Villa - 2009    15 
contributed to increasing morbidity and mortality. This continues to be an important public 
health challenge, particularly among countries in South and Southeast Asia and South 
America. The apparent emergence of malaria drug resistance in parts of Africa is also a 
growing concern.  
 
Drug resistance has been confirmed in two of the four human malaria parasite species. 
Chloroquine resistant P. falciparum (CRPF) emerged as a major problem in the late 1950's 
and early 1960's in Southeast Asia, Oceania, and South America. Chloroquine resistant 
P.vivax (CRPV) malaria was identified in 1989 and has now also been found in Southeast 
Asia, the Indian subcontinent, and South America. 
 
In the last half century chloroquine resistance has spread to nearly all areas of the world 
where P.falciparum malaria is transmitted. More concern is being generated over the fact 
that P.falciparum has also developed resistance to nearly all the currently available malaria 
drugs, such as sulfadoxine  pyrimethamine, mefloquine and quinine.  
 
The emergence of drug resistance, high cost of production, or high toxicity has lead to the 
investigation of other compounds with therapeutic applications.  
1.9 Artemisinin 
One such compound is Artmesinin. Artemisinin (4) has been used in Chinese medicines for 
2000 years, and was utilised as an antimalarial during the Vietnam War by Chinese 
soldiers. 
 
These compounds produce a quick response in (and are well tolerated by) people with 
malaria. They have also been shown to be active against multi drug resistant P.falciparum 
malaria. Artemisinin compounds are usually used in combination with other antimalarials M.V.J. Villa - 2009    16 
to treat the parasite as this can improve the efficiency of treatment and lead to reduced risk 
of the parasite developing resistance to the individual drugs in the combination.  
  
Research is currently being undertaken to try and understand the mechanism of action of 
Artemisinin. It is thought that the iron in the haem generated in consumption of 
haemoglobin, reduces the peroxide bond in artemisinin; generating high valent iron oxo 
species. The subsequent reaction cascade produces reactive oxygen radicals, which damage 
the parasite leading to its death.  
The total synthesis of Artemisinin has been performed using basic organic reagents 
(5).  
As a response to increasing levels of antimalarial resistance, The World Health 
Organization (WHO) now recommends that all countries experiencing therapy resistant 
malaria cases to use combination therapies. 
However, as artemisinin compounds are isolated from the plant Artemisia annua, the 
cultivation of the plants and production of the drugs takes at least eight months.  Therefore 
the stockpile of drug must be guaranteed to be greater than any increased demand. This, 
coupled with its short shelf life of 3 years, makes it difficult to provide for people in 
remote areas. 
Private/ Public partnerships are beginning to create solutions to the growing problem of 
malaria. Governments provide funding, removing the financial burden on private 
companies, and the private companies provide the research staff to find new compounds. 
 
One example of such a private/ public partnership is the Medicines for Malaria Venture 
(MMV). With funding from the Gates Foundation, MMV strike up effective working 
relationships with companies such as Novartis and GSK, in the hope to provide new leads. 
One such lead is Triclosan (GSK) (8) which is currently used as an antibiotic, and has been 
shown to have anti  P.falciparum properties.  
 M.V.J. Villa - 2009    17 
 
Figure 1.9.1 
 
The WHO now regularly publish lists of diagnostic tests that work, enabling healthcare 
workers to pick out best ones, in a bid to provide a much quicker and efficient diagnosis. 
 
As more drugs are rolled out, our understanding of the biochemistry of malaria increases 
and development of known working drugs can be modified. With the emergence of further 
resistant strains, the need for new drugs and drug targets is ever more apparent. Until a 
vaccine is generated, the future of malaria chemotherapy lies in the development of non 
toxic, (and ultimately) cheap, treatments useful for combination therapies. 
 
With the advancement of biochemical validation, new targets have been identified for 
potential new anti malarial drugs. Two metabolic pathways in particular have been under 
investigation in recent years, the CoA biosynthetic and Non mevalonate pathways. M.V.J. Villa - 2009    18 
2  Pantothenate, the CoA Biosynthetic Pathway, 
CJ-15,801 and enamides 
2.1 The CoA Biosynthetic Pathway 
Pantothenic acid, otherwise known as vitamin B5, is a water soluble vitamin whose name is 
derived from the Greek pantothen meaning "from everywhere". It gets this name due to the 
fact that small quantities of pantothenic acid are found in nearly every natural food source. 
Although no specific role has been determined, pantothenic acid deficiencies can result in 
fatigue, allergies, nausea, and abdominal pain. Any of these symptoms are quickly reversed 
by supplementation.  
Biologically, pantothenic acid (9) is the starting substrate in the biosynthesis of coenzyme 
A (CoA), an enzyme cofactor necessary for a number of metabolic processes including the 
Citric Acid Cycle. Coenzyme A (14) plays a major role in the biosynthesis of many 
important compounds such as fatty acids, cholesterol, and acetylcholine. In certain 
bacteria, the ability to synthesize CoA comes from the necessity to import pantothenic acid 
from its surrounding environment to survive. 
In vivo studies in both eukaryotic and bacterial cells show Coenzyme A is synthesized in a 
five step process from pantothenate (Figure 2.1.1): 
Pantothenate is phosphorylated to 4' phosphopantothenate (10) by pantothenate kinase 
(Pan K). A cysteine is added to 4' phosphopantothenate by the enzyme 
phosphopantothenoylcysteine synthetase to form 4' phospho   pantothenoylcysteine 
(PPC) (11).  M.V.J. Villa - 2009    19 
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Figure 2.1.1- CoA biosynthetic pathway 
PPC is then decarboxylated to 4' phosphopantetheine (12) by phosphopantothenoyl 
cysteine decarboxylase. Adenylation of 4' phosphopantetheine by the enzyme 
phosphopantetheine adenylyl transferase generates dephospho CoA (13). Finally, 
dephospho CoA is phosphorylated using ATP to coenzyme A (14) by dephosphocoenzyme 
A kinase. 
Studies have shown that the dextrorotatory (D) ( ) isomer of pantothenic acid is 
biologically active, whereas the levorotatory (L) (+) form may antagonize the effects of the 
dextrorotatory isomer.
(6) 
2.2 Pantothenate 
As pantothenic acid is needed to form CoA, and is necessary for so many biological roles, 
it is considered an essential nutrient to sustain life. Because of this, its commercial 
applications have become extremely diverse.  M.V.J. Villa - 2009    20 
Although pantothenic acid can be found in numerous foods, no RDA has been proposed. 
However, it is possible to find Vit B5 in many dietary supplements (as calcium D 
pantothenate), and a number of companies are now adding pantothenic acid to their 
beverages. 
The cosmetic industry routinely add pantothenic acid to various cosmetic products, 
including shampoo, and advertise pantothenic acid additives. Studies have also shown that 
pantothenic acid has a positive effect on the treatment of acne 
(7).  
 Perhaps on a more important, and widely significant role, pantothenic acid has shown a 
measurable benefit on patients suffering from diabetes 
(8). 
Due to the increased demand for pantothenic acid, there exist some industrial applications 
for a synthesis of this compound, although the emergence of the use of microbial cultures 
has been favoured over classic synthetic routes (Fig 2.3.1).  
2.3 Synthesis of Pantothenate 
2.3.1 Synthetic 
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Figure 2.3.1- Current synthetic approach towards pantothenate 
Vandamme 
(9) discusses the most efficient syntheses of pantothenic acid. Isobutyraldehyde 
(15) is reacted, first with formaldehyde, then sodium cyanide to generate cyanohydrin (17). M.V.J. Villa - 2009    21 
This is then cyclised to the racemic pantolactone (18). Optical resolution using quinine, 
quinidine, cinchonidine and brucine isolates the stereospecific (D) ( )  pantolactone (19). 
Reaction with β alanine provides pantothenic acid as the Ca salt (21). Although no yields 
were given, the limitations for production scale reactions are evident. The use of cyanide is 
dangerous on a large scale, but also the difficult optical resolution using numerous reagents 
is also a key limiting factor. 
2.3.2 Microbial 
To overcome these limitations on an industrial scale, a mixture of chemical and 
biochemical synthesis is used. The use of keto reductase enzymes, such as R.minuta or 
C.parapsilosis, allows the generation of the enantiomerically pure pantolactone (19) from 
its respective keto pantolactone (24). The ketopantolactone is generated in one pot using 
isobutyraldehyde (15) and formalin (22) as before; sodium methoxide, and diethyl oxalate 
(23). This produces the required ketopantolactone (24) in 81% yield. Introduction of the 
ketoreductases (along with glucose for energy) generates the optically pure (D) ( )  
pantolactone (19) in a molar yield of 100%. 
 
 
Figure 2.3.2- Current microbial approach towards pantothenate synthesis 
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Other enzymes have been used in reduction of ketopantolactone to the corresponding (D) 
( ) pantolactone including one isolated from Pseudomonas maltophilia 845 
(10). 
2.4 Pantothenate and CoA as Drug target 
Numerous studies have shown that a range of bacteria are unable to synthesize CoA, and 
are therefore dependent on the transport of pantothenic acid from their environment 
(11). 
The same dependence is exhibited in the malarial parasite P. falciparum also. It is now 
known that blood cells infected by Plasmodia, utilise new permeability pathways to bring 
in small molecules such as pantothenate, whereas uninfected cells do not exhibit these 
molecule permeability pathways 
(12, 13).  
Work by Saliba has shown this pathway is validated in P. falciparum 
(14). Lethal 
phenotypes, generated from gene disruption of the proteins in this pathway, demonstrate 
that the CoA biosynthetic pathway is essential in plasmodia. This, coupled with the fact 
that there is little sequence similarity between human PanK and its bacterial or malarial 
equivalent, provides us with a potential new drug target  necessary due to the emergence of 
drug resistant strains of P. falciparum. 
2.4.1 Pantothenate analogues 
For a review of a number of pantothenate analogues that have been developed as potential 
CoA biosynthesis inhibitors, please see Spry et al.
(11).  A selection of these analogues are 
highlighted below (Fig.2.4.1). 
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Figure 2.4.1- Range of current pantothenate derived analogues 
 
Some of these analogues have clear structural similarities to pantothenate, such as the   
pantoylsubstituted amine (30) and methylpantothenone (32). Others are as varied as 
including sulphur; as in the pantoyltauramides (25 28). 
It was observed that the inhibitory effect of these   pantoyltauramides could be reversed 
by increasing levels of pantothenate available to the parasite. This finding demonstrated 
that the   pantoyltauramides were acting as a CoA biosynthesis inhibitor, and validating 
this metabolic pathway as a drug target. 
The pantoyltauramides were designed to reduce the water solubility of pantoyltaurine, 
whilst showing structural similarity to pantothenate. These compounds showed stronger 
inhibition than the pantoyltaurines they were designed to replace. 
Methylpantothenone (32) showed some biological activity, but interestingly, its inhibition 
was not reversed by pantothenic acid. Although the idea of it being a non competitive 
inhibitor was not discussed, the generation of similar compounds may prove to be of 
interest, as the phenylpantothenone derivative also proved to be active against a range of 
bacteria. M.V.J. Villa - 2009    24 
2.5 CJ-15,801 
2.5.1 Isolation and characterisation 
 
Figure 2.5.1- Structural similarities/ differences between pantothenate and CJ-15,801  
 
One pantothenic acid analogue gaining some attention from biochemists (and chemists) 
over recent years is a natural product known as CJ 15,801 (33). Isolated from 
Seimatosporum sp. CL28611, this compound differs from pantothenate (9) only in the fact 
it has a double bond in the β alanine moiety 
(15) (Fig 2.5.1).  
Its activity as an inhibitor was limited against some bacteria, but was shown to be active 
against multidrug resistant Staphylococcus aureus with MIC values between 30 and 
230 m.  
CJ 15,801 has hence become a major target in the generation of potential new drug 
therapies. 
2.5.2 CJ-15,801 Synthesis 
 
Although CJ 15,801 has only been relatively recently isolated, its promising biological 
profile, coupled with its interesting enamide bearing structure has already attracted the 
attention from highly revered chemists such as Porco and Nicolaou. 
 
The first published synthesis of CJ 15,801 was done so by Porco and collaborators 
(16). 
This synthesis requires the key coupling of a vinyl halide (35) and an amide (34) under Cu 
catalysed conditions. The resulting enamide (36) has the allyl ester removed using a M.V.J. Villa - 2009    25 
synthesised solid supported reagent (38) to generate the required CJ 15,801 (33). Although 
successful, this synthesis has its limitations.  
The vinyl halide synthesis from the regioselective hydroiodination of the corresponding 
alkyne is non trivial, and this limits its use in wider situations.  
The approaches available for the synthesis of a substituted vinyl halide, also limits its use 
in the generation of potential CJ 15,801 analogues. The inclusion of an allyl ester is also an 
interesting one as it requires the use of the solid supported reagent for removal.  
 
 
Scheme 2.5.1 
The second synthesis of CJ 15,801 was reported by Nicolaou 
(17). This approach relies on 
the oxidation of amide (36) with Dess Martin Periodinane.  
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Scheme 2.5.2 
 
Nicolaou’s IBX oxidation is believed to go through the following mechanism: 
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Figure 2.5.2- Mechanism for IBX oxidation to generate enamides 
 
 
The first stage of the proposed mechanism involves the nucleophilic attack of the amide 
(40) onto the iodine core of the IBX reagent. Simultaneous release of an acetate group 
provides intermediate (41). After a spontaneous intramolecular rearrangement, Ac IBA 
and AcOH are produced as side products, leaving the   acyl imine intermediate (42). The M.V.J. Villa - 2009    27 
highly reactive intermediate is then transformed into imide (43). This occurs via 
tautomerization of intermediate (42) resulting in the enamide generation. 
 
Although Nicolaou’s approach successfully introduced the required enamide unit in a 
single step, from amide (36), the stereocontrol of the geometry of the enamide was non 
existent. A 9:1 mixture of diastereomers was reported, in which the desired E  isomer was 
the minor product. Furthermore, Nicolaou uses the same allyl ester as the Porco synthesis, 
making this synthesis impractical. 
 
In conclusion, the key difference between the growth promoter pantothenate and the 
inhibitor CJ 15,801, is the presence of its internal double bond. The synthesis proposed by 
Porco, was in fact derived from work performed on the synthesis of other enamides 
(18).  
2.6 Enamides 
Enamides are present as subunits in a variety of biologically active natural products and 
pharmaceutical drug lead compounds. Examples include the antibiotic CJ 15,801 (33), the 
lituarines (44) and crocacin A (45) (Figure 2.6.1). 
 
 
 
Figure 2.6.1- Range of known enamides M.V.J. Villa - 2009    28 
 
Enamides are considered highly reactive, thus making them key intermediates in the 
synthesis of a variety of heterocyclic compounds. It is due to this importance as both 
building blocks and target units, that a number of approaches to their synthesis have been 
investigated. 
 
In the synthetic methods developed to date, varying degrees of success have been achieved 
when considering yield and control of the double bond stereochemistry; sometimes in the 
latter case, control is non existent. 
 
Such syntheses have made the following disconnections: 
  
C N (via N acylation), N C (coupling reaction with transition metal chemistry), C=C 
(condensation of amide and aldehyde) (Figure 2.6.2). 
 
 
Figure 2.6.2- Enamide synthesis disconnections 
2.7 Current Synthetic approaches to enamides 
Based on the increased biological importance, a number of synthetic approaches have been 
developed for the synthesis of enamide units. 
 
Early syntheses of enamides all occured under mild conditions, but to a reduced yield and 
efficiency. Since then, syntheses have focussed on increasing the yields and efficiencies. 
Current syntheses of enamides are varied, and all have respective advantages and 
disadvantages.  M.V.J. Villa - 2009    29 
Zezza and Smith 
(19) have shown the successful condensation reaction of amide (46) and 
aldehyde (47) to generate the enamide (48). 
 
Scheme 2.7.1 
 
 
Although this procedure is stereoselective, the option of influencing the reaction to 
generate either the E or Z isomer is not available. By relying on the use of the aldehyde to 
introduce the double bond, this synthesis is also limited to unsubstituted enamides and 
prevents the generation of potential analogues. 
 
Kim and colleagues 
(20) have reported the successful palladium catalysed coupling of an 
ylide (50) and an amide (49), to generate the enamide (51). In contrast to the report by 
Zezza, this synthesis could allow the introduction of a substituted enamide unit, but appear 
to have no control for the generation of the E isomer. 
 
 
Scheme 2.7.2 
 
For an excellent review on some of the current approaches to enamide synthesis please see 
Tracey et al 
(21). M.V.J. Villa - 2009    30 
The production of enamide bearing natural products (and pharmaceutically relevant 
heterocyclic systems) would be far more attainable if there existed a reliable, flexible, and 
stereoselective procedure for their synthesis. 
 
We therefore set out to develop an approach to the efficient and stereocontrolled synthesis 
of enamides, and then to apply this towards the synthesis of natural products pantothenate 
and CJ 15,801. It was also instrumental that the same approach would open up new areas 
towards the development of potential new analogues. 
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3  Synthesis of Enamides, CJ-15,801, analogues 
and Pantothenate 
3.1 Enamides 
As part of our novel approach, we envisioned the enamide units coming from the 
unprecedented olefination of the respective   formylated amide (imide). The key to our 
approach lies in considering that the   formyl unit could potentially behave as a pseudo 
aldehyde unit, as opposed to a normal amide group. It was reasoned that the nitrogen lone 
pair would be effectively delocalised into the adjacent carbonyl. This delocalisation would 
render the   formyl group to being significantly more reactive than a typical formamide. 
 
 
Figure 3.1.1- Resonance of imide giving rise to reactivity 
 
This approach would have the benefit of being able to take advantage of the myriad of 
aldehyde olefination conditions to stereoselectively generate polyfunctionalised enamides. 
 
Unfortunately, the   formylation of amides has not been that well documented 
(22), 
although an abundance of literature for amine formylation exists. This lead us to 
investigate whether the choice of reagents for use on amines could also be applied to 
amides. M.V.J. Villa - 2009    32 
3.1.1 Model Lactam systems 
 
Our chosen model system was the Lactam family of compounds; due to their affordability 
and availability. The range of ring sizes available would help to investigate any potential 
limitations of our methodology. 
Originally we attempted our amide formylation using known amine formylating agents 
such as ethyl chloroformate, but to no avail. We then investigated the use of mixed 
anhydrides, with formic acetic anhydride (53) our mixed anhydride of choice 
(23). Formic 
acid and acetic anhydride were pre mixed before addition of the amide. The lack of 
formylated product suggested that as the mixed anhydride was being generated in situ, we 
could not be sure the full generation of the required mixed anhydride was occurring in the 
short time it was being pre mixed for. Optimisation of the conditions included mixing 
formic acid and acetic anhydride at elevated temperature before addition of amide, and also 
the continued stirring of the reaction mixture at elevated temperature. Although the 
generation of the imide was apparent by 
1H NMR, we sought after a more effective method 
of generating our formic acetic anhydride.  
 
 
Scheme 3.1.1 
 
Fife and co workers 
(24) describe a way of generating mixed anhydrides, which cleanly 
generated our acetic formic anhydride (53). This mixed anhydride was also stable at room 
temperature for many weeks. 
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Once the acetic formic anhydride was produced, the attempted formylation of a range of 
simple lactams was performed.  Azetidinone (n = 1) to 1 aza 2 cyclooctanone (n = 6) 
membered units were formylated (Table 3.1.1) 
(25). 
 
 
 
 
 
  n=  yield 
54  1  56% 
55  2  75% 
56  3  80% 
57  4  85% 
58  5  70% 
59  6  87% 
Table 3.1.1- Lactam formylations 
 
Ring size appeared to have a marginal effect on the yield of the formylation, the bigger the 
lactam ring, the greater the yield. The yields discovered could be considered surprising, as 
β lactams are distinguished for their inability to delocalise, and therefore more formylation 
product expected, however we have no satisfying explanation for this loss of yield. 
 
Having successfully synthesized the imine intermediates, the pivotal Wittig olefination was 
then attempted using a commercially available Wittig salt ethoxycarbonylmethylene 
triphenylphosphorane 
(25). 
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  n=  yield  E:Z 
60  1  77%  E only 
61  2  66%  E only 
62  3  47%  E only 
63  4  55%  E only 
64  5  37%  E only 
65  6  57%  E only 
Table 3.1.2- Lactam Wittig Olefinations 
 
It was gratifying to observe that the olefination proceeded in good yield and excellent E 
selectivity (Table 3.1.2). 
The double bond geometry was assigned based on the alkene coupling constant (J = 14.4 
Hz), on 2 dimensional nOe. 
 
 
Figure 3.1.2- Coupling constant for E isomer characterization 
 
Interestingly, it appears that even numbered rings generated a lower un optimised yield 
than the odd numbered rings.  
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3.1.2 Acyclic Systems 
Having developed a set of successful conditions for the synthesis of lactam derived 
enamides, we looked to expand the scope of the methodology. We were particularly keen 
to explore their application to acyclic systems, as the naturally occurring enamides are 
generally acyclic also.  
For our acyclic model systems it was decided to focus on commercially available 
Benzamide (66) and Picolinamide (67), in addition to (D ) pantolactone derived amide 
(68). 
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Scheme 3.1.2 
 
We proceeded to use the conditions already established for our lactams, in an attempt to 
formylate each of the three amides (66 68). The mixed anhydride was mixed at high 
temperature as before, with the amide being added after a period of time. Initially, the only 
evidence of formylation returned by this method was by NMR, with a small peak present M.V.J. Villa - 2009    36 
towards the high end of 
1H NMR (~9 ppm). Despite attempts to optimise these conditions, 
no further formylation was observed.  
The noticeable difference in efficiencies between our model lactam and model acyclic 
systems, prompted us to consider that the secondary nature of the lactams may have been 
contributing to the increased efficiency over the primary acyclic systems. 
 
As such, it was decided to generate the secondary amide (72) from the protection of (D) ( 
) pantolactone derived amide (68). The choice of a benzyl group as a protecting group was 
based on the feasibility of the removal of this group at a later stage. 
 
 
Scheme 3.1.3 
 
Despite repeated experimentation, amide (72) failed to be formylated using mixed 
anhydride. Faced with this set back, we turned back to the literature where the use of   
formylbenzotriazole as an amine formylating agent has been described by Katritzky and 
co workers 
(26).  
The   formylbenzotriazole was prepared in the same manner as in the literature. 
Benzotriazole (74) was mixed with formic acid in the presence of DCC, then recrystallised 
from DCM to afford the desired formylating agent (75). This formylating agent could then 
be stored at room temperature for weeks with no loss of activity. 
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Scheme 3.1.4 
 
Whereas before, our initial formylations were relying on the nucleophillic attack of the 
nitrogen lone pair on the mixed anhydride, this method uses more aggressive conditions by 
deprotonation of the amide with n BuLi before introduction of   formylbenzotriazole as 
the formylating agent. 
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Scheme 3.1.5 
 
The imides (69, 70 and 71) were generated in good yields 
(25), and their structures 
corroborated by X ray analysis. Benzamide (Fig 3.1.3), Picolinamide (Fig 3.1.4) and 
pantolactone derived (Fig 3.1.5) are shown below. M.V.J. Villa - 2009    38 
 
 
Figure 3.1.3- Benzamide derived imide (69)        Figure 3.1.4- Picolinamide derived imide (70) 
 
                                       
 
Figure 3.1.5- Pantolactone derived imide 
 
Subjecting the acyclic imides (69 71) to the same Wittig olefination conditions as those 
used for the synthesis of the lactam derived enamides, generated the desired enamides (76, 
77, and 78). 
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Scheme 3.1.6 
 
Satisfyingly, the respective enamides were obtained in much higher yields than previous 
lactam examples 
(25). Furthermore, the conditions were still exhibiting E selectivity, albeit 
with lower selectivity than the lactam examples. This lower selectivity could potentially be 
explained by the starting imide geometry, although at this point the reason is still not 
completely clear. 
 
 
Figure 3.1.6- Benzamide derived enamide (76Z) M.V.J. Villa - 2009    40 
Additionally, the structure of (76Z) was determined by X ray analysis (Fig 3.1.7), and 
matches that of the previously reported data 
(20).  
3.2 Substituted Enamides 
Having successfully generated the unsubstituted E enamides, we focussed our attention on 
the generation of substituted enamides. Until now, there had been minimal literature 
precedence for substituted enamide synthesis 
(21). 
As part of our approach, we attempted the olefination using the substituted ylide 1 
carbethoxyethylidene triphenylphosphorane, which could allow us to explore the feasibility 
of generating substituted enamides whilst exploring their selectivity.  
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Scheme 3.2.1 
We were delighted to observe that selectivity had been maintained, and in some cases 
increased over those observed for the unsubstituted ylide. 
Although the yields had decreased, they were still satisfactory enough for us to consider 
this an effective generation of the enamide functionalities.  M.V.J. Villa - 2009    41 
 
Unsubstituted  Substituted 
   
Yield     98%  E : Z     3:1  Yield   65%  E : Z   3:1 
   
Yield     87%  E : Z 51:49  Yield   88%  E : Z   5:1 
   
Yield     87%  E : Z     3:1  Yield   68%  E : Z 41:1 
Table 3.2.1- Comparison of effects on yield and selectivity by double bond substitution 
 
Although a small range of data has been compiled to date, there are some preliminary 
conclusions that can be drawn from it. 
As the aromaticity of the imide increases, the E selectivity appears to decrease. Increasing 
substitution appears to decreases yield, whilst simultaneously increasing selectivity.  
This can be attributable to the stability of the ylide during the Wittig olefination.  
The introduction of the substituted enamide functionality could prove to be significant; if 
used to assess their use as analogues for existing enamides such as the crocacins and 
lituarines discussed earlier. 
 
3.3 CJ-15,801 
Having demonstrated the successful stereoselective generation of enamides from their 
imide precursors, we set out to attempt the novel synthesis of CJ 15,801 (33).  
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Scheme 3.3.1 
 
As part of our approach, we envisioned using a similar formylation/ olefination strategy as 
before to introduce the conjugated ester which could selectively be deprotected (Scheme 
3.3.1). By utilising the same starting material, it was proposed that we could selectively 
deprotect the ketal in the presence of the ester, or alternatively investigate the removal of 
the ester group to generate the free acid in the presence of the ketal.  
 
 
We felt one of the restrictions in the Porco and Nicolaou procedures was in the final 
deprotection step. In trying to remove the allyl ester, the need for a complicated solid 
supported reagent was needed; a reagent that needed synthesising itself.  
 
To avoid the problems posed by deprotections, we decided to introduce a range of different 
esters. The theory being that each one would require different, but ultimately simple, de 
protection procedures. This would therefore enable us to investigate and optimise the final 
deprotection step.   
 
We were particularly intrigued by the work of Still and co workers 
(27) which shows the 
simple deprotection of esters using TMSOK. This procedure could be utilised in the 
deprotection of simple esters such as methyl and ethyl esters, which could be generated 
from their commercially available ylides. The advantage of this approach is that the 
deprotection could be performed before or after ketal deprotection at the opposite end of 
the molecule. 
 M.V.J. Villa - 2009    43 
Imide (71) was synthesised from (D) ( ) pantolactone as described earlier. Treatment of 
imide (71) with the stabilised ylide methyltriphenylphosphoranylidene acetate gave the 
methyl ester (82). Ketal deprotection was performed using BiCl3 with a catalytic amount of 
water, generating the desired free diol (83) in good yield 
(29). TMSOK treatment of ester 
(83) failed to generate the acid (33) largely due to the starting material being insoluble in 
THF. The insoluble nature of the diol in the chosen solvent system prompted us to attempt 
the ester removal before the ketal removal. Treatment of ketal (82) with TMSOK (up to 
5eq) failed to return any of the desired acid (84), only starting material. 
  
 
Scheme 3.3.2 
 
 
 
Scheme 3.3.3 
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Not to be deterred by the difficulties encountered using the deprotection conditions, 
alternative esters and their corresponding deprotection conditions were explored. 
Initially we turned our attentions to using a benzyl ester unit. The benzyl ester would have 
the advantage of potentially being removed by hydrogen transfer hydrogenolysis 
conditions. 
 
 
Scheme 3.3.4 
 
Olefination of imide (71) with the stabilised ylide benzyltriphenylphosphoranylidene gave 
the benzyl ester containing enamide (85) in good yield and as a 3:1 mixture of E: Z 
isomers. Before attempting the hydrogenolysis of the benzyl group, the ketal group was 
removed in good yield using our previously employed conditions, to give diol (86). A 
controlled hydrogen transfer hydrogenolysis was then attempted, using ammonium formate 
and Pd/C, to remove the benzyl ester in the presence of the double bond. The crude NMR 
showed a 1:1 ratio of CJ 15,801 (33): Pantothenic Acid (9). Extensive experimentation was 
carried out to see if the conditions could be adapted to increase the rate of benzyl group 
hydrogenolysis relative to that of double bond reduction. Disappointingly, it appeared that 
the rate of reduction of the double bond was faster than the desired ester hydrogenolysis, 
evident by the significant increase in the ratio of pantothenate upon increased amounts of 
sodium formate used. 
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Scheme 3.3.5 
We then decided to change source of hydrogen to formic acid and then cyclohexene in a 
bid to slow down the rate of reduction. However, the adjusted conditions yielded similar 
results to earlier conditions. 
 
 
Scheme 3.3.6 
 
Further experimentation included changing the type of catalyst, and also the amounts used. 
These still failed to selectively cleave the benzyl ester without reducing the double bond. 
 
Having failed to cleave the benzyl group, a new approach was devised. Literature evidence 
(30) suggests that benzyl esters can be converted to TBS esters by treatment with TBS 
silane and palladium catalyst. The conversion of the benzyl esters into the corresponding 
TBS ester would be an attractive one, as this would allow the TBS and ketal to be removed 
simultaneously by treatment with acid. 
 
Conversion of the benzyl ester (85) to the TBS ester (87) was performed, but returned little 
to no product.  
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Scheme 3.3.7 
 
The low yield and unnecessary additional step was not considered beneficial to the 
synthesis, and therefore an alternative was sought after. 
 
The notion of being able to perform a global deprotection step inspired us to use a t butyl 
ester as an alternative protecting group. Literature precedence suggested that a t butyl ester 
can be hydrolysed under acidic conditions 
(31), and we were optimistic the ketal could be 
removed under the same acidic conditions 
(32). 
Gratifyingly, when ester (88) was stirred with formic acid, the clear generation of the free 
acid was achieved, along with the liberation of the free diol to give CJ 15,801 (33). 
 
 
Scheme 3.3.8 
3.3.1 Mechanism of Reaction 
Interestingly, during the deprotection step, it was noticed that the NMR of the crude 
compound did not match that of the compound after column chromatography. Furthermore 
it was noticed that the Rf of the compound had also changed significantly. Treatment of the 
crude mixture with catalytic acidic methanol also caused the Rf and NMR to change to that M.V.J. Villa - 2009    47 
of the required product. We can propose that the ketal is converted to the free diol through 
a stable orthoester type intermediate (90) formed by the association of formic acid with the 
free diol. This intermediate is only then completely hydrolysed upon the addition of acidic 
methanol.  
 
Scheme 3.3.9 
A possible mechanism for this process involves:  
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Scheme 3.3.10 M.V.J. Villa - 2009    48 
 
After removal of the tBu group, protonation of the ketal (89) causes its spontaneous 
degradation to intermediate (90). This occurs via the formation of the unstable intermediate 
(93). Addition of acidic MeOH allows protonation of the hemi orthoester (90), and the free 
methoxide ion removing the formate group generating CJ 15,801 (33) and methyl formate 
sideproduct.  
 
The structure of CJ 15, 801 was corroborated by comparison of NMR and optical rotation 
data previously reported 
(16). 
 
Figure 3.3.1- 
1H NMR product CJ-15,801 (33) 
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Figure 3.3.2- 
1H NMR natural CJ-15,801 
(16) 
 
3.4 Synthesis of Pantothenate 
After observing over reduction of our benzyl ester whilst trying to produce CJ 15,801, it 
was decided that optimisation of this process would provide us with viable and efficient 
access to the production of pantothenic acid. 
 
Enamide (85) was subjected to standard BiCl3 ketal deprotection conditions, liberating the 
free diol in good yield. Hydrogenation using (H2 Pd/C) was then performed on ester (86) 
generating pantothenic acid (9) in good overall yield. 
 
 
Scheme 3.4.1 M.V.J. Villa - 2009    50 
 
Although this procedure was initially performed on the isolated E isomer, the conditions 
were then applied to a mixture of the E and Z benzyl ester bearing enamides to generate 
(D) ( ) pantothenic acid in comparable yield to the isolated esters. 
 
Having completed the synthesis of pantothenic acid, it was decided that the enamide (85) 
could be subjected to hydrogenation conditions without the removal of the ketal protecting 
group. As Pantothenic acid is a growth promoter, it is possible that this ketal protected 
analogue (97) may be useful to determine structure activity relationships (SAR). We 
believe this is one of the most efficient chemical syntheses towards (D) ( ) pantothenic 
acid without isolation as the Ca salt to date. Furthermore, our approach also allows for the 
synthesis of (L) (+) pantothenic acid by simply switching the pantolactone starting 
material. 
 
 
Scheme 3.4.2 
 
3.5 CJ-15,801 analogues 
The current syntheses in literature for CJ 15,801 only focus on the target molecule. 
However, as this compound exhibits inhibitory activity against the validated CoA 
biosynthesis target PanK, we decided to utilise our enamide procedure for the synthesis of 
new potential inhibitors based on CJ 15,801 framework. 
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Our approach relies on the Wittig Olefination of imide (71) with a number of different 
ylides which would help retain the key enamide functionality whilst exploring potential 
hydrogen bond donor/ acceptors. 
The vast majority of pantothenic acid analogues developed previously showed some 
success through modification of the β alanine moiety. However, the fact that these 
analogues were designed before the discovery of CJ 15,801, the decision was made to 
focus on a different class of inhibitors. In our design, we decided to combine the enamide 
characteristic of CJ 15,801, along with a drastically modified β alanine moiety. 
 
3.5.1 Ketone 
Methylpantothenone (32) derived analogues have shown reasonable success in plasmodia 
studies 
(11), hence our initial studies focussed on the synthesis of an enamide bearing 
analogue. The treatment of imide (71) under the same Wittig conditions as before, using 
the ketone containing ylide (94) generated the desired enone analogue in good yield and as 
a single Z isomer (99). 
 
 
Scheme 3.5.1 
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3.5.2 Aldehyde 
  pantoylsubstituted amides have also shown promising anti parasitic activities 
(11). A 
closely related analogue would be the aldehyde bearing CJ 15,801 analogue (101). This 
was interesting as we are introducing a substituted double bond in addition to an aldehyde 
functionality. 
 
Although this analogue could potentially be accessed through the Wittig olefination of 
imide (71) with ylide (100), there were concerns that a double Wittig olefination could take 
place which would generate the potentially unstable dienamide unit (102).  
 
 
Scheme 3.5.2 
 
Gratifyingly, the treatment of imide (71) with ylide (100) gave the desired enamide (101) 
in good yield and as a single E isomer. Although the yields are lower than the previous 
ester analogues, no dienamide side products were observed either in the aldehyde or the 
methyl ketone cases. 
 
 
Scheme 3.5.3 M.V.J. Villa - 2009    53 
 
It was also noted that in the example of the aldehyde, starting material was still present 
after reaction completion. This, coupled with the reduced yield of the ketone and aldehyde 
examples, could be attributed to the Wittig reagent reacting with itself. 
3.5.3 Nitrile 
Finally, the synthesis of nitrile bearing enamide (104) was attempted. The choice of nitrile 
unit emanated from its potential use not only as inhibitor, but also as a versatile handle 
opening up a range of further analogues including aldehydes and amines. 
 
The treatment of imide (71) with the ylide (103) afforded the enamide (104) in excellent 
yield, and again with a predominance of the Z enamide. 
 
Scheme 3.5.4 
This reversal of selectivity could potentially be explained by difference between the 
hybridisation of the ester carbon and that of the nitrile carbon. Our results would suggest 
that the delocalisation of the phosphorus carbon bond is more effective with the ester 
carbonyl than with the nitrile group. The reduced delocalisation would effectively make 
the nitrile ylide behave more like an unstabilised ylide, (Figure 3.5.5) thus favouring the Z 
olefin. M.V.J. Villa - 2009    54 
 
Figure 3.5.5- Comparison of ylides giving rise to observed selectivities 
 
4  Biological Assessment 
Having achieved the synthesis of a number of CJ 15,801 analogues, a number of 
compounds were sent for testing in the labarotories of Dr. Kevin Saliba at ANU. These 
compounds were tested against the Plasmodium parasite. These included compounds from 
our lactam, benzamide, picolinamide, and pantolactone derived enamides. 
 
4.1 Selection Rationale 
Although Pf PanK has not been characterized 
(33), information from SARs with bacterial 
PanK 
(34 36) has lead to the generation of potential inhibitors for this class of kinases. Our 
decision to generate and test compounds based on CJ 15,801 came from the same SARs as 
these investigations coupled with the known antiplasmodial activity of CJ 15,801 
(10). 
A number of aspects of the structure of pantothenate, and its affinity for E.Coli PanK (Fig 
4.1.1 
10) were considered as part of the selection process, before the compounds were sent 
for testing: 
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Figure 4.1.1- Known structure activity relationships of pantothenate and PanK 
 
4.2 Lactam derived Enamides 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
1  N
O
OEt
O
63  
196  1  N/A  0.94 
2 
 
98  1  N/A  1.36 
3 
 
55  1  N/A  1.78 
Table 4.2.1- Testing results for lactam derived enamides against whole parasite lysate 
 
In the case of the lactam derived analogues, the activities observed were very surprising as 
these compounds only share the enamide functionality with the naturally occurring CJ 
15,801, and no pantoyl functionality. It seems that the size of the lactam ring increases a 
uniform increase in the compound’s inhibition. This higher potency may be attributed to a M.V.J. Villa - 2009    56 
couple of possible factors. The increase in size may be affecting the compounds ability to 
pass through cell membranes. Alternatively, the ring might be filling space in the target 
active site. 
4.3 Benzamide derived Enamides 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
4 
O
N
H
O EtO
76Z  
141  2  17  1.63 
Table 4.3.1- Testing results for lactam derived enamides against whole parasite lysate 
 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
5 
 
183  2  6  1.63 
6 
 
139  2  5  1.98 
Table 4.3.2- Testing results for lactam derived enamides against whole parasite lysate 
 
The benzamide derived analogues proved to be weaker inhibitors than the lactam 
analogues. Interestingly, the Z isomer appears to be a better inhibitor than the E isomer 
(Entries 4 and 5). 
 
Furthermore, comparison of entries 5 and 6 also shows greater inhibition when the double 
bond is trisubstituted. This could be attributable to a “tighter fit” scenario similar to that 
seen with the lactam examples. 
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4.4 Picolinamide derived Enamides 
 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
7 
 
185  2  9  0.71 
8 
 
>200  2  N/A  0.71 
9 
 
125  2  7  1.06 
Table 4.4.1- Testing results for lactam derived enamides against whole parasite lysate 
 
As with the benzamide derived enamides, the picolinamides show a similar pattern of 
inhibition. Although the differences between the Z and E isomers are masked by the fact 
the E isomer inhibition is outside the upper limit, it still appears the Z isomer is a more 
potent inhibitor. However, the difference between the methyl substituted analogue (Entry 
9) and the Z enamide (Entry 7) is more marked than that observed for benzamide derived 
analogues. 
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4.5 Pantolactone derived Enamides 
The CJ 15,801 related analogues on the other hand provided the most interesting results. 
By comparing the esters in entries (11, 13 and 14) we can see that the increase in size of 
the ester group, generates an increase in inhibition. This could be due to the lipophyllic 
effect of the ester, helping the compound to pass through the cell wall. Alternatively, the 
larger group can be responsible for increasing the interactions with the biological target’s 
active site. 
 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
10 
 
>200  1  N/A  0.90 
11 
 
>200  1  N/A  0.90 
12 
 
172  1  N/A  1.24 
13 
 
158  1  N/A  1.24 
Table 4.5.1- Testing results for methyl and ethyl ester containing enamides against whole 
parasite lysate 
 
The pantolactone derived enamides appear to show different trends to the previously 
mentioned benzamide and picolinamide examples. Whereas before, the Z was better than 
E, in entries 12 and 13 we can see that the E isomer is slightly better inhibitor than Z in the 
un substituted model. 
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Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
14 
 
124  2  3  1.77 
15 
 
4  2  0.6  1.77 
16 
 
118  2  67  2.63 
17 
 
63  2  2  2.63 
Table 4.5.2- Testing results for larger ester containing enamides against whole parasite 
lysate 
 
In addition to the increase in inhibition the increase in ester size generates, another trend 
also appears. Comparison of entries 16 and 17 show that as the size of the ester is 
increased, the predominance of the Z ester as the better inhibitor is far more apparent. The 
same increase in inhibition of the Z over the E isomer is also exhibited in entries 18 and 19. 
We were also pleased to see that the inclusion of a benzyl ester (entries 16 and 17) 
improved its inhibition against the whole parasite over the previous enamides. As E. Coli 
PanK I has two phenylalanine side residues 
(34) present just beyond the carboxylate end of 
pantothenate, we believe similar residues in Pf PanK may be interacting via ring stacking 
with the benzyl ester. 
The most successful lead to date is Entry 15. A high inhibition was demonstrated against 
the whole parasite, possibly due to the increased size of the ester group as before. Again, 
the added lipophilicity of the Z isomer appears to make it more potent than its E 
counterpart (Entry 14). This compound will now require testing against the parasite lysate 
Pan K assays. M.V.J. Villa - 2009    60 
 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
18 
 
86  1  N/A  1.59 
19 
 
110  2  9  1.06 
Table 4.5.3- Testing results for substituted enamides against whole parasite lysate 
 
The generation of the substituted enamide (81) opened up the investigation for substituted 
enamides; as potential analogues of their unsubstituted counterpart. Comparison of entries 
12, 13, 18 and 19 suggest that increasing the substitution of the double bond not only 
increases the inhibition of the compound, but also switches the predominant inhibitor from 
the E isomer to the Z. 
The changes in inhibition observed imply that the molecular size added, through increasing 
the ester size or the double bond substitution, is perhaps providing a space filling/ 
lipophillic effect. To understand this effect in its entirety, further testing against specific 
isoforms of PanK needs to be performed. 
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4.6 CJ-15,801 Analogues 
 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
20 
 
163  1  N/A  1.11 
21 
 
179  1  N/A  1.11 
 
22 
 
>200  2  N/A  0.49 
23 
 
42  1  N/A  0.72 
Table 4.6.1- Testing results for CJ-15,801 analogues against whole parasite lysate 
 
The results from the non ester bearing compounds were intriguing. The nitrile containing 
enamide (entries 20 and 21), although not as good as some of the other analogues, was still 
showing some comparable activity. Although this compound does not contain the carboxyl 
group the other compounds (and CJ 15,801) contain, the nitrile may well be providing 
hydrogen bonding much like the carboxyl group in pantothenate, CJ 15,801 and other 
compounds tested. 
After the initial success of methyl pantothenone in earlier trials
10 we were interested in the 
methylpantothenone’s enamide counterpart (entry 22). However, the Z isomer provided no 
worthwhile results. 
Our excitement was instead focussed on our aldehyde containing analog (entry 23). It not 
only showed some activity, but was almost as efficient as CJ 15,801 (IC50 39 M). This is 
probably due to the presence of the aldehyde group acting as a more reactive electrophile 
than the ester. M.V.J. Villa - 2009    62 
 
 
Figure 4.6.1 
 
4.6.1 Deprotections 
Encouraged by the positive preliminary test results obtained with the ketal protected 
enamides, the decision was taken to remove the ketal next to unmask the free 1,3 diol. It 
was decided that these free diols could be considered a second class of inhibitors bearing a 
closer resemblance to pantothenic acid, and ideally increase the binding interaction would 
translate into a corresponding decrease of inhibitory concentration. 
Treatment of enamides (99, 101, and 104) with BiCl3 / cat.H2O gave the desired free diol 
containing enamides (105, 106 and 107) in excellent yield for all 3 cases. M.V.J. Villa - 2009    63 
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Scheme 4.6.1 
Testing of the deprotected diols against the same whole parasite assays as before, returned 
some intriguing results (Table 4.6.2). 
Entry  Structure  Average 
IC50 ( m) 
No. 
repeats  Std. Dev.  clogP 
24 
 
>200  2  N/A   0.24 
25 
 
>200  2  N/A   0.87 
26 
 
9  2  0.7  1.28 
27 
 
68  2  5  1.28 
Table 4.6.2- Testing results for deprotected enamides against whole parasite lysate 
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Comparison of entries 21 and 24 clearly shows that the removal of the ketal group makes 
the compound less effective against the whole parasite when compared with its ketal 
protected form. This is possibly due to increased hydrophilicity preventing it from entering 
the parasite. 
Entries 16, 17, 26 and 27 show a very interesting result. In the case of the Z isomer (entries 
16 and 26), the removal of the ketal slightly reduced inhibition as expected. However, 
when the ketal was removed from the E isomer (entries 17 and 27), the inhibition increased 
drastically.   
 
It might be possible that the combination of the free diol, the E enamide, and the benzyl 
ester provide the right balance of hydrophilicity/ hydrophobicity to maintain a high level of 
the compound in the parasite. 
 
Until now, the compounds described have only been tested against parasite lysate. As the 
Plasmodium genome contains two different PanK enzymes, we are still unsure as to which 
is being inhibited. More comprehensive testing would enable more information on the 
compound target enzyme, and enable further structure activity relationships to be 
determined. 
4.7 Further analogue generation 
 
A number of preliminary conclusions can be drawn from the biological data, with some 
apparent trends bringing the inhibition levels below 100 M.  
It appears that space filling such as increased lactam size, changing configuration from E 
to Z, or the inclusion of methyl substituted double bonds appears to improve inhibition. 
This leads to a number of questions: Can the inhibition of CJ 15,801 be improved by 
incorporating these characteristics? Can previous pantothenate analogues’ inhibition be 
improved simply through the introduction of an enamide double bond? 
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4.7.1 Future CJ-15,801 analogues 
With the apparent increase in inhibition exhibited by the methyl substituted enamides 
generated earlier, the incorporation of a methyl group into the CJ 15,801 may see 
improved inhibition.  
 
Scheme 4.7.1 
 
Oxidation of aldehyde (101) would provide the methyl substituted CJ 15,801 intermediate 
which, after ketal deprotection, could provide the CJ 15,801 analogue (108). Alternatively, 
the further functionalisation of the enamide nitrogen (109) may see further space filling 
potential (Fig 4.7.1). 
In addition to these, the synthesis and testing of Z  CJ 15,801 (110) may also be worth 
considering, as testing results appear to exhibit slightly higher inhibition from the Z 
enamides in comparison to their E counterpart.  
 
 
Figure 4.7.1 
 
4.7.2 Pantothenate analogues 
The quest for further inhibitors/ analogues is an ongoing one. Pantothenate is still a widely 
chosen lead for such analogues 
(37). In addition to ketal protected Pantothenate (97), our 
process provides access to a further generation of analogues. By generating the relevant M.V.J. Villa - 2009    66 
substituted ylides, the generation of substituted enamides could see the generation of the 
branch chained pantothenate (R= CH3) (Scheme 4.7.3) already shown to be biologically 
active 
(11) or further branch chained derivatives.  
 
 
Scheme 4.7.2 
 
 
 
Scheme 4.7.3 
 
However, testing so far has been against the parasite, not the target enzyme. Thus, we still 
don’t know how these compounds are working. The rational approach, therefore, would be 
to test these compounds against the PanK enzyme, in an attempt to elucidate the mode of 
inhibition.  
Further testing could then provide more information on the identification of the receptor, 
and this information coupled with modelling crystallography could help provide new 
structure activity relationships and drive the generation of a new library of compounds. M.V.J. Villa - 2009    67 
5  Conclusions and Further Work 
The successful generation of a unique class of   imide intermediates has been reported. 
These   imides have provided access to naturally occurring enamide functionalities – most 
notably the unique total synthesis of natural antimicrobial CJ 15,801 and previously 
unreported analogues. 
Additionally, the apparent behaviour of   formyl imides as “pseudo aldehydes” has 
opened up a number of reactions traditionally only accessible through aldehydes. 
 
Although time constraints prevented us from exploring a number of these reactions in 
depth, the initial results suggest that   formyl imides have significant potential in synthetic 
chemistry. Some are highlighted below. 
 
5.1 Dienamides 
Dienamides provide a difficult synthetic challenge, requiring the introduction of a diene 
unit with the correct selectivity. Furthermore, the use of dienamides in Diels Alder 
reactions makes them very useful intermediates. 
 
There have been a number of approaches to the synthesis of dienamides 
(21). 
However, the difficulty endured with the control of stereoselectivity and yield lead us to 
consider an alternative, more general approach to generating a dienamide unit. 
 
As discussed earlier, one concern with the generation of the enamide (101) was the 
possibility of a double Wittig reaction occurring. However, in the synthesis of dienamides 
we decided to exploit enamide (101)’s ability to undergo a second Wittig olefination.  
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Enamide (101) was reacted with methyltriphenylphosphoranylidene acetate under the same 
olefination conditions used before. Although the scale of the reaction was small (0.2mmol) 
preliminary 
1H NMR of the crude product mixture shows evidence of the presence of the 
diene unit (111). 
 
 
Scheme 5.1.1 
 
Despite its initial success, a number of issues need to be addressed as part of this approach. 
A possible limitation exists in that the initial enamide (101) is produced as an E only 
isomer. This limits the available dienamides to E, E and E, Z . 
 
A possible way to circumvent this problem would be to generate the Z isomer of an 
aldehyde bearing enamide, and use this as the starting material. This could be done by 
using Ando or Stille Gennari conditions 
(38 40).  
 
 
Figure 5.1.1 
 
Alternatively, it would also be possible to perform a DIBAL reduction of the nitrile 
bearing enamide (104). This would generate the enamide (112) and allow for a two step 
Wittig olefination. 
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Figure 5.1.2 
 
Any of these approaches would open the way for the possible selective generation of Z, E 
and Z, Z dienamides. 
 
5.2 Ene-ynes 
Enynes are another class of compounds which could potentially be generated from   
formyl imides, this time through the generation of haloenamide intermediates. 
We have shown that the use of unstabilized ylide conditions 
(41) can be used to generate 
vinyl halide (114) from imide (56).  
 
 
Scheme 5.2.1 
The unstabilized ylide bromomethyl triphenylphosphonium bromide was treated with 
KHMDS before addition of imide (56) to generate the sole Z isomer of the   vinylhalide 
(114). M.V.J. Villa - 2009    70 
Although not yet optimised, this reaction appears to return expected results for an 
aldehyde, i.e. the Z isomer being the major isomer. 
 
Having obtained the required halide, this opens up the possibility of generating ene ynes 
suitable for Pd
0 mediated Sonagashira couplings 
(21). 
 
 
Scheme 5.2.2 
 
5.3 Ynamides 
Ynamides are another prospective functional group that can be prepared from our   formyl 
imide intermediates. 
 
However, until now there exists no universal method for the synthesis of ynamides. 
 
 
Scheme 5.3.1 
 
Generation of the dihalo enamide (116) via Cory Fuchs and subsequent Fritsch 
rearrangement could lead to the preparation of ynamide (117) giving rise to a general 
method for the functionalisation of amides with   alkyne groups 
(42). 
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Before starting this project, we hypothesised that a large range of different   
functionalised compounds would be available from one key intermediate. The reactivity of 
imides observed to date suggests that   formyl imides may well be that intermediate. 
The future for   functionalisation through imide intermediates is now under investigation 
in the Marquez group (publication in print). 
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6  Section A: Experimental 
General Information.  All reactions were performed in oven dried glassware under an 
inert argon atmosphere unless otherwise stated.  Anhydrous DMF was purchased from 
Aldrich  Chemical  Co.    Tetrahydrofuran  (THF),  diethyl  ether,  and  dichloromethane 
(DCM)  were  purified  through  a  Pure  Solv  400 5MD  solvent  purification  system 
(Innovative Technology, Inc).  All reagents were used as received, unless otherwise 
stated.    Solvents  were  evaporated  under  reduced  pressure  at  40  °C  using  a  Büchi 
Rotavapor. 
  IR  spectra  were  recorded  as  thin  films  on  NaCl  plates  using  a  Jasco  FT/IR  4100 
Fourier Transform spectrometer.  Only significant absorptions (ν
max) are reported in 
wavenumbers  (cm
 1)  with  the  following  abbreviations  used  to  describe  absorption 
intensity: w, weak; m, medium; s, strong and br, broad. 
  Proton magnetic resonance spectra (
1H NMR) were recorded at 300MHz or 400MHz 
using a Bruker DPX Avance300 or 400 instrument, respectively.  Chemical shifts (δH) 
are reported in parts per million (ppm), and are referenced to the residual solvent peak.  
The order of citation in parentheses is (1) number of equivalent nuclei (by integration), 
(2) multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, m = 
multiplet, br  =  broad),  and  (3)  coupling  constant  (J) quoted in  Hertz to the  nearest 
0.5Hz.  Carbon magnetic resonance spectra (
13C) were recorded at 75MHz or 100MHz 
using a Bruker DPX Avance300 or 400 instrument respectively.  Chemical shifts (δC) 
are  quoted  in  parts  per  million (ppm)  and  are  referenced  to the  appropriate  solvent 
peak. 
  High resolution mass spectra were recorded on a JEOL JMS 700 spectrometer by 
electrospray ionisation mass spectrometer operating at a resolution of 15000 full widths 
at half height.   M.V.J. Villa - 2009    73 
  Flash chromatography was performed using silica gel (Apollo Scientific Silica Gel 
60, 40 63 micron) as the stationary phase.  TLC was performed on aluminium sheets 
pre coated with silica (Merck Silica Gel 60 F254).  The plates were visualised by the 
quenching  of  UV  fluorescence  (λmax254nm)  and/or  by  staining  with  either 
anisaldehyde, potassium permanganate or iodine followed by heating. 
All cLogP values were calculated using Chemoffice Chemdraw Version 10. 
Any  biological  testing  was  performed  by  Dr  C.  Spry  at  the  Australian  National  University, 
Australia, to the following procedures: 
For whole parasite testing , in vitro P. falciparum growth assays were set up in 96 well microtitre 
plates (NUNC) starting with ring stage P.  falciparum infected erythrocytes.  Test compounds were 
initially dissolved in dimethylsulfoxide (DMSO), and then diluted in complete medium.  The 
concentration of DMSO introduced into the assay never exceeded 0.01 % (v/v).  Two fold serial 
dilutions of the test compounds in complete medium were added to the wells of the plates in 
duplicate or triplicate (final well volume 100 µL).  A suspension of infected erythrocytes (2 % 
haematocrit and 1 % parasitemia) was prepared in complete medium and 100 µL of this suspension 
added to the wells (final well volume 200 µL, haematocrit 1 %, parasitemia 1 %).  Wells 
containing uninfected erythrocytes (1 % haematocrit) served as blank controls and wells containing 
infected erythrocytes (2 % haematocrit and 1 % parasitemia) in the absence of any drugs served as 
an estimate of 100 % parasite growth.  The plates were then incubated at 37 
oC under an 
atmosphere of 96 % nitrogen, 3 % carbon dioxide and 1 % oxygen for 96 h.  To investigate 
specificity in some experiments the medium was supplemented with 100 µM pantothenate. 
Following the 48 or 96 h, the cells in the microtitre plates were resuspended before 100 µL from 
each well was transferred to a second 96 well microtitre plate containing 100 µL of Sybr Green I 
(0.2 µL/mL; Molecular Probes, Inc) in lysis buffer (20 mM Tris, pH 7.5; 5 mM EDTA; 0.008 % 
(w/v) saponin; 0.08 % (v/v) Triton X 100) per well.  The cells were mixed with the buffer, and the 
fluorescence in the wells of the microtitre plates measured using a FLUOstar OPTIMA 
multidetection microplate reader from BMG LABTECH. 
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For PanK testing, Parasites were diluted 1/10 in a 10 mM Tris buffer (pH 7.4) and triturated 10 
times through a 25 gauge needle. The lysate was then clarified by three centrifugation steps at 
2000g for 30 min. At the end of each centrifugation step, the supernatant was transferred to a new 
tube. The lysates were stored at  20°C, and aliquots were thawed when required. The assay was 
performed in 50 µl volumes in a 96 well microtiter plate. The phosphorylation reaction was 
commenced by adding the lysate (125 µl/ml) to a solution containing 50 mM Tris, 5 mM ATP, 
5mM MgCl2, and 0.1 µCi/ml [
14C]pantothenate in the absence or presence of the testing compound 
(200 µM). The reaction was terminated at predetermined time points by the addition of 5 µl of 
acetic acid (10% v/v). The phosphorylated [
14C]pantothenate was separated from the 
nonphosphorylated species by binding the phosphorylated [
14C]pantothenate to DE 81 filters 
contained in a 96 well Unifilter plate (Whatman, Florham Park, NJ). A 50 µl volume of the 
reaction solution was transferred into the Unifilter plate and was allowed to dry. The 
nonphosphorylated [
14C]pantothenate was removed by three washes, each with 200 µl of a solution 
of ethanol/acetic acid/water (95:1:4; v/v/v). The filters were allowed to dry before being soaked in 
30 µl of scintillation fluid (Microscint; PerkinElmer Life and Analytical Sciences). The 
radioactivity was measured in a Top Count scintillation counter (PerkinElmer Life and Analytical 
Sciences). 
 
Representative Procedures. 
 
General Procedure (A) for the Synthesis of Lactam Derived   Formyl Imides (54 59).  A 
mixture of formic acid (0.1 mol) and acetic acid (0.1 mol) was heated under argon at 55
 oC for 3 
hours.  In each case, the lactam (0.01 mmol) was then added, and the resulting reaction mixture 
stirred at 60
 oC for 15 hours.  The reaction solution was then cooled to room temperature and the 
excess mixed anhydride removed under vacuum (10 mbar).  The resulting crude product was then 
suspended in ethyl acetate (10 mL) and the resulting solution filtered through a plug of neutral 
alumina to afford the desired lactam derived n formyl imides (54 59). 
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N
O
CHO
 
 
2 Oxo azetidine 1 carbaldehyde, (54).  
Prepared as per procedure A, using Azetidinone (213mg) to generate imide (54) (551mg, 56%) 
1H NMR (400MHz, CDCl3) δ: 8.60 (1H, s, O=CH), 3.60 (2H, m, N CH2), 3.10 (2H, m, CH2C=O).   
NMR (100MHz, CDCl3) δ: 166.0 (O=CH), 156.3 (NC=O), 22.1 (CH2), 20.5 (CH2).   
IR νmax(film)/cm
 1 2981 (s), 1830 (s), 1652(s).   
HRMS calcd for C4H5O2N (M+  ): 99.0320.  Found 99.0321. 
 
 
 
N
O
CHO
 
 
2 Oxo pyrrolidine 1 carbaldehyde, (55).  
Prepared as per procedure A, using pyrrolidinone (851mg) to generate imide (55) (848mg, 75%) 
1H NMR (400MHz, CDCl3) δ: 9.01 (1H, s, O=CH), 3.67 (2H, td, J = 7.3, 0.8 Hz, N CH2), 2.54 
(2H, t, J = 7.9 Hz, CH2C=O), 2.07 (2H, m, CH2).   
13C NMR (100MHz, CDCl3) δ: 176.8 (O=CH), 160.3 (NC=O), 42.1 (CH2), 32.2 (CH2), 17.8 (CH2).   
IR νmax(film)/cm
 1  2905 (s), 1750 (s), 1698 (s), 1351 (s), 1300 (m).   
HRMS calcd for C5H7O2N (M+  ): 113.0477.  Found 113.0479. 
 
N
O
CHO
 
 
2 Oxo piperidine 1 carbaldehyde, (56). 
Prepared as per procedure A, using valerolactam (991mg) to generate imide (56) (1.02g, 80%)  M.V.J. Villa - 2009    76 
1H NMR (400MHz, CDCl3) δ: 9.42 (1H, s, O=CH), 3.55 (2H, bs, N CH2), 2.55 (2H, bm, 
CH2C=O), 1.80 (4H, bm, 2x CH2 ).   
13C NMR (100MHz, CDCl3) δ: 173.2 (O=CH), 162.8 (NC=O), 41.6 (CH2), 33.3(CH2), 21.7(CH2), 
19.9(CH2). 
IR νmax(film)/cm
 1 2958 (s), 1690 (s), 1717 (s).  
HRMS calcd for C6H10O2N (M+H
+): 128.0712. Found 128.0710. 
 
N
O
CHO
 
 
2 Oxo azepane 1 carbaldehyde, (57). 
Prepared as per procedure A, using Ε caprolactam (1.13g) to generate imide (57) (1.19g, 85%) 
1H NMR (400MHz, CDCl3) δ: 9.41 (1H, s, O=CH), 3.81 (2H, m, N CH2), 2.70 (2H, m, CH2C=O), 
1.81 (4H, m, 2x CH2), 1.71 (2H, m, CH2).   
13C NMR (100MHz, CDCl3) δ: 178.1(O=CH), 162.2 (NC=O), 40.2(NCH2), 38.3(O=CCH2), 
29.6(CH2), 28.6(CH2), 23.6(CH2).   
IR νmax(film)/cm
 1 2986 (s), 1700 (s), 1695 (s).   
HRMS calcd for C7H12O2N (M+H
+): 142.0868. Found 142.0870. 
 
N
O
CHO
 
 
2 Oxo azocane 1 carbaldehyde, (58).  
Prepared as per procedure A, using aza 2 cyclooctanone (1.27g) to generate imide (58) (1.08g, 
70%) 
1H NMR (400MHz, CDCl3) δ: 9.39 (1H, s, O=CH), 3.77 (2H, m, N CH2), 2.59 (2H, m, CH2C=O), 
1.85 (2H, m, CH2), 1.65 (2H, m, CH2), 1.50 (2H, m, CH2), 1.45 (2H, m, CH2).   M.V.J. Villa - 2009    77 
13C NMR (100MHz, CDCl3) δ: 178.3(O=CH), 162.6 (NC=O), 40.5(NCH2), 35.0( O=CCH2), 
29.0(CH2), 28.6(CH2), 25.8(CH2), 24.3(CH2).   
IR νmax(film)/cm
 1 2935 (s), 1652 (s), 1635 (s).   
HRMS calcd for C8H14O2N (M+H
+): 156.1025. Found 156.1024. 
 
N
O
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2 Oxo azonane 1 carbaldehyde, (59). 
Prepared as per procedure A, using 2 azacyclononanone (1.41g) to generate imide (54) (1.48g, 
87%) 
1H NMR (400MHz, CDCl3) δ: 9.35 (1H, s, O=CH), 3.75 (2H, m, N CH2), 2.61 (2H, m, CH2C=O), 
1.84 (2H, m, CH2), 1.65 (2H, m, CH2), 1.55 (2H, m, CH2), 1.47 (4H, m, CH2).    
13C  NMR  (100MHz,  CDCl3)  δ:  178.8  (O=CH),  162.9  (NC=O),  42.3(NCH2),  36.2  (O=CCH2, 
28.1(CH2), 27.1(CH2), 25.1 (2x CH2), 22.5(CH2).   
IR νmax(film)/cm
 1 2932 (s), 1695 (s), 1635 (s).   
HRMS calcd for C9H16O2N (M+H
+): 170.1181. Found 170.1182. 
 
General Procedure (B) for the Synthesis of Lactam Derived Enamides (60 65).  In each case, a 
solution of the lactam derived n formyl imide (1.0 mmol) in benzene (10 mL) was treated with 
ethoxycarbonylmethylene triphenylphosphorane (3.0 mmol) and the resulting homogeneous 
mixture heated to 80
oC for 18 hours.  Once the reaction was complete by TLC analysis, the solvent 
was then removed in vacuo to generate a semi solid crude residue.  Purification of the crude 
product by flash column chromatography (silica gel, 30% EtOAc in 40 60 petroleum ether) 
proceeded to generate the desired lactam derived E enamides (60 65), as a single double bond 
isomer in each case. 
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(E) 3 (2 Oxo azetidin 1 yl) acrylic acid ethyl ester, (60). 
Imide (54) (127mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure B to generate enamide (60) (166mg, 77%) as 
a single E isomer.  
1H NMR (400MHz, CDCl3) δ: 7.65 (1H, d, J = 14.0 Hz, HC=CH), 5.20 (1H, d, J = 14.0 Hz, 
HC=CH), 4.12 (2H, q, J = 7.1 Hz, OCH2CH3), 3.45 (2H, t, J = 4.9 Hz, N CH2), 3.09 (2H, t, J = 4.9 
Hz, CH2C=O), 1.20 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 166.9 (OC=O), 164.9 (NC=O), 134.9 (C=C), 100.0 (C=C), 60.3 
(OCH2CH3) , 38.8 (CH2), 37.3 (CH2), 14.3 (OCH2CH3).   
IR νmax(film)/cm
 1 3029 (m), 2983 (s), 1774 (s), 1701 (s), 1632 (s), 1178 (s).   
HRMS calcd for C8H11O3N (M+  ): 169.0739. Found 169.0738. 
 
N
O
OEt
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(E) 3 (2 Oxo pyrrolidin 1 yl) acrylic acid ethyl ester, (61).  
Imide (55) (105mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure B to generate enamide (61) (112mg, 66%) as 
a single E isomer. 
1H NMR (400MHz, CDCl3) δ: 8.04 (1H, d, J = 14.3 Hz, HC=CH), 5.14 (1H, d, J = 14.2 Hz, 
HC=CH), 4.13 (2H, q, J = 7.1 Hz, OCH2CH3), 3.49 (2H, t, J = 7.2 Hz, N CH2), 2.49 (2H, t, J = 7.9 
Hz, CH2C=O), 2.1 (2H, appq, J = 7.5 Hz, CH2), 1.23 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 174.2 (OC=O), 167.1 (NC=O), 137.2 (C=C), 100.8 (C=C), 60.2 
(OCH2CH3), 44.9 (CH2), 30.9 (CH2), 17.4 (CH2), 14.3 (OCH2CH3).   
IR νmax(film)/cm
 1 3049 (s), 2981 (s), 1728 (s), 1699 (s), 1630 (m), 1260 (m), 1159 (m).   
HRMS calcd for C9H13O3N (M+  ): 183.0895. Found 183.0888. M.V.J. Villa - 2009    79 
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(E) 3 (2 Oxo piperidin 1 yl) acrylic acid ethyl ester, (62). 
Imide (56) (188mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure B to generate enamide (62) (122mg, 42%) as 
a single E isomer.  
1H NMR (400MHz, CDCl3) δ: 8.65 (1H, d, J = 14.5 Hz, HC=CH), 5.30 (1H, d, J = 14.5 Hz, 
HC=CH), 4.25 (2H, q, J = 7.1 Hz, OCH2CH3), 3.45 (2H, t, J = 6.1 Hz, N CH2), 2.60 (2H, t, J = 6.7 
Hz, CH2C=O), 1.88 (2H, m, CH2), 1.78 (2H, m, CH2), 1.30 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 169.5 (OC=O), 167.4 (NC=O), 140.7 (C=C), 100.0 (C=C), 60.1 
(OCH2CH3), 45.6 (CH2), 33.1 (CH2), 22.4 (CH2), 20.2 (CH2), 14.4 (OCH2CH3).   
IR νmax(film)/cm
 1 3057 (s), 2957 (s), 1708 (s), 1683 (s), 1622 (s), 1255 (s), 1159 (m).   
HRMS calcd for C10H15O3N (M+  ): 197.1052. Found 197.1050. 
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(E) 3 (2 Oxo azepan 1 yl) acrylic acid ethyl ester, (63).  
Imide (57) (191mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure B to generate enamide (63) (155mg, 55%) as 
a single E isomer.  
1H NMR (400MHz, CDCl3) δ: 8.39 (1H, d, J = 14.5 Hz, HC=CH), 5.22 (1H, d, J = 14.4 Hz, 
HC=CH), 4.15 (2H, q, J = 7.1 Hz, OCH2CH3), 3.55 (2H, m, CH2), 2.64 (2H, m, CH2), 1.70 (6H, m, 
3x CH2), 1.25 (3H, t, J = 7.06 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 174.8 (OC=O), 167.7 (NC=O), 140.7 (C=C), 98.8 (C=C), 60.0 
(OCH2CH3), 45.4 (CH2), 37.0 (CH2), 29.1 (CH2), 27.2 (CH2), 23.4 (CH2), 14.3 (OCH2CH3).   M.V.J. Villa - 2009    80 
IR νmax(film)/cm
 1 3069 (s), 2936 (s),1706 (s), 1684 (s), 1621 (s), 1173 (s), 1148 (m).   
HRMS calcd for C11H17O3N (M+  ): 211.1208. Found 211.1207. 
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(E) 3 (2 Oxo azocan 1 yl) acrylic acid ethyl ester, (64). 
Imide (58) (214mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure B to generate enamide (64) (114mg, 37%) as 
a single E isomer.  
  
1H NMR (400MHz, CDCl3) δ: 8.45 (1H, d, J = 14.6 Hz, HC=CH), 5.25 (1H, d, J = 14.6 Hz, 
HC=CH), 4.15 (2H, q, J = 7.1 Hz, OCH2CH3), 3.75 (2H, m, CH2), 2.60 (2H, m, CH2), 1.80 (2H, m, 
CH2), 1.65(2H, m, CH2), 1.50 (2H, m, CH2), 1.40 (2H, m, CH2), 1.22 (3H, t, J = 7.1 Hz, 
OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 174.6 (OC=O), 167.6 (NC=O), 139.6 (C=C), 100.2 (C=C), 60.1 
(OCH2CH3), 44.0 (CH2), 34.5 (CH2), 29.0 (CH2), 27.2 (CH2), 26.1 (CH2), 24.0 (CH2), 14.4 
(OCH2CH3).   
IR νmax(film)/cm
 1 3048 (m), 2935 (s), 1702 (s), 1678 (s), 1621 (s), 1130 (s).   
HRMS calcd for C12H19O3N (M+  ): 225.1365. Found 225.1364. 
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(E) 3 (2 Oxo azonan 1 yl) acrylic acid ethyl ester, (65). M.V.J. Villa - 2009    81 
 Imide (59) (219mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure B to generate enamide (65) (176mg, 57%) as 
a single E isomer.  
 
1H NMR (400MHz, CDCl3) δ: 8.45 (1H, d, J = 14.6 Hz, HC=CH), 5.21 (1H, d, J = 14.6 Hz, 
HC=CH), 4.14 (2H, q, J = 7.1 Hz, OCH2CH3), 3.74 (2H, m, CH2), 2.50 (2H, m, CH2), 1.80 (2H, m, 
CH2), 1.70 (2H, m, CH2), 1.50 (2H, m, CH2), 1.40 (4H, m, 2x CH2), 1.25 (3H, t, J = 7.1 Hz, 
OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 175.5 (OC=O), 167.6 (NC=O), 140.0 (C=C), 100.3 (C=C), 60.1 
OCH2CH3), 45.7 (CH2), 35.2 (CH2), 28.1 (CH2), 25.3 (CH2), 25.2 (CH2), 25.1 (CH2), 22.2 (CH2), 
14.4 (OCH2CH3).   
IR νmax(film)/cm
 1 3045 (s), 2931 (s), 1703 (s), 1676 (s), 1620 (s), 1155 (m).   
HRMS calcd for C13H21O3N (M+  ): 239.1521. Found 239.1524. 
General Procedure (C) for the Synthesis of   Formyl Imides, (69 71). A solution of the acyclic 
amide (1 mmol) in anhydrous THF (10 mL) was cooled to 0
 oC before being treated with n BuLi 
(1.1 mmol, 1.6 M solution in hexanes).  The reaction mixture was then stirred at 0
 oC for 5 minutes 
before  being  treated  with    formylbenzotriazole  (1.2  mmol).  The  resulting  mixture  was  then 
allowed to warm up to room temperature and then stirred for a further 2 hours.  The reaction 
mixture was diluted with t butylmethyl ether (10 mL), and quenched with a saturated aq. NaHCO3 
solution (10 mL).  The aqueous phase was then extracted with diethyl ether (3 x 20 mL) and the 
combined organic layers dried over Na2SO4.  The solvent was removed under vacuum to afford the 
crude product, which was then purified by flash column chromatography (silica gel, 10% to 20% 
ethyl acetate in 40 60 petroleum ether) to afford the desired   formyl imides (69 71). 
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  Formylbenzamide, (69). 
n BuLi (1.88 mL) and   formylbenzotriazole (756 mg) were added to a solution of benzamide 
(519 mg) in THF as per procedure C, to generate the imide (69) (333 mg, 52%). 
 
1H NMR (400MHz, CDCl3) δ: 10.36 (1H, bd, J = 7.7 Hz, NH), 9.33 (1H, d, J = 9.5 Hz, O=CH), 
7.91 (2H, m, 2x ArH), 7.56 (1H, m, ArH), 7.46 (2H, m, 2x ArH).  
13C NMR (100MHz, CDCl3) δ: 165.8 (NC=O), 164.1 (O=CH), 132.9 (ArC q), 130.0 (ArC), 128.0 
(ArC), 127.1 (ArC).   
IR νmax(film)/cm
 1 3414 (m), 3029 (s), 1728 (s), 1683 (s), 1463 (s), 1364 (m), 1252 (s), 1208 (s).   
HRMS calcd for C8H7O2N (M+  ): 149.0477. Found 149.0474. 
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  Formylpicolinamide, (70).  
n BuLi (1.80 mL) and   formylbenzotriazole (726 mg) were added to a solution of picolinamide 
(502 mg) in THF as per procedure C, to generate the imide (70) (389 mg, 49%). 
 
1H NMR (400MHz, CDCl3) δ: 10.3 (1H, bs, NH), 9.26 (1H, d, J = 10.6 Hz, O=CH), 8.58 (1H, dm, 
J = 4.8 Hz, ArH), 8.19 (1H, dm, J = 7.8 Hz, ArH), 7.89 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.53 (1H, 
ddd, J = 7.6, 4.7, 1.1 Hz, ArH).   
13C NMR (100MHz, CDCl3) δ: 164.4 (NC=O), 161.8 (O=CH), 148.7 (ArC q), 147.1 (ArC), 137.8 
(ArC), 128.1 (ArC), 123.3 (ArC).   
IR νmax(film)/cm
 1 3347 (s), 3029 (s), 2926 (s), 1736 (s), 1697 (s), 1462 (m), 1367 (s), 1183 (m).   
HRMS calcd for C7H6O2N2 (M+  ): 150.0427. Found 150.0429. 
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  Formyl (R) 2,2,5,5 tetramethyl [1,3]dioxane 4 carboxylic acid amide, (71). 
n BuLi (1.37 mL) and   formylbenzotriazole (551 mg) were added to a solution of (D ) 
pantolactone derived amide (591 mg) in THF as per procedure C, to generate the imide (71) (431 
mg, 64%). 
1H NMR (400MHz, CDCl3) δ: 9.08 (1H, d, J = 10.4 Hz, O=CH), 8.80 (1H, bs, NH), 4.12 (1H, s, 
CH(O)), 3.65 (1H, d, J = 11.8 Hz, CHA, HB), 3.27 (1H, d, J = 11.8 Hz, CHA, HB), 1.41 (3H, s, OCCH3), 
1.39 (3H, s, OCCH3), 0.99 (3H, s, CCH3), 0.98 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 170.6 (O=CH), 161.4 (NC=O), 99.7 (OCCH3), 77.0 (CH(O)) , 71.1 
(OCH2), 33.3 (CCH3), 29.3 (OCCH3), 21.7 (OCCH3), 18.9 (CCH3), 18.6 (CCH3).   
IR νmax(film)/cm
 1 3385 (s), 2874 (s), 1743 (s), 1699 (s).   
HRMS calcd for C10H18O4N (M+H
+): 216.1236. Found 216.1233.  
[α]D  +48.0 (c = 1.4, CHCl3). 
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  Benzyl 2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamide, (72)  
A solution of amide (68) (191 mg, 1.01mmol) in THF (5 mL) was added to a suspension of 
previously washed sodium hydride (60% oil dispersion, (81mg) in dry THF (5 mL) at 0 
oC. After 
generation of H2 subsided, the mixture was stirred for 30 min at 0 
oC. Benzyl bromide was then 
added (0.24ml, 2.0mmol), followed by tetrabutylammonium iodide (37mg, 0.1mmol) at 0 
oC. The 
reaction was allowed to warm up to room temperature over 1 hr, and was then stirred for a further 
2hrs. The reaction mixture was then extracted with EtOAc (20mL) and water (15 mL). The organic 
layer was dried over Na2SO4, filtered, and the solvent evaporated under vacuum to give a crude oil 
which was purified by flash column chromatography (silica gel, 20% EtOAc in 40 60 petroleum 
ether) to afford   benzyl amide (72), as a clear oil (185mg, 67%).   M.V.J. Villa - 2009    84 
1H NMR (400MHz, CDCl3) δ: 7.24 (5H, m, 5x ArH), 6.80 (1H, bs, NH), 4.39 (2H, s, BnH), 4.09 
(1H,s, CH(O)), 3.63 (1H, d, J = 11.7 Hz, CHA, HB), 3.22 (1H, d, J = 11.7 Hz, CHA, HB), 1.36 (6H, s, 2x 
OCCH3), 1.01 (3H, s, CCH3), 0.95 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 169.7 (NC=O), 138.3 (ArC q), 128.7 (2x ArC), 127.6 (2x ArC), 
127.4 (ArC) , 99.1 (OCCH3), 77.3 (CH(O)), 71.5 (NCH2), 42.6 (OCH2), 33.2 (CCH3), 29.5 
(OCCH3), 22.2(OCCH3), 19.0 (CCH3), 18.7(CCH3). 
IR νmax(film)/cm
 1 3322 (s), 3032(s), 2992 (s), 1716 (s), 1649 (s), 1460 (s).   
HRMS calcd for C16H23O3N (M+  ): 277.1678. Found 277.1677.   
[α]D  +103.0 (c = 1.2, CHCl3). 
 
General Procedure (D) for the Synthesis of Acyclic Enamides (76 78).  A solution of   formyl 
imide  (69 71)  (1.0  mmol)  in  benzene  (10  mL)  was  treated  with  ethoxycarbonylmethylene 
triphenylphosphorane (3.0 mmol) and the resulting mixture heated to 95
  oC for 19 hours. Upon 
reaction completion as indicated by TLC analysis, the solvent was removed under vacuum.  The 
crude residue was then purified by flash column chromatography (silica gel, 10% to 30% EtOAc in 
40 60 petroleum ether) to afford the desired enamides (76 78). 
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(Z) 3 Benzoylamino acrylic acid ethyl ester, (76Z). 
Imide (69) (184mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure D to generate enamide (76) (236mg, 87%) as 
a mixture of E and Z  isomers, E:Z ratio 51: 49.  
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1H NMR (400MHz, CDCl3) δ: 11.5 (1H, bs, NH), 7.90 (2H, m, 2x ArH), 7.68 (1H, dd, J = 9.1, 8.8 
Hz, HC=CH), 7.53 (1H, m, ArH), 7.44 (2H, m, 2x ArH), 5.20 (1H, d, J = 8.8 Hz, HC=CH), 4.17 
(2H, q, J = 7.1 Hz, OCH2CH3), 1.27 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 169.6 (OC=O), 164.5 (NC=O), 138.8 (ArC q), 132.9 (ArC), 132.2 
(C=C), 128.9 (ArC), 127.7 (ArC), 97.2 (C=C), 60.3 (OCH2CH3), 14.3 (OCH2CH3).   
IR νmax(film)/cm
 1 3337 (s), 3056(s), 2985 (s), 1679 (s), 1627 (s), 1396 (m), 1381 (m), 1210 (m), 
739 (s).  HRMS calcd for C12H13O3N (M+  ): 219. 0895. Found 219. 0898. 
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(E) 3 Benzoylamino acrylic acid ethyl ester, (76E). 
1H NMR (400MHz, CDCl3) δ: 8.28 (1H, dd, J = 14.1, 11.8 Hz, HC=CH), 8.08 (1H, bd, J = 11.8 
Hz, NH), 7.88 (2H, m, 2x ArH), 7.64 (1H, m, ArH), 7.54 (2H, m, 2x ArH), 5.65 (1H, d, J = 14.1 
Hz, HC=CH), 4.25 (2H, q, J = 7.1 Hz, OCH2CH3), 1.33 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 167.3 (OC=O), 164.9 (NC=O), 137.9 (ArC q), 132.9 (ArC), 132.3 
(C=C), 128.9 (ArC), 127.5 (ArC), 102.5 (C=C), 60.3 (OCH2CH3), 14.4 (OCH2CH3).   
IR νmax(film)/cm
 1 3400 (s), 3033 (m), 2993 (s), 1694 (s), 1639 (s), 1095 (m), 1051 (m), 908 (s).  
HRMS calcd for C12H13O3N (M+  ): 219.0895. Found 219.0897. 
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(Z) 3 [(Pyridine 3 carbonyl) amino] acrylic acid ethyl ester, (77Z). 
Imide (70) (112mg) was added to a solution of ethoxycarbonylmethylene 
triphenylphosphorane in benzene as per procedure D to generate enamide (77) (143mg, 87%) as 
a mixture of E and Z  isomers, E:Z ratio 3: 1.  
1H NMR (400MHz, CDCl3) δ: 12.35 (1H, bs, NH), 8.67 (1H, dm, J = 4.7 Hz, ArH), 8.18 (1H, dt, J 
= 7.8, 1.0 Hz, ArH), 7.83 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.60 (1H, dd, J = 11.9, 8.9 Hz, HC=CH), M.V.J. Villa - 2009    86 
7.44 (1H, ddd, J = 7.6, 4.7, 1.2 Hz, ArH), 5.22 (1H, d, J = 8.8 Hz, HC=CH), 4.21 (2H, q, J = 7.2 
Hz, OCH2CH3), 1.28 (3H, t, J = 7.17 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 168.6 (OC=O), 162.9 (NC=O), 148.9 (ArC q), 148.5 (ArC), 137.5 
(ArC), 137.0 (C=C), 127.2 (ArC), 123.3 (ArC), 98.4 (C=C), 60.3 (OCH2CH3), 14.4 (OCH2CH3).   
IR νmax(film)/cm
 1 3424 (s), 3078 (s), 2985 (s), 1688 (s), 1625 (s), 1204 (m), 735 (s). 
HRMS calcd for C11H12O3N2 (M+  ): 220.0848. Found 220. 0850. 
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(E) 3 [(Pyridine 3 carbonyl) amino] acrylic acid ethyl ester, (77E)  
1H NMR (400MHz, CDCl3) δ: 10.05 (1H, bd, J = 10.4 Hz, NH), 8.66 (1H, dm, J = 4.8 Hz, ArH), 
8.29 (1H, dm, J = 7.8 Hz, ArH), 8.22 (1H, dd, J = 14.2, 12.2 Hz, HC=CH), 7.95 (1H, td, J = 7.7, 
1.7 Hz, ArH), 7.57 (1H, ddd, J = 7.6, 4.8, 1.2 Hz, ArH), 5.76 (1H, d, J = 14.2 Hz, HC=CH), 4.26 
(2H, q, J = 7.1 Hz, OCH2CH3), 1.35 (3H, t, J = 7.12 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 167.3 (OC=O), 162.2 (NC=O), 148.4 (ArC q), 147.9 (ArC), 137.8 
(ArC), 136.8 (C=C), 127.4 (ArC), 123.1 (ArC), 103.3 (C=C), 60.3 (OCH2CH3), 14.4 (OCH2CH3).   
IR νmax(film)/cm
 1 3274 (s), 3034 (m), 2971 (s), 1694 (s), 1637 (s), 1498 (s), 1150 (m).   
HRMS calcd for C11H12O3N2 (M+  ): 220.0848. Found 220.0847. 
 
O O
N
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O
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(Z) 3 [((R) 2,2,5,5 Tetramethyl [1,3]dioxane 4 carbonyl) amino] acrylic acid ethyl ester, 
(78Z). 
Imide (71) (69mg) was added to a solution of ethoxycarbonylmethylene triphenylphosphorane 
in benzene as per procedure D to generate enamide (78) (89mg, 98%) as a mixture of E and Z  
isomers, E:Z ratio 3: 1.  M.V.J. Villa - 2009    87 
1H NMR (400MHz, CDCl3) δ: 11.05 (1H, bs, NH), 7.36 (1H, dd, J = 11.8, 8.9 Hz, HC=CH), 5.10 
(1H, d, J = 8.9 Hz, HC=CH), 4.14 (1H, s, CH(O)), 4.13 (2H, q, J = 7.4 Hz, OCH2CH3), 3.66 (1H, 
d, J = 11.7 Hz, CHA, HB), 3.26 (1H, d, J = 11.7 Hz, CHA, HB), 1.52 (3H, s, OCCH3), 1.40 (3H, s, 
OCCH3), 1.23 (3H, t, J = 7.2 Hz, OCH2CH3), 0.98 (3H, s, CCH3), 0.97 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 168.7 (NC=O), 168.2 (OC=O), 135.9 (C=C), 99.3 (C=C), 98.1 
(OCCH3), 76.7 (OCH2CH3), 71.3 (OCH2), 60.1 (CH(O)), 33.3 (CCH3), 29.3 (OCCH3), 21.9 
(OCCH3), 19.0 (CCH3), 18.6 (CCH3), 14.3 (OCH2CH3).   
IR νmax(film)/cm
 1 3402 (s), 3012 (s), 2992 (s), 1690 (s), 1629 (s), 1197 (s), 731 (s).   
HRMS calcd for C14H23O5N (M+  ): 285.1576. Found 285.1574. 
 
O O
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(E) 3 [((R) 2,2,5,5 Tetramethyl [1,3]dioxane 4 carbonyl) amino] acrylic acid ethyl ester, 
(78E).   
1H NMR (400MHz, CDCl3) δ: 8.35 (1H, bd, J = 11.9 Hz, NH), 7.91 (1H, dd, J = 11.9, 14.2 Hz, 
HC=CH), 5.25 (1H, d, J = 14.2 Hz, HC=CH), 4.13 (1H, s, CH(O)), 4.12 (2H, q, J = 7.1 Hz, 
OCH2CH3), 3.65 (1H, d, J = 11.8 Hz, CHA, HB), 3.25 (1H, d, J = 11.8 Hz, CHA, HB), 1.44 (3H, s, 
OCCH3), 1.38 (3H, s, OCCH3), 1.21 (3H, t, J = 7.1 Hz, OCH2CH3), 0.98 (3H, s, CCH3), 0.94 (3H, 
s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 166.9 (NC=O), 166.1 (OC=O), 134.8 (C=C), 102.1 (C=C), 98.5 
(OCCH3), 77.2 (OCH2CH3), 70.2 (OCH2), 59.1 (CH(O)), 32.3 (CCH3), 28.4 (OCCH3), 20.8 
(OCCH3), 17.8 (CCH3), 17.6 (CCH3), 13.3 (OCH2CH3).   
IR νmax(film)/cm
 1 3399 (s), 3056 (s), 2993 (s), 1716 (s), 1639 (s), 910 (s), 733 (m).  HRMS calcd 
for C14H23O5N (M+  ): 285.1576. Found 285.1572.  [α]D  +45.6 (c = 0.5, CHCl3). 
 
 
General Procedure (E) for the Synthesis of Acyclic Methyl Enamides (79 81).  A solution of n 
formyl  imide  (1.0  mmol)  in  benzene  (10  mL)  was  treated  with  1 carbethoxyethylidene M.V.J. Villa - 2009    88 
triphenylphosphorane (3.0 mmol) and the resulting mixture heated to 95
  oC for 19 hours. Upon 
reaction completion as indicated by TLC analysis, the solvent was removed under vacuum.  The 
crude residue was then purified by flash column chromatography (silica gel, 10% to 30% EtOAc in 
40 60 petroleum ether) to afford the desired enamides (79 81). 
 
N
H
O
EtO O 
 
(Z) 3 Benzoylamino 2 methyl acrylic acid ethyl ester, (79Z). 
Imide (69) (150mg) was added to a solution of 1 carbethoxyethylidene triphenylphosphorane in 
benzene as per procedure D to generate enamide (79) (205mg, 88%) as a mixture of E and Z  
isomers, E:Z ratio 5: 1. 
1H NMR (400MHz, CDCl3) δ: 11.40 (1H, d, J = 10.8 Hz, NH), 7.87 (2H, m, 2x ArH), 7.56 (1H, 
dd, J = 10.9, 1.2 Hz, HC=CH), 7.49 (1H, m, ArH), 7.42 (2H, m,2x ArH), 4.20 (2H, q, J = 7.1 Hz, 
OCH2CH3), 1.85 (3H, d, J = 1.3 Hz, =CCH3), 1.29 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 169.0 (OC=O), 168.1 (NC=O), 134.3 (ArC q). 132.3 (ArC), 131.6 
(C=C), 127.8 (ArC x2), 126.5 (ArC x2), 104.6 (C=C), 59.6 (OCH2CH3), 16.3 (OCH2CH3), 13.2 
(C=CCH3). 
IR νmax(film)/cm
 1 3335 (s), 3078 (m), 2983 (s), 1684 (s), 1649 (s), 1267 (m), 1133 (s).   
HRMS calcd for C13H15O3N (M+  ): 233.1052. Found 233.1053. 
 
N
H
O
OEt
O
 
 
(E) 3 Benzoylamino 2 methyl acrylic acid ethyl ester, (79E)  
1H NMR (400MHz, CDCl3) δ: 8.19 (1H, bd, J = 11.7 Hz, NH), 8.10 (1H, dd, J = 11.6, 1.2 Hz, 
HC=C), 7.73 (2H, m, 2x ArH), 7.45 (1H, m, ArH), 7.34 (2H, m, 2x ArH), 4.09 (2H, q, J = 7.1 Hz, 
OCH2CH3), 1.82 (3H, d, J = 1.3 Hz, =CCH3), 1.20 (3H, t, J = 7.1 Hz, OCH2CH3).   M.V.J. Villa - 2009    89 
13C NMR (100MHz, CDCl3) δ: 168.1 (OC=O), 164.5 (NC=O), 132.8 (ArC q), 132.7 (ArC), 131.9 
(C=C), 128.9 (ArC x2), 127.3 (ArC x2), 109.0 (C=C), 60.6 (OCH2CH3), 14.4 (OCH2CH3), 10.8 
(C=CCH3).   
IR νmax(film)/cm
 1 3335 (s), 3015 (s), 2983 (s), 1684 (s), 1649 (s), 1267 (m), 1133 (s).   
HRMS calcd for C13H15O3N (M+  ): 233.1052. Found 233.1053. 
 
N
N
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O
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(Z) 2 Methyl 3 [(pyridine 3 carbonyl) amino] acrylic acid ethyl ester, (80Z). 
Imide (70) (158mg) was added to a solution of 1 carbethoxyethylidene triphenylphosphorane in 
benzene as per procedure D to generate enamide (80) (175mg, 68%) as a mixture of E and Z  
isomers, E:Z ratio 41: 1. 
 
1H NMR (400MHz, CDCl3) δ: 8.64 (1H, dm, J = 4.8 Hz, ArH), 8.17 (1H, dt, J = 7.8, 1.1 Hz, ArH), 
7.82 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.49 (1H, dq, J = 11.8, 1.3 Hz, HC=C), 7.41 (1H, ddd, J = 7.6, 
4.7, 1.1 Hz, ArH), 4.25 (2H, q, J = 7.2 Hz, OCH2CH3), 1.87 (3H, d, J = 1.3 Hz, =CCH3), 1.20 (3H, 
t, J = 7.1 Hz, OCH2CH3).    
13C NMR (100MHz, CDCl3) δ: 167.9 (OC=O), 161.3 (NC=O), 147.9 (ArC q), 147.8 (ArC), 136.3 
(ArC), 132.4 (C=C), 125.8 (ArC), 122.1 (ArC), 105.9 (C=C), 59.5 (OCH2CH3), 15.5 (OCH2CH3), 
13.3 (C=CCH3).   
IR νmax(film)/cm
 1 3391 (s), 3012 (s), 2963 (s), 1694 (s), 1632 (s), 996 (s).
   
HRMS calcd for C12H14O3N2 (M+  ): 234.1004. Found 234.1007. 
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(E) 2 Methyl 3 [(pyridine 3 carbonyl) amino] acrylic acid ethyl ester, (80E). 
1H NMR (400MHz, CDCl3) δ: 9.87 (1H, d, J= 12.4 Hz, NH), 8.52 (1H, dm, J = 4.8 Hz, ArH), 8.14 
(1H, dm, J= 7.8 Hz, ArH), 8.06 (1H, dq J = 12.5, 1.3 Hz, HC=C), 7.82 (1H, td, J = 7.7, 1.6 Hz, M.V.J. Villa - 2009    90 
ArH), 7.45 (1H, ddd, J = 7.6, 4.7, 1.2 Hz, ArH), 4.15 (2H, q, J = 7.1 Hz, OCH2CH3), 1.89 (3H, d, J 
= 1.4 Hz, =CCH3), 1.22 (3H, t, J = 7.1 Hz, OCH2CH3).   
13C NMR (100MHz, CDCl3) δ: 168.2 (OC=O), 161.7 (NC=O), 148.4 (ArC q), 148.3 (ArC), 137.7 
(ArC), 131.05 (C=C), 127.2 (ArC), 123.0 (ArC), 109.9 (C=C), 60.52 (OCH2CH3), 14.43 
(OCH2CH3), 10.84 (C=CCH3).   
IR νmax(film)/cm
 1 3367 (s), 3018 (m), 2986 (s), 1692 (s), 1652 (s), 1498 (s), 1265 (m).   
HRMS calcd for C12H14O3N2 (M+  ): 234.1004. Found 234.1006. 
 
 
O O
N
H
O
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(Z) 2 Methyl 3 [((R) 2,2,5,5 tetramethyl [1,3]dioxane 4 carbonyl) amino] acrylic acid ethyl 
ester, (81Z). 
Imide (71) (186mg) was added to a solution of 1 carbethoxyethylidene triphenylphosphorane in 
benzene as per procedure D to generate enamide (81) (175mg, 65%) as a mixture of E and Z  
isomers, E:Z ratio 3: 1 
1H NMR (400MHz, CDCl3) δ: 10.9 (1H, bd, J = 12.4 Hz, NH), 7.26 (1H, dd, J = 11.5, 1.3 Hz, 
HC=C), 4.18 (2H, qd, J = 7.2, 1.4 Hz, OCH2CH3)), 4.13 (1H, s, CH(O)), 3.66 (1H, d, J = 11.7 Hz, 
CHA, HB), 3.26 (1H, d, J = 11.7 Hz, CHA, HB), 1.79 (3H, d, J = 1.3 Hz, CH3), 1.51 (3H, s, OCCH3), 
1.39 (3H, s, OCCH3), 1.25 (3H, t, J = 7.1 Hz, OCH2CH3), 0.98 (3H, s, CCH3), 0.96 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 167.6 (NC=O), 167.3 (OC=O), 131.3 (C=C), 105.5 (C=C), 98.2 
(OCCH3), 75.7 (OCH2CH3), 70.4 (OCH2), 60.1 (CH(O)), 32.2 (CCH3), 28.4 (OCCH3), 20.9 
(OCCH3), 18.0 (CCH3), 17.6 (CCH3), 15.4 (C=CCH3), 13.4 (OCH2CH3). 
IR νmax(film)/cm
 1 3410 (s), 3036 (m), 2992 (s), 1695 (s), 1652 (s).  HRMS calcd for C15H25O5N 
(M+  ): 299.1733. Found 299.1735.  [α]D  +62.1 (c = 1.1, CHCl3). 
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(E) 2 Methyl 3 [((R) 2,2,5,5 tetramethyl [1,3]dioxane 4 carbonyl) amino] acrylic acid ethyl 
ester, (81E).  
1H NMR (400MHz, CDCl3) δ: 8.25 (1H, bd, J = 12.3, NH), 7.86 (1H, dq, J = 12.3, 1.4 Hz, HC=C), 
4.14 (1H, s, CH(O)), 4.10 (2H, qd, J = 7.2, 1.2 Hz, OCH2CH3)), 3.64 (1H, d, J = 11.8 Hz, CHA, HB), 
3.22 (1H, d, J = 11.8 Hz, CHA, HB), 1.71 (3H, d, J = 1.4 Hz, =CCH3), 1.41 (3H, s, OCCH3), 1.39 
(3H, s, OCCH3), 1.25 (3H, t, J = 7.1 Hz, OCH2CH3), 0.97 (3H, s, CCH3), 0.91 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 168.0 (NC=O), 167.4 (OC=O), 130.1 (C=C), 109.2 (C=C), 99.3 
(OCCH3), 77.2 (OCH2CH3), 71.2 (OCH2), 60.5 (CH(O)), 33.2 (CCH3), 29.4 (OCCH3), 21.8 
(OCCH3), 18.8 (CCH3), 18.6 (CCH3), 14.38 (C=CCH3), 10.4 (OCH2CH3).   
IR νmax(film)/cm
 1 3410 (s), 3028 (s), 2992 (s), 1695 (s), 1652 (s).  HRMS calcd for C15H25O5N (M+ 
 ): 299.1733. Found 299.1735.  [α]D  +40.7 (c = 1.1, CHCl3). 
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(R,E) Methyl 3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate, (82E).   
A solution of   formyl imide (71) (193mg, 0.89 mmol) in benzene (10 mL) was treated with 
methyltriphenylphosphoranylidene acetate (888mg, 2.7 mmol) and the resulting mixture heated to 
95
  oC  for  19  hours.  Upon  reaction  completion  as  indicated  by  TLC  analysis,  the  solvent  was 
removed under vacuum.  The crude residue was then purified by flash column chromatography 
(silica  gel,  10% to  30%  EtOAc  in  40 60  petroleum  ether)  to  afford  the  desired  enamide  (82) 
(220mg, 91%) as a mixture of E and Z isomers, E: Z ratio 2:1. 
1H NMR (400MHz, CDCl3) δ: 8.42 (1H, bd, J = 12.0 Hz, NH), 8.01 (1H, dd, J = 12.0, 14.2 Hz, 
HC=CH), 5.62 (1H, d, J = 14.2 Hz, HC=CH), 4.22 (1H, s, CH(O)), , 3.73 (4H, m, OCH3 and CHA, M.V.J. Villa - 2009    92 
HB), 3.34 (1H, d, J = 11.8 Hz, CHA, HB), 1.54 (3H, s, OCCH3), 1.47 (3H, s, OCCH3), 1.07 (3H, s, 
CCH3), 1.03 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 167.9 (NC=O), 167.6 (OC=O), 136.2 (C=C), 102.5 (C=C), 99.6 
(OCCH3), 77.2 (OCH3), 71.3 (CH2), 51.4 (CH(O)), 33.4 (CCH3), 29.5 (OCCH3), 21.9 (OCCH3), 
18.8 (CCH3), 18.7 (CCH3).   
IR νmax(film)/cm
 1 3330 (s), 3016 (s), 2992 (s), 2954 (s), 1720 (s), 1640 (s).  HRMS calcd for 
C13H22O5N (M+H
+): 272.1498. Found 272.1494.  [α]D  +137.6 (c = 1.0, CHCl3). 
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(R,Z) Methyl 3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate, (82Z). 
1H NMR (400MHz, CDCl3) δ: 11.02 (1H, bd, J = 11.7Hz, NH), 7.37 (1H, dd, J = 9.0, 11.7 Hz, 
HC=CH), 5.11 (1H, d, J = 8.9 Hz, HC=CH), 4.15 (1H, s, CH(O)), , 3.67 (4H, m, OCH3 and CHA, 
HB), 3.26 (1H, d, J = 11.7 Hz, CHA, HB), 1.53 (3H, s, OCCH3), 1.41 (3H, s, OCCH3), 0.98 (3H, s, 
CCH3), 0.97 (3H, s, CCH3). 
13C NMR (100MHz, CDCl3) δ: 168.8 (NC=O), 168.6 (OC=O), 136.1 (C=C), 99.3 (OCCH3), 97.6 
(C=C), 77.3 (OCH3), 71.3 (CH2), 51.3 (CH(O)), 33.3 (CCH3), 29.4 (OCCH3), 21.9 (OCCH3), 19.0 
(CCH3), 18.6 (CCH3). 
IR νmax(film)/cm
 1 3325 (s), 3056 (s), 2955 (s), 1696 (s), 1629 (s).  HRMS calcd for C13H22O5N 
(M+H
+): 272.1498. Found 272.1501.  [α]D  +108.0 (c = 1.1, CHCl3).  
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(R,E) Methyl 3 (2,4 dihydroxy 3,3 dimethylbutanamido)acrylate, (83E).  
A solution of enamide (82E) (391mg, 1.44 mmol) in MeCN (12 mL) was treated with Bi (III)Cl3 
(45mg, 0.14 mmol) and H2O (4 drops) and stirred at room temperature for 3hrs. Upon completion M.V.J. Villa - 2009    93 
by TLC analysis, the reaction was quenched with NaHCO3 (2 mL) and stirred for a further 20mins. 
After this time, the mixture was filtered through Celite, dried over Na2SO4, filtered a second time, 
and then the solvent removed under vacuum. The crude residue was then purified by flash column 
chromatography (silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to afford the desired diol 
(83E) (73mg, 50%). 
1H NMR (400MHz, CDCl3) δ: 7.99 (1H, d, J = 14.2 Hz, HC=CH), 5.78 (1H, d, J = 14.2 Hz, 
HC=CH), 4.05 (1H, s, CH(O)), 3.74 (3H, s, OCH3), 3.52 (1H, d, J = 10.9 Hz, CHA, HB), 3.41 (1H, d, 
J = 10.9 Hz, CHA, HB), 0.96 (3H, s, CCH3), 0.95 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 175.1 (NC=O), 170.2 (OC=O), 138.9 (C=C), 102.5 (C=C), 77.1 
(CH(O)), 69.8 (CH2), 51.9 (OCH3), 40.8 (CCH3), 21.5 (CCH3), 20.5 (CCH3)  
IR νmax(film)/cm
 1 3291 (s), 3068 (s), 2992 (s), 1721 (s), 1670 (s), 1169 (s). HRMS calcd for 
C10H18O5N (M+H
+): 232.1185. Found 232.1184. [α]D  +131.7 (c = 1.4, CHCl3). 
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(R,Z) Methyl 3 (2,4 dihydroxy 3,3 dimethylbutanamido)acrylate, (83Z). 
A solution of enamide (82Z) (154mg, 0.57 mmol) in MeCN (6 mL) was treated with Bi (III)Cl3 
(89mg, 0.28 mmol) and H2O (4drops) and stirred at room temperature for 3hrs. Upon completion 
by TLC analysis, the reaction was quenched with NaHCO3 (1.5ml) and stirred for a further 20mins. 
After this time, the mixture was filtered over Celite, dried over Na2SO4 , filtered a second time, and 
then the solvent removed under vacuum. The crude residue was then purified by flash column 
chromatography (silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to afford the desired 
diol, (83Z). 
1H NMR (400MHz, CDCl3) δ: 7.47 (1H, d, J = 9.1 Hz, HC=CH), 5.24 (1H, d, J = 8.9 Hz, 
HC=CH), 4.09 (1H, s, CH(O)), 3.75 (3H, s, OCH3), 3.53 (1H, d, J = 10.8 Hz, CHA, HB), 3.44 (1H, d, 
J = 10.8 Hz, CHA, HB), 0.97 (3H, s, CCH3), 0.96 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 174.6 (NC=O), 170.3 (OC=O), 137.6(C=C), 98.0(C=C), 
76.7(CH(O)), 69.8 (CH2), 51.8(OCH3), 40.9(CCH3), 21.4(CCH3), 20.6(CCH3). M.V.J. Villa - 2009    94 
IR νmax(film)/cm
 1 3321 (s), 3019 (s), 2956 (s), 1721 (s), 1650 (s). HRMS calcd for C10H18O5N 
(M+H
+): 232.1185. Found 232.1188. [α]D  +120.7 (c = 1.3, CHCl3). 
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(R,E) Benzyl 3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate, (85E).   
A solution of n formyl imide (71) (2.162g, 9.9 mmol) in benzene (100 mL) was treated with 
benzyltriphenylphosphoranylidene (12.3g, 0.03 mol) and the resulting mixture heated to 95
 oC for 
19 hours. Upon reaction completion as indicated by TLC analysis, the solvent was removed under 
vacuum.  The crude residue was then purified by flash column chromatography (silica gel, 10% to 
30% EtOAc in 40 60 petroleum ether) to afford the desired enamides (85) (2.99g, 87%) as a 
mixture of E and Z isomers E: Z ratio 3: 1. 
1H NMR (400MHz, CDCl3) δ: 8.44 (1H, bd, J = 12.1, NH), 8.04 (1H, dd, J = 14.2, 12.1 Hz, 
HC=CH), 7.37 (5H, m, 5x ArH), 5.68 (1H, d, J = 14.2 Hz, HC=CH), 5.22 (2H, s, BnH), 4.23 (1H, 
s, CH(O)), 3.74 (1H, d, J = 11.8 Hz, CHA, HB), 3.34 (1H, d, J = 11.8 Hz, CHA, HB), 1.54 (3H, s, 
OCCH3), 1.48 (3H, s, OCCH3), 1.08 (3H, s, CCH3), 1.03 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 167.9 (NC=O), 166.9 (OC=O), 136.4 (C=C), 136.2 (ArC q), 128.5 
(C=C), 128.2 (2x ArC), 128.1 (2x ArC), 102.7 (ArC), 99.6 (OCCH3), 77.2 (CH(O)), 71.3 (Bn 
CH2), 66.0 (CH2), 33.4 (CCH3), 29.5 (OCCH3), 21.9 (OCCH3), 18.8 (CCH3), 18.7 (CCH3). 
IR νmax(film)/cm
 1 3332 (s), 3057(s), 2992 (s), 2959 (s), 2872 (s), 1716 (s), 1637 (s), 1496 (s).   
HRMS calcd for C19H26O5N (M+H
+): 348.1811. Found 348.1812.   
[α]D  +125.1 (c = 1.1, CHCl3). 
 
 
 M.V.J. Villa - 2009    95 
O O
N
H
O
O BnO
 
 
(R,Z) Benzyl 3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate, (85Z). 
1H NMR (400MHz, CDCl3) δ: 11.19 (1H, bd, J = 11.5, NH), 7.49 (1H, dd, J = 11.7, 9.0 Hz, 
HC=CH), 7.39 (5H, m, 5x ArH), 5.26 (1H, d, J = 8.9 Hz, HC=CH), 5.22 (2H, s, BnH), 4.25 (1H, s, 
CH(O)), 3.77 (1H, d, J = 11.7 Hz, CHA, HB), 3.37 (1H, d, J = 11.7 Hz, CHA, HB), 1.63 (3H, s, OCCH3), 
1.51 (3H, s, OCCH3), 1.09 (3H, s, CCH3), 1.08 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 168.8 (NC=O), 168.1(OC=O), 136.6 (C=C), 135.9 (ArC q), 128.6 
(2x ArC), 128.3 (C=C), 128.2 (2x ArC), 99.3 (OCCH3), 97.6 (C=C), 77.3 (CH(O)), 71.3 (CH2), 
65.9 (CH2), 33.3 (CCH3), 29.3 (OCCH3), 21.9 (OCCH3), 19.0 (CCH3), 18.6 (CCH3).   
IR νmax(film)/cm
 1 3329 (s), 3067 (s), 2992 (s), 2957 (s), 2872 (s), 1712 (s), 1692 (s).   
HRMS calcd for C19H26O5N (M+H
+): 348.1811. Found 348.1809.   
[α]D  +75.6 (c = 0.9, CHCl3) 
 
O O
N
H
O
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(R,Z) tert Butyl 3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate, (88Z).   
A solution of n formyl imide (71) (500mg, 2.3 mmol) in benzene (20 mL) was treated with t 
butoxycarbonylmethylene  triphenylphosphorane  (2.59g,  6.9  mmol)  and  the  resulting  mixture 
heated to 95
 oC for 19 hrs. Upon reaction completion as indicated by TLC analysis, the solvent was 
removed under vacuum.  The crude residue was then purified by flash column chromatography 
(silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to afford the desired enamides (88) 
(614mg, 85%) as a mixture of E and Z isomers E: Z ratio 4:1. 
1H NMR (400MHz, CDCl3) δ: 11.19 (1H, bd, J = 11.1 Hz, NH), 7.35 (1H, dd, J = 11.5, 8.9 Hz, 
HC=CH), 5.08 (1H, d, J = 9.0 Hz, HC=CH), 4.19 (1H, s, CH(O)), 3.72 (1H, d, J = 11.7 Hz, CHA, M.V.J. Villa - 2009    96 
HB), 3.32 (1H, d, J = 11.7 Hz, CHA, HB), 1.58 (3H, s, OCCH3), 1.49 (9H, s, C(CH3)3), 1.47 (3H, s, 
OCCH3), 1.05 (6H, s, 2x CCH3).  
13C NMR (100MHz, CDCl3) δ:. 168.8 (NC=O), 167.8 (OC=O), 135.1 (C=C), 99.9 (C=C), 99.2 
(OCCH3), 80.5 (C (CH3)3), 77.3 (CH(O)), 71.4 (CH2), 33.2 (CCH3), 29.3 (OCCH3), 28.3 (CH3 x2), 
21.9 (OCCH3), 19.1 (CCH3), 18.6 (CCH3).   
IR νmax(film)/cm
 1 3320 (s), 3019(s), 2980 (s), 2872 (s), 1686 (s), 1628 (s).   
HRMS calcd for C16H28O5N (M+H
+): 314.1967. Found 314.1965.   
[α]D  +85.5 (c = 1.9, CHCl3). 
 
O O
N
H
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 (R,E) tert Butyl 3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate, (88E). 
1H NMR (400MHz, CDCl3) δ: 8.46 (1H, bd, J = 11.8 Hz, NH), 7.76 (1H, dd, J = 11.7, 14.2 Hz, 
HC=CH), 5.48 (1H, d, J = 14.2 Hz, HC=CH), 4.10 (1H, s, CH(O)), 3.61 (1H, d, J = 11.8 Hz, CHA, 
HB), 3.20 (1H, d, J = 11.8 Hz, CHA, HB), 1.39 (3H, s, OCCH3), 1.38 (9H, s, C(CH3)3), 1.35 (3H, s, 
OCCH3), 0.95 (3H, s, CCH3), 0.91 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 167.9 (NC=O), 166.4 (OC=O), 134.9 (C=C), 105.1 (C=C), 99.5 
(OCCH3), 80.2 (C(CH3)3), 77.2 (CH(O)), 71.3 (CH2), 33.4 (CCH3), 29.5 (OCCH3), 28.2 (CH3 x2), 
21.9 (OCCH3), 20.2 (CH3), 18.8 (CCH3), 18.7 (CCH3) 
IR νmax(film)/cm
 1 3336 (s), 3028 (s), 2976 (s), 1709 (s), 1638 (s) 1499 (s).   
HRMS calcd for C16H28O5N (M+H
+): 314.1967. Found 314.1971.  [α]D  +105.9 (c = 1.5, CHCl3). 
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(R,E) 3 (2,4 Dihydroxy 3,3 dimethylbutanamido)acrylic acid, CJ 15,801 (30).   
A  solution  of  (R,E) tert butyl  3 (2,4 dihydroxy 3,3 dimethylbutanamido)acrylate  (33)    (195mg, 
0.62 mmol) in formic acid (7 mL) was stirred at room temperature for 90 mins. After this time, the 
excess formic acid was removed under vacuum.  The crude residue was then taken up into MeOH 
(7 mL) and p toluenesulfonic acid added (11mg, 0.062 mmol) and the resulting mixture stirred for 
75 mins. After this time, the solvent was removed under vacuum, and the crude residue purified by 
flash column chromatography (silica gel, 50% EtOAc in 40 60 petroleum ether) to afford CJ 
15,801 (33) in 20% yield. All spectral data matches literature (Org. Lett. 2004, 6, 27). 
1H NMR (400MHz, MeOD) δ: 7.94 (1H, d, J = 14.2 Hz, HC=CH), 5.69 (1H, d, J = 14.2 Hz, 
HC=CH), 4.02 (1H, s, CH(O)), 3.50 (1H, d, J = 10.9 Hz, CHA, HB), 3.38 (1H, d, J = 10.9 Hz, CHA, 
HB), 0.94 (3H, s, CCH3), 0.93 (3H, s, CCH3).  
13C NMR (100MHz, MeOD) δ: 173.4 (OC=O), 170.4 (NC=O), 137.1 (C=C), 102.1 (C=C), 75.6 
(CH(O)), 68.2 (CH2), 39.2 (CCH3), 19.9 (CCH3), 18.8 (CCH3).   
IR νmax(film)/cm
 1 3398 (br), 3011 (s), 2952 (s), 1774 (s), 1639 (s).   
HRMS calcd for C9H15O5N (M+H
+): 218.1028 Found 218.1025.   
[α]D  +58.0 (c = 0.6, MeOH). 
 
OH OH
N
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(R,E) Benzyl 3 (2,4 dihydroxy 3,3 dimethylbutanamido)acrylate, (86E) 
A solution of enamide (85E) (1.01g, 2.9 mmol) in MeCN (40 mL) was treated with Bi(III)Cl3 
(92mg, 0.29 mmol) and H2O (6drops) and stirred at room temperature for 3hrs. Upon completion 
by TLC analysis, the reaction was quenched with NaHCO3 (7ml) and stirred for a further 20mins. 
After this time, the mixture was filtered over Celite, dried over Na2SO4 filtered a second time, and 
then the solvent removed under vacuum. The crude residue was then purified by flash column M.V.J. Villa - 2009    98 
chromatography (silica gel, 10% to 50% EtOAc in 40 60 petroleum ether) to afford the desired diol 
(86E). 
1H NMR (400MHz, CDCl3) δ: 8.04 (1H, bd, J = 14.2Hz, HC=CH), 7.34 (5H, m, 5x ArH), 5.83 
(1H, d, J = 14.2Hz, HC=CH), 5.18 (2H, s, BnH), 4.11 (1H, s, CH(O)), 3.52 (1H, d, J = 10.9 Hz, 
CHA, HB), 3.42 (1H, d, J = 10.9 Hz, CHA, HB), 0.97 (3H, s, CCH3), 0.96 (3H, s, CCH3) 
13C NMR (100MHz, CDCl3) δ: 175.1 (NC=O), 169.5 (OC=O), 139.2 (ArC), 137.8 (ArC q), 129.6 
(2x ArC), 129.5 (CH(O)), 129.2 (2x ArC), 102.7 (C=C), 77.12 (C=C), 69.9 (CH2), 67.1 (CH2), 40.9 
(CCH3), 21.6 (CCH3), 20.6 (CCH3) 
IR νmax(film)/cm
 1 3327 (s), 3045 (s), 2962 (s), 1698 (s), 1634 (s).   
HRMS calcd for C16H22O5N (M+H
+): 308.1498. Found 308.1501.  
[α]D  +75.0 (c = 1.8, CHCl3). 
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(R,Z) Benzyl 3 (2,4 dihydroxy 3,3 dimethylbutanamido)acrylate, (86Z) 
A solution of enamide (85Z) (1.11g, 3.2 mmol) in MeCN (40 mL) was treated with Bi(III)Cl3 
(100mg, 0.32 mmol) and H2O (6drops) and stirred at room temperature for 3hrs. Upon completion 
by TLC analysis, the reaction was quenched with NaHCO3 (7ml) and stirred for a further 20mins. 
After this time, the mixture was filtered over Celite, dried over Na2SO4 filtered a second time, and 
then the solvent removed under vacuum. The crude residue was then purified by flash column 
chromatography (silica gel, 10% to 50% EtOAc in 40 60 petroleum ether) to afford the desired diol 
(86Z). 
1H NMR (400MHz, CDCl3) δ: 7.49 (1H, d, J = 9.0Hz, HC=CH), 7.35 (5H, m, 5x ArH), 5.26 (1H, 
d, J = 9.0Hz, HC=CH), 5.18 (2H, s, BnH), 4.11 (1H, s, CH(O)), 3.53 (1H, d, J = 10.9 Hz, CHA, HB), 
3.44 (1H, d, J = 10.9 Hz, CHA, HB), 0.97 (3H, s, CCH3), 0.96 (3H, s, CCH3)  
13C NMR (100MHz, CDCl3) δ: 174.6 (NC=O), 169.5 (OC=O), 137.8 (C=C), 137.6 (ArC q), 
129.6(2x ArC), 129.4 (2x ArC), 129.3 (CH(O)) , 98.8 (C=C), 76.8 (C=C), 69.9 (CH2), 67.0 (CH2), 
40.9 (CCH3), 21.4 (CCH3), 20.7 (CCH3) M.V.J. Villa - 2009    99 
IR νmax(film)/cm
 1 3336 (s), 3028 (s), 2962 (s), 2876 (s), 1691 (s), 1626 (s), 1189 (s).   
HRMS calcd for C16H22O5N (M+H
+): 308.1498. Found 308.1501 
 [α]D  +53.3 (c = 1.8, CHCl3) 
OH OH
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(R) 3 (2,4 Dihydroxy 3,3 dimethylbutanamido)propanoic acid, (9).   
A solution of (R,Z) benzyl 3 (2,4 dihydroxy 3,3 dimethylbutanamido)acrylate (86E) (218mg, 0.7 
mmol) in MeOH (5 mL) was treated with Pd/C (10% wt/wt). The heterogenous mixture was then 
stirred under a H2 atmosphere for 24hrs. Upon reaction completion as indicated by TLC analysis, 
the solvent was removed under vacuum.  The crude residue was found by NMR to be the desired 
pantothenate (9) in 83% yield, with no further purification necessary. 
1H NMR (400MHz, MeOD) δ: 3.92 (1H, s, CH(O)), 3.46 (4H, m, OCH2 and NCH2), 2.56 (2H, t, J 
= 6.4 Hz, CH2), 0.94 (6H, s, 2x CCH3). 
13C NMR (100MHz, CDCl3) δ: 176.1 (OC=O), 175.5 (NC=O), 77.3 (CH(O)), 70.4 (OCH2), 40.4 
(CCH3), 35.8 (NCH2), 34.8 (CH2), 21.3 (CCH3), 20.9 (CCH3).   
IR νmax(film)/cm
 1 3700 (v, br), 3023 (s), 2948 (s), 1721 (m), 1650 (s).   
HRMS calcd for C9H17O5N (M+  ): 219.1107. Found 219.1110.   
[α]D  +82.4 (c = 1.3, MeOH). 
 
 
(R) 3 (2,2,5,5 Tetramethyl 1,3 dioxane 4 carboxamido)propanoic acid, (97). 
A  solution  of  (R,Z) benzyl  3 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)acrylate  (85) 
(220mg,  6.3  mmol)  in  MeOH  (5  mL)  was  treated  with  Pd/C  (10%  wt/wt).  The  heterogenous 
mixture was then stirred under a H2 atmosphere for 24hrs. Upon reaction completion as indicated 
by TLC analysis at 24hrs, the solvent was removed under vacuum.  The crude residue was found M.V.J. Villa - 2009    100 
by NMR to be the clean, desired ketal pantothenate (97) in 85% yield, with no further purification 
necessary. 
1H NMR (400MHz, CDCl3) δ: 7.07 (1H, t, J = 6.0Hz, NH), 4.13 (1H, s, CH(O)), 3.71 (1H, d, J = 
11.7 Hz, CHA, HB), 3.56 (2H, m, NCH2), 3.30 (1H, d, J = 11.7 Hz, CHA, HB), 2.63 (2H, t, J = 6.2Hz, 
CH2),  1.48 (3H, s, OCCH3), 1.45 (3H, s, OCCH3), 1.05 (3H, s, CCH3), 0.99 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 176.7 (OC=O), 170.2 (NC=O), 99.1 (OCCH3), 77.1 (CH(O)), 71.4 
(OCH2), 34.1 (NCH2), 33.9 (CH2), 32.9 (CCH3), 29.4 (OCCH3), 22.0 (OCCH3), 18.8 (CCH3), 18.7 
(CCH3) 
IR νmax(film)/cm
 1 3420 (s), 2992 (br), 1731 (s), 1642 (s).   
HRMS calcd for C12H22O5N (M+H
+): 260.1498. Found 260.1495.   
[α]D  +104.0 (c = 1.2, MeOH). 
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(R,E) 2,2,5,5 Tetramethyl   (3 oxobut 1 enyl) 1,3 dioxane 4 carboxamide, (99).  
A  solution  of    formyl  imide  (71)  (894mg,  4.1  mmol)  in  benzene  (50  mL)  was  treated  with 
triphenylphosphoranylidene 2 propanone (3.82g, 0.012 mmol) and the resulting mixture heated to 
95
 oC for 19 hours. Upon reaction completion as indicated by TLC analysis (19hrs), the solvent was 
removed under vacuum.  The crude residue was then purified by flash column chromatography 
(silica  gel,  10% to  30%  EtOAc  in  40 60  petroleum  ether)  to  afford  the  desired  enamide  (99) 
(682mg, 65%) as the Z only isomer. 
1H NMR (400MHz, CDCl3) δ: 11.95 (1H, bd, J = 9.7, NH), 7.33 (1H, dd, J = 11.5, 8.6 Hz, 
HC=CH), 5.58 (1H, d, J = 8.6 Hz, HC=CH), 4.20 (1H, s, CH(O)), 3.72 (1H, d, J = 11.7 Hz, CHA, 
HB), 3.32 (1H, d, J = 11.7 Hz, CHA, HB), 2.23 (3H, s, O=CCH3), 1.65 (3H, s, OCCH3), 1.45 (3H, s, 
OCCH3), 1.01 (3H, s, CCH3), 1.00 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 200.6 (O=CCH3), 169.7 (NC=O), 135.1 (C=C), 105.3 (C=C), 99.3 
(OCCH3), 77.3 (O=CCH3), 71.3 (CH2), 33.3 (CCH3), 30.7 (CH(O)), 29.4 (OCCH3), 21.8 (OCCH3), 
19.0 (CCH3), 18.6 (CCH3).   M.V.J. Villa - 2009    101 
IR νmax(film)/cm
 1 3290 (s), 3011 (s), 2961 (s), 1702 (s), 1588 (s).   
HRMS calcd for C13H22O4N (M+H
+): 256.1549. Found 256.1541.   
[α]D  +120.4 (c = 1.1, CHCl3). 
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(R,E) 2,2,5,5 Tetramethyl   (3 oxobut 1 enyl) 1,3 dioxane 4 carboxamide, (101).   
A solution of n formyl imide (71) (895mg, 4.1 mmol) in benzene (50 mL) was treated with 2 
triphenylphosphoranylidene propionaldehyde (3.82g, 0.012 mmol) and the resulting mixture was 
heated to 95
  oC for 19 hrs. Upon reaction completion as indicated by TLC analysis (19hrs), the 
solvent  was  removed  under  vacuum.    The  crude  residue  was  then  purified  by  flash  column 
chromatography (silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to afford the desired 
enamide (101) (651mg, 62%) as the E only isomer. 
1H NMR (400MHz, CDCl3) δ: 9.32 (1H, s, O=CH), 8.59 (1H, bd, J = 12.0 Hz, NH), 7.58 (1H, d, J 
= 12.2 Hz, HC=C), 4.20 (1H, s, CH(O)), 3.68 (1H, d, J = 11.8 Hz, CHA, HB), 3.28 (1H, d, J = 11.8 
Hz, CHA, HB), 1.68 (3H, s, =CCH3), 1.47 (3H, s, OCCH3), 1.41 (3H, s, OCCH3), 1.01 (3H, s, CCH3), 
0.97 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 192.3 (O=CH), 167.7 (NC=O), 139.9 (C=C), 121.0 (C=CCH3), 
99.6 (OCCH3), 77.4 (CH(O)), 71.2 (CH2), 33.4 (CCH3), 29.4 (C=CH3), 21.8 (OCCH3), 18.9 
(OCCH3), 18.7 (CCH3), 7.4 (CCH3).   
IR νmax(film)/cm
 1 3403 (s), 3012 (s), 2991 (s), 2960 (s), 2873 (s), 1716 (s), 1644 (s).   
HRMS calcd for C13H22O4N (M+H
+): 256.1549. Found 256.1546.   
[α]D  +123.1 (c = 1.4, CHCl3). 
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(R,E)   (2 Cyanovinyl) 2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamide (104E).   
A  solution  of  n formyl  imide  (71)  (806mg,  3.7mmol)  in  benzene  (50  mL)  was  treated  with 
triphenylphosphoranylidene acetonitrile (3.31g, 0.01 mmol) and the resulting mixture heated to 95
 
oC for 19 hours. Upon reaction completion as indicated by TLC analysis (20hrs), the solvent was 
removed under vacuum.  The crude residue was then purified by flash column chromatography 
(silica gel, 10% to 20% EtOAc in 40 60 petroleum ether) to afford the desired conjugated enamide 
(104) (822mg, 93%) as a mixture of E and Z isomers in a 1: 6 ratio. 
1H NMR (400MHz, CDCl3) δ: 8.45 (1H, bd, J = 10.7Hz, NH), 7.50 (1H, dd, J = 10.7, 14.7 Hz, 
HC=CH), 5.15 (1H, d, J = 14.7 Hz, HC=CH), 4.12 (1H, s, CH(O)), 3.65 (1H, d, J = 11.82Hz, CHA, 
HB), 3.25 (1H, d, J = 11.81 Hz, CHA, HB), 1.45 (3H, s, OCCH3), 1.40 (3H, s, OCCH3), 1.00 (3H, s, 
CCH3), 0.95 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 167.8 (NC=O), 140.1 (C=C), 117.6 (C≡N), 99.7 (OCCH3), 81.1 
(C=C), 77.2 (CH(O)), 71.2 (OCH2), 33.5 (CCH3), 29.5 (OCCH3), 21.8 (OCCH3), 18.9 (CCH3), 
18.7 (CCH3). 
IR νmax(film)/cm
 1 3346 (s), 3025 (s), 2992 (s), 2219 (s), 1700 (s), 1623 (s). 
HRMS calcd for C12H19O3N2 (M+H
+): 239.1396. Found 239.1399.   
[α]D  +127.3 (c = 1.0, CHCl3). 
 
 
 
 (R,Z)   (2 Cyanovinyl) 2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamide, (104Z). 
1H NMR (400MHz, CDCl3) δ: 9.00 (1H, bd, J = 10.9 Hz, NH), 7.56 (1H, dd, J = 10.9, 8.9 Hz, 
HC=CH), 4.71 (1H, d, J = 8.9 Hz, HC=CH), 4.25 (1H, s, CH(O)), 3.75 (1H, d, J = 11.8Hz, CHA, HB), M.V.J. Villa - 2009    103 
3.35 (1H, d, J = 11.8 Hz, CHA, HB), 1.55 (3H, s, OCCH3), 1.50 (3H, s, OCCH3), 1.06 (3H, s, CCH3), 
1.05 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 167.8 (NC=O), 139.1 (C=C), 115.2 (C≡N), 99.7 (OCCH3), 77.5 
(C=C), 77.1 (CH(O)), 71.1 (OCH2), 33.4 (CCH3), 29.3 (OCCH3),  21.8 (OCCH3), 18.9 (CCH3), 
18.7 (CCH3)  
IR νmax(film)/cm
 1 3374 (s), 2992 (s), 2962 (s), 2210 (s), 1719 (s), 1627 (s), 1478 (s)   
HRMS calcd for C12H19O3N2 (M+H
+): 239.1396. Found 239.1400 
  [α]D  +110.8 (c = 1.3, CHCl3).  
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(R,E) 2,4 Dihydroxy 3,3 dimethyl   (3 oxobut 1 enyl)butanamide, (105). 
A solution of enamide (99) (1.0 mmol) in MeCN (10 mL) was treated with Bi (III)Cl3 (0.1 mmol) 
and H2O (3drops) and stirred at room temperature for 3hrs. Upon completion by TLC analysis, the 
reaction was quenched with NaHCO3 (4ml) and stirred for a further 20mins. After this time, the 
mixture was filtered over Celite, dried over Na2SO4 , filtered a second time, and then the solvent 
removed under vacuum. The crude residue was then purified by flash column chromatography 
(silica gel, 10% to 50% EtOAc in 40 60 petroleum ether) to afford the desired diol (105). 
1H NMR (400MHz, CDCl3) δ: 7.31 (1H, dd, J = 11.4, 8.63 Hz, HC=CH), 5.53 (1H, d, J = 8.60 Hz, 
HC=CH), 4.14 (1H, d, J = 4.7 Hz, CHA, HB), 3.87 (1H, d, J = 4.8 Hz, CHA, HB), 3.51 (2H, m, CH(O) 
and OH), 2.44 (1H, bs, OH), 2.15 (3H, s, O=CCH3),  0.98 (3H, s, CCH3), 0.92 (3H, s, CCH3). 
13C NMR (100MHz, CDCl3) δ: 200.9 (O=CCH3), 172.7 (NC=O), 135.5 (HC=CH), 105.4(HC=CH), 
78.3 (O=CCH3), 71.5(CH2), 39.4(CCH3), 30.8(CH(O)), 21.0 (CCH3), 20.4 (CCH3).   
IR νmax(film)/cm
 1 3600 (s, br), 3281 (s), 3016 (s), 2949 (s), 1702 (s), 1588 (s), 1394 (s), 1099 (s).   
HRMS calcd for C10H17NO4 (M+  ): 215.1158. Found 215.1152   
[α]D  +84.3 (c = 0.9, CHCl3). 
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(R,E)   (2 Cyanovinyl) 2,4 dihydroxy 3,3 dimethylbutanamide, (106E). 
A solution of enamide (104E) (1.0 mmol) in MeCN (10 mL) was treated with Bi(III)Cl3 (0.1 
mmol) and H2O (3drops) and stirred at room temperature for 3hrs. Upon completion by TLC 
analysis, the reaction was quenched with NaHCO3 (4ml) and stirred for a further 20mins. After this 
time, the mixture was filtered over Celite, dried over Na2SO4 , filtered a second time, and then the 
solvent  removed  under  vacuum.  The  crude  residue  was  then  purified  by  flash  column 
chromatography (silica gel, 10% to 50% EtOAc in 40 60 petroleum ether) to afford the desired diol 
(106E). 
1H NMR (400MHz, CDCl3) δ: 7.62 (1H, d, J = 14.7 Hz, HC=CH), 5.41 (1H, d, J = 14.7 Hz, 
HC=CH), 3.92 (1H, s, CH(O)), 3.49 (1H, d, J = 10.9 Hz, CHA, HB), 3.40 (1H, d, J = 10.9 Hz, CHA, 
HB), 1.31 (3H, s, CCH3), 0.95 (3H, s, CCH3).  
IR νmax(film)/cm
 1 3487 (s, br), 3140 (s), 2980 (s), 2190 (s), 1693 (s), 1580 (s).   
HRMS calcd for C9H15O3N2 (M+H
+): 199.1083. Found 199.1087.   
[α]D  +70.3 (c = 0.8, CHCl3). 
OH OH
N
H
O
N 
 
(R,Z)   (2 Cyanovinyl) 2,4 dihydroxy 3,3 dimethylbutanamide, (106Z).  
A solution of enamide (104Z) (124mg, 0.52 mmol) in MeCN (5 mL) was treated with Bi(III)Cl3 
(16mg, 0.05mmol) and H2O (2drops) and stirred at room temperature for 3hrs. Upon completion by 
TLC analysis, the reaction was quenched with NaHCO3 (4ml) and stirred for a further 20mins. 
After this time, the mixture was filtered over Celite, dried over Na2SO4 , filtered a second time, and 
then the solvent removed under vacuum. The crude residue was then purified by flash column 
chromatography (silica gel, 10% to 50% EtOAc in 40 60 petroleum ether) to afford the desired diol 
(106Z). M.V.J. Villa - 2009    105 
1H NMR (400MHz, CDCl3) δ: 9.49 (1H, bd, J = 10.8Hz), 7.60 (1H, dd, J = 12.3, 8.9 Hz), 4.72 (1H, 
d, J = 8.9 Hz), 4.27 (1H, s, CH(O)), 3.69 (1H, d, J = 10.7 Hz, CHA, HB), 3.62 (1H, d, J = 10.7 Hz, 
CHA, HB), 1.11 (3H, s, CCH3), 1.02 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 173.5 (NC=O), 140.9 (C=C), 116.5 (C≡N), 77.3 (C=C), 76.4 
(CH(O)), 69.5 (CH2), 41.1 (CCH3), 21.4 (CCH3), 20.7 (CCH3). 
IR νmax(film)/cm
 1 3366 (s, br), 2965 (s), 2932 (s), 2213 (s), 1708 (s), 1628 (s), 1251 (s).  HRMS 
calcd for C9H15O3N2 (M+H
+): 199.1083. Found 199.1087.   
[α]D  +58.2 (c = 0.9, CHCl3). 
OH OH
N
H
O
H
O
 
 
(R,E) 2,4 Dihydroxy 3,3 dimethyl   (2 methyl 3 oxoprop 1 enyl)butanamide, (107). 
A solution of enamide (101) (1.0 mmol) in MeCN (10 mL) was treated with Bi(III)Cl3 (0.1 mmol) 
and H2O (3drops) and stirred at room temperature for 3hrs. Upon completion by TLC analysis, the 
reaction was quenched with NaHCO3 (4ml) and stirred for a further 20mins. After this time, the 
mixture was filtered over Celite, dried over Na2SO4 , filtered a second time, and then the solvent 
removed under vacuum. The crude residue was then purified by flash column chromatography 
(silica gel, 10% to 50% EtOAc in 40 60 petroleum ether) to afford the desired diol (107). 
1H NMR (400MHz, CDCl3) δ: 9.35 (1H, s, O=CH), 7.76 (1H, s, C=CH), 4.19 (1H, s, CH(O)), 3.52 
(1H, d, J = 10.9 Hz, CHA, HB), 3.46 (1H, d, J = 10.9 Hz, CHA, HB), 1.69 (3H, s, C=CCH3), 1.00 (3H, s, 
CCH3), 0.98 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 194.9 (CH(O)), 173.9 (NC=O), 143.1 (C=C), 122.0 (C=CH3),76.9 
(CH(O)), 69.6 (CH2), 41.1 (CCH3), 21.5 (C=CCH3), 20.9 (CCH3), 7.5 (CCH3).  
IR νmax(film)/cm
 1 3631 (s, br), 3298 (s), 2999 (s), 1716 (s), 1669 (s).   
HRMS calcd for C10H17NO4 (M+  ): 215.1158. Found 215.1157.  
[α]D  +80.7 (c = 1.0, CHCl3). 
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(Z) 1 (2 Bromovinyl)piperidin 2 one, (114).  
A solution of bromomethyl triphenylphosphonium bromide (2.29g, 5.24mmol) in THF (8 mL) was 
stirred at  78 
oC for 5mins. KHMDS (10.5 mL, 5.24mmol) was then added dropwise, before 
stirring for a further 10mins. Imide (56) (222mg, 1.75mmol) was then added as solution in THF (2 
mL) at  78 
oC. The reaction mixture was allowed to warm to room temperature and was stirred for 
70hrs. After this time, the solvent was removed under vacuum, and the crude mixture was purified 
by flash column chromatography (silica gel, 30% EtOAc in 40 60 petroleum ether) to generate the 
halo enamide (114). 
   
1H NMR (400MHz, CDCl3) δ: 7.81 (1H, d, J = 13.2, HC=CH), 5.51 (1H, d, J = 13.2 Hz, HC=CH), 
3.23 (2H, t, J = 6.2 Hz, N CH2), 2.34 (2H, t, J = 6.6 Hz, CH2C=O), 1.71 (4H, m, 2x CH2).  
 
13C NMR (100MHz, CDCl3) δ: 167.8 (NC=O), 132.4 (C=C), 88.8 (C=C), 45.4 (NCH2), 32.8 
(O=CCH2), 22.4 (CH2), 20.5 (CH2).   
 
O O
N
H
O
OMe
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(R,2E,4E) Methyl  4 methyl 5 (2,2,5,5 tetramethyl 1,3 dioxane 4 carboxamido)  penta 2,4 
dienoate, (111).   
A solution of aldehyde (101) (58mg, 0.23 mmol) in benzene (5 mL) was treated with methyl 
triphenylphosphoranylidene acetate (152mg, 0.45 mmol) and the resulting mixture heated to 95
 oC 
for  18  hrs.  Upon  reaction  completion  as  indicated  by  TLC  analysis  (18hrs),  the  solvent  was 
removed under vacuum.  The crude residue was then purified by flash column chromatography 
(silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to afford the desired dienamide (111). M.V.J. Villa - 2009    107 
1H NMR (400MHz, CDCl3) δ: 8.59 (1H, bd, J = 11.6Hz, NH), 7.49 (1H, d, J = 15.2 Hz, HC=CH), 
6.88 (1H, d, J = 11.7 Hz, N HC=C), 5.81 (1H, d, J = 15.2 Hz, HC=CH), 4.12 (1H, s, CH(O)), 3.71 
(3H, s, OCH3), 3.66 (1H, d, J = 11.7 Hz, CHA, HB), 3.26 (1H, d, J = 11.7 Hz, CHA, HB), 1.79 (3H, s, 
=CCH3), 1.50 (3H, s, OCCH3), 1.40 (3H, s, OCCH3), 1.00 (3H, s, CCH3), 0.96 (3H, s, CCH3). 
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7  Isoprenoid Biosynthesis 
Isoprenoids are key factor in a number of different metabolic pathways. They are utilised 
in processes such as cell membrane maintenance, hormone production, protein anchoring 
and   glycosylation 
(43). Isoprenoids have shared functionalities between eukaryotes and 
prokaryotes, for example ubiquinone (118) and menaquinone (119) being utilised in 
electron transport pathways. Some isoprenoids are species specific, for example dolichol 
(120), which plays a key role in post translational modification in eukaryotes. Examples 
exist whereby different isoprenoids perform similar roles in different species. Cholesterol 
(121) in eukaryotes and hopanoids (122) in prokaryotes are both responsible for membrane 
stability. To understand whether these differences can be exploited in a drug design 
capacity, the method of biosynthesis needs to be understood.  
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Figure 5.3.1- Various isoprenoids 
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7.1 The Mevalonate Pathway 
 
For a long time the Mevalonate pathway was thought to be the only pathway for isoprenoid 
synthesis, and is considered an important metabolic pathway present in all higher 
eukaryotes, plants and many bacteria. It is responsible for the production of isopentenyl 
pyrophosphate (IPP, 129) and dimethylallyl pyrophosphate (DMAPP, 130). DMAPP and 
IPP form the base units for a range of isoprenoids 
(44). 
Acetyl CoA is acetylated by a thiolase ERG10 to generate acetoacetyl CoA (124). HMG  
CoA synthase (ERG13) then mediates the condensation reaction of acetoacetyl CoA with a 
second acetyl  CoA molecule to form 3 hydroxy 3 methylglutaryl CoA (HMG CoA) 
(125).  
HMG CoA reductase then facilitates the rate determining step of this pathway. HMG CoA 
is reduced using NADPH to mevalonate (126), the key intermediate from which the 
pathway takes its name. This reaction occurs in the cytosol. Mevalonate is then 
phosphorylated by mevalonate kinase (ERG12) to generate 5 phosphomevalonate (127). 
  
5 phosphomevalonate is then phosphorylated by phosphomevalonate kinase (ERG8) to 
yield 5 pyrophosphomevalonate (128).  
  
Pyrophosphate (128) is decarboxylated to IPP (129) by mevalonate 5 pyrophosphate 
decarboxylase, before isomerisation to DMAP (130). 
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Figure 7.1.1- The Mevalonate pathway 
 
7.2 The Non-Mevalonate Pathway 
 
A second pathway for isoprenoid biosynthesis has been identified recently 
(45). This second 
pathway has become widely referred to as the Non mevalonate pathway or 2 C methyl D 
erythritol 4 phosphate (MEP) pathway, due to the absence of mevalonate in the pathway. 
 A range of organisms utilise the MEP pathway for isoprenoid biosynthesis. These 
organisms include plants 
(46), along with many organisms responsible for disease such as: 
eubacteria (Mycobacterium tuberculosis) and Apicomplexan protozoa (Plasmodium 
falciparum) 
(47). Crucially though, this pathway is not present in higher eukaryotes 
(48). 
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Figure 7.2.1- The Non-mevalonate (MEP) pathway 
 
Thanks to the exquisite and extensive mechanistic studies of Rohmer 
(49 51) and Arigoni 
(52) 
with their respective co workers, the MEP reaction pathway is known to start with the 
coupling of pyruvate (131) and glyceraldehyde 3 phosphate (132) by DOXP synthase 
(Dxs) to DOXP (133). DOXP (133) is then converted by IspC to 2 C methyl D erythritol 
4 phosphate (MEP) (134). 
 
The next step involves the simultaneous conversion to a pyrophosphate and addition of a 
cytidine monophosphate group by IspD. Phosphorylation of the tertiary 2C hydroxyl by 
IspE generates pyrophosphate (136). Cyclisation of the pyrophosphate to the cyclic 
diphosphate MecPP (137) by IspF then occurs. 
Finally, MEcPP is converted to (E) 4 hydroxy 3 methyl but 2 enyl pyrophosphate (HMB 
PP) by IspG, and HMB PP is converted to IPP and DMAPP by HMB PP reductase IspH 
(53). M.V.J. Villa - 2009    112 
The presence of the MEP pathway in pathogenic organisms, coupled with its apparent 
absence in humans or any other agriculturally important animal, provides us with an 
attractive drug target. 
 
7.3 Validation and Characterisation 
The importance of this pathway as a drug target has been confirmed through a number of 
investigations 
(54). The generation of lethal phenotypes through knockout experiments, 
have shown the pathway to be essential for parasite survival 
(55, 56).  
Chemically, the pathway has also been shown to be a feasible drug target due to the 
inhibition of DOXP Reductase by the known antibacterial Fosmidomycin (138) 
(57 59). 
 
 
Figure 7.3.1 
 
 
 
Structural studies have resolved the structure of the pathway enzymes along with their 
substrate interactions 
(60, 61). 
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Figure 7.3.2- IspE complexed with substrate 
(60) 
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Figure 7.3.3- Interactions of IspE active site 
(60) 
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7.4 Previous syntheses 
Due to the interest in the MEP pathway as a potential drug target, a range of syntheses of 
MEP have been published, using a variety of different approaches.  
Kis K. and collaborators’ synthesis of MEP began with the sugar (139) which allowed the 
incorporation of the relevant stereochemistry from the start 
(62). 
 
 
Scheme 7.4.1 
Kis’ approach was tailored towards the introduction of radiolabelled isotopes, and no 
derivatives were reported. 
 
MEP intermediates have also been synthesised from small linear starting materials. Work 
published by Koppisch described the synthesis of MEP using a synthesis starting with from 
1 methyl ethylene glycol (142) and comprising 7 linear steps 
(63). This approach hinged 
around intermediate (143). 
 
 
Scheme 7.4.2 M.V.J. Villa - 2009    115 
 
Epoxides have also been used as key intermediates in MEP synthesis. Independent work by 
Fontana and Giner, have used a Sharpless asymmetric epoxidation to generate key epoxide 
intermediates with the relevant MEP stereochemistry in place. A regioselective opening of 
the epoxide then generates the required MEP framework 
(64, 65), in the development of 
synthetic routes towards MEP 
(66) and other pathway intermediates 
(67). 
 
 
Scheme 7.4.3 
 
Giner 
(65) utilises an acid mediated rearrangement to generate the intermediate orthoester 
(145a). The breakdown of this orthoester intermediate generates a mixture of the mono 
protected diols. 
 
Scheme 7.4.4 
 
 
Until recently the main focus was on the synthesis of MEP, due to its small size, and 
densely packed functionality. However, recently the generation of analogues has become 
the main focus. 
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7.5 Current Analogues/ Inhibitors 
With the emergence of drug resistance, the quest for new compounds for which resistance 
cannot be evolved is an ongoing one. When one pathway enzyme is knocked out, the 
parasite can develop a way round it. This can occur by single point mutations in the 
enzyme, or by utilising other enzymes to perform the task. 
 
Alongside the known syntheses of MEP, the synthesis of known MEP pathway inhibitors 
are few and far between. Only reports on Fosmidomycin (138) and its analogue FR00098 
(147) were known until recently 
(68). 
  
  
 
Figure 7.5.1- Known MEP pathway inhibitors 
 
 
Coates and colleagues 
(69, 70) have reported a new synthesis of MEP (134), along with the 
pyrophosphate (137), and two analogues (149 and 150). This approach relies on the 
dioxanone derived key intermediate (148). 
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Figure 7.5.2- MEP pathway intermediates/ inhibitors currently synthesised 
 
A number of collaborators have also started to exploit the abundance of crystal structure 
data to begin to generate inhibitors based on analogues of the cytidyl group present in the 
substrate for IspE 
(71). 
Our group recently published the synthesis of 2 fluoro MEP (151) 
(72) and the conjugated 
analogue (152). This approach took advantage of a key epoxide intermediate (144). 
Analogue (152) has been successfully co crystallised with IspC (unpublished data).  
 
 
Scheme 7.5.1 
 
Efforts in our group have been focussed on targeting Isp D, Isp E, and Isp F using C 2 
isosteres for the MEP 2 hydroxy group. 
The reason behind this is the availability of crystallographic data for these three enzymes, 
along with the pathway implications they present. M.V.J. Villa - 2009    118 
In our approach towards MEP inhibitors, we reasoned that a hydroxyl group isostere at the 
C2 position could potentially inhibit Isp E from the outset. Failing that, the resemblance of 
the compound to MEP would potentially allow it to be turned over by Isp E and F to 
generate the corresponding cyclic diphosphate. This diphosphate could then in turn act as 
an inhibitor for Isp G and H enzymes. 
We were therefore keen to see if one compound could act as an inhibitor in 3 consecutive 
enzymes, and possibly reduce the chances of resistance developing.  
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8  Synthesis of 2, 2-Dimethyl MEP 
Our initial target for an MEP analogue was the replacement of the MEP 2 hydroxy group 
with a methyl isostere.We reasoned that this would provide us with a compound that 
resembled MEP in spatial size, with no ability to be phosphorylated by Isp E. The 
synthesis would also allow the later generation of MEP from the same intermediate, 
epoxide (145). 
 
 
Scheme 7.5.1 
 
Our synthesis began with the protection of readily available PMB alcohol as the allyl ether 
(153) in excellent yield. Ozonolysis of allyl ether (153) afforded the aldehyde (154), again 
in good yield. Wittig olefination of aldehyde (154) using ylide (155) generated the E 
conjugated ester (156) as a single diastereomer. 
 
 
Scheme 7.5.2 
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Scheme 7.5.3 
 
Lithium aluminium hydride reduction of ester (156) generated the required allylic alcohol 
(157) in good yield. 
Finally, epoxidation of the allylic alcohol (157) under Sharpless Assymetric Epoxidation 
conditions 
(72) afforded the epoxyalcohol (145) in good yield and good e.e. 
8.1 Epoxide Opening 
Based on literature examples 
(72) the decision was made to attempt the generation of a 2,2 
dimethyl analogue by opening the epoxide directly.  
Our approach towards the desired 2,2  dimethyl analogue commenced with the attempted 
opening of epoxide (145) using Me3Al, under a number different conditions 
(73, 74), to the 
2,2 dimethyl MEP analogue (158). 
 
 
Scheme 8.1.1 
 
Disappointingly, continued adaptation of these conditions returned either starting material 
or a mixture of degraded products of no further interest. M.V.J. Villa - 2009    121 
Due to the investigation into the synthesis of CJ 15,801, the existence of the commercially 
available (S) (+) pantolactone, was recognised as having the required methyl and hydroxyl 
groups in the correct stereochemistry for a 2,2 dimethyl MEP analogue. 
  
Although the correct stereochemistry for MEP is provided by (S) (+) pantolactone, the 
relative expense of this compound in relation to its (R) ( ) enantiomer meant establishing 
the synthetic route with (R) ( ) pantolactone, and subsequently applying this to the more 
expensive (S) (+) enantiomer. 
 
To access the corresponding alcohol intermediate (161) needed for 2,2 DMEP generation, 
ketal amide (34) was resynthesized using the same conditions as before 
(75). (D ) 
pantolactone (19) was opened using liquid ammonia, and the resulting diol was protected 
as the ketal (34). Amide (34) was then dehydrated using cyanuric chloride to generate the 
nitrile (159). Unfortunately the reaction proceeded in too low yield to generate enough 
nitrile to attempt the reduction to aldehyde (160).  
 
 
Scheme 8.1.2 
 
We were keen to access the aldehyde (160), as it would provide us a handle for a further 
range of analogues through relatively simple approaches. M.V.J. Villa - 2009    122 
 
Figure 8.1.1 
 
It  was  reasoned  that  the  low  yield  encountered  during  the  dehydration  step  could  be 
accounted for by the small size of the nitrile produced (159), and its likely volatility during 
solvent removal under vacuum. Therefore, a decision was made to increase the molecular 
weight of the molecule, in an attempt to reduce its volatility. 
 
 
Scheme 8.1.3 
 
Our modified approach began with opening (D) ( ) pantolactone with liquid ammonia, and 
the resulting diol intermediate was protected using cyclohexanone diethyl acetal to 
generate the bulkier cyclohexyl ketal (164) in good yield.  
Faced with the low yield of the cyanuric chloride dehydration, an alternative dehydration 
procedure was required. Claremon and Phillips 
(76) report the use of M.V.J. Villa - 2009    123 
methoxycarbonylsulfamoyl triethylammonium hydroxide inner salt (Burgess Reagent) to 
dehydrate amides. However, although a greatly improved yield over our previous cyanuric 
chloride dehydration, the high expense of Burgess Reagent meant its long term use was not 
feasible. We therefore returned to the previously used cyanuric chloride approach. 
Dehydration of the amide (164) to the nitrile (165) was achieved in improved yield. 
With the successful generation of nitrile (165), focus was returned to reducing to the 
aldehyde (166) in good yield 
(77). 
 
Scheme 8.1.4 
 
Although the yield for this approach was acceptable, it still involved a significant number 
of steps. A new approach was based on work of Oniciu and colleagues 
(78), who reported 
the conversion of pantolactone (19) to the corresponding ester (168), in a single step and in 
good yield.  
 
 
Scheme 8.1.5 
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Treatment of (D) ( ) pantolactone with benzaldehyde dimethyl acetal successfully 
generated ester (168), which was then subsequently reduced with LAH to afford the alcohol 
(169) in reasonable yield over the 2 step sequence.  
 
 
Scheme 8.1.6 
 
 
Advantages of this approach over the previous one include the fact that there are less steps 
involved to generate the alcohol (169) or its corresponding aldehyde. The structure of ester 
(168) was corroborated using X ray analysis. 
 
Figure 8.1.2- Crystal structure ester (168) 
 
Alcohol (169) was then phosphorylated in a single step using conditions 
(72) previously 
used in our group, to generate diethyl phosphate (171).  M.V.J. Villa - 2009    125 
 
 
Scheme 8.1.7 
 
Having successfully generated the phosphate (171), the same synthetic sequence was 
applied to (S) (+) pantolactone, providing the correct enantiomer for 2,2 DMEP. 
 
 
Scheme 8.1.8 
 
Unfortunately, due to time constraints, the global deprotection of diethyl phosphates (171) 
and (174) could not be explored to our satisfaction. This was considered unfortunate, as we M.V.J. Villa - 2009    126 
are confident the synthesis of this potential MEP pathway inhibitor can be completed 
shortly. 
 
8.2 Other analogues 
 
In addition to the generation of MEP analogues at the 2  hydroxy position, the 
modification of the phosphate unit was explored. 
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Scheme 8.2.1 
 
Our synthesis of the new analogues began with the Swern oxidation of alcohols (169) and 
(173) to provide the corresponding aldehydes (175 and 176) in good yield. As discussed 
earlier, these aldehyde units could be key intermediates for the parallel generation of 
analogues. M.V.J. Villa - 2009    127 
Our initial analogue target was the phosphonate (177) due to its potential ability to undergo 
irreversible bonding through a Michael like addition process, not dissimilar to the enamide 
examples discussed earlier. Aldehyde (175) was reacted with tetraethylmethylene 
diphosphonate to successfully generate the protected phosphonate (177) in reasonable 
yield. 
 
 
Scheme 8.2.2 
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9  Synthesis of MEP 
Simultaneous to the 2,2 DMEP synthesis, a parallel approach to the synthesis of MEP itself 
was investigated.  
 
 
Scheme 8.2.1 
 
We envisioned MEP as the result of a regioselective opening of an epoxide (Scheme 
8.2.1). Our synthesis began with the previously synthesised epoxide (145) which was 
treated with NaI and CO2 
(79). It was envisioned that epoxide (145) would be initially 
opened at the least hindered position by NaI to generate alkoxide (178). Alkoxide (178) 
would then trap the CO2 present in the reaction, to generate anion (179) which would then 
perform an intramolecular SN2 reaction to generate carbonate (180). 
 
 
Scheme 8.2.2 
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More traditional epoxide opening methods were also investigated but failed to open the 
epoxide. NH4OAc and Ti iOPr 
(80) and H
+ /H2O 
(81). 
 
9.1 Opening epoxides via NGP 
Faced with the failure of intermolecular methods to generate the desired erythrol, our 
modified approach considered the incorporation of an additional functional group, which 
could be utilised in a Neighbouring Group Participation epoxide opening. 
 
 
Scheme 9.1.1 
 
Previous reports have shown that epoxides can be opened selectively under Lewis Acid 
mediated conditions to their corresponding carbonates 
(82 85). 
Epoxy alcohol (145) was treated with phenyl isocyanate to generate the carbamate (181). 
Gratifyingly, cyclisation in the presence of diethylaluminiumchloride generated the 
carbonate (182). 
 
 
Scheme 9.1.2 M.V.J. Villa - 2009    130 
Mechanistically, the reaction proceeds through the intramolecular attack of the carbamate 
carbonyl on the Lewis Acid coordinated epoxide, to generate imine (183). Acid hydrolysis 
of the imine affords the carbonate (182). 
 
 
Scheme 9.1.3 
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10  Conclusions and Further Work 
The synthesis of 2, 2 DMEP from a lactone has been started, alongside the initial 
investigation into the generation of previously unpublished MEP pathway inhibitors.  
A parallel synthesis of MEP has also been initiated. By utilising neighbouring group 
participation, the ability to open the key epoxide intramolecularly under Lewis Acid 
conditions has been demonstrated and has opened up the opportunity to use this 
methodology to generate MEP and further 2 hydroxy isosteres. The key intermediate in 
this approach has all stereocentres in place and differentially protected hydroxyl groups. 
10.1 Further Work: MEP 
Having successfully generated carbonate (182) we were then keen to progress to the latter 
stages of our proposed approach. 
The generation of carbonate (182) proved to be a key intermediate in our approach to 
MEP. Although time constraints prevented us from moving this synthesis further forward, 
we reasoned we could follow literature methods already established within the group 
(72) to 
complete the transformation of the carbonate (182) to the final compound MEP (134). 
 
 
Scheme 10.1.1 
 
After the successful opening of the epoxide using NGP and Lewis acid conditions, we 
would like to explore the introduction of an amine isostere at the C 2 position. This could M.V.J. Villa - 2009    132 
be performed by protecting the epoxyalcohol (145) as the trichloroacetimidate (187). 
Rearrangement under Lewis acid conditions would then afford the amine (189) via the 
intermediate (188).  
 
 
Scheme 10.1.2 
 
10.2 Further Work: 2,2- DMEP 
Molecular modelling studies carried out in the Hunter group at the University of Dundee, 
has suggested that a number of amines could be potential cytidyl mimics (Fig 10.2.1).  
 
 
Figure 10.2.1 
 
Preliminary data suggests that when aldehyde (166) was stirred with 1 piperonylpiperazine 
and sodium triacetoxyborohydride the amine (190) is generated in reasonable yield. 
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Scheme 10.2.1 
 
Therefore, we would like to explore the generation of further amines utilising reductive 
amination conditions 
(86). These new conditions could be used to generate a range of 
amines (Fig 10.2.2) from their corresponding, commercially available amines (Fig 10.2.2), 
selected for their potential as cytidyl mimics.  
 
Figure 10.2.2- Potential cytidyl mimics available for reductive aminations M.V.J. Villa - 2009    134 
 
11  Section B: Experimental 
General Information.  As in Section A experimental. 
 
O
H3CO
 
 
1 (Allyloxymethyl) 4 methoxybenzene, (153).  
A solution of 1 (allyloxymethyl) 4 methoxybenzene (6.96g, 0.05 mol) in THF (20 mL) was added 
to a suspension of previously washed sodium hydride as a 60% oil dispersion, (3.2g, 0.08 mol) in 
dry THF (150 mL) at 0 
oC, and the mixture was stirred for 30 min. The reaction mixture was 
cooled to 0 
oC before addition of allyl bromide (12.99 mL, 0.15mol) and tetrabutylammonium 
iodide (0.93g, 2.52 mmol). The reaction was allowed to warm up to room temperature and was then 
stirred overnight. The reaction mixture was then extracted with DCM (200 mL) and water (100 
mL). The organic layer was dried over Na2SO4, filtered, and the solvent evaporated to give 1 
allyloxymethyl 4 methoxybenzene (153) (8.8g, 98%). 
Spectral data matches those of literature reportings Org. Biomol. Chem 2007, 5, 97 102. 
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2 (4 Methoxybenzyloxy)acetaldehyde, (154).  
A solution of 1 allyloxymethyl 4 methoxybenzene (153) (12.3g, 0.07 mol) in DCM (300 mL), was 
treated with ozone at −78 
oC until the blue colour of ozone remained. At this point, argon was 
bubbled through until the blue colour disappeared. Methyl sulfide (102 mL, 1.38 mol) was then 
added to the solution and the resulting mixture stirred until TLC analysis indicated reaction 
completion (13hrs). The solvents were evaporated under vacuum, and the crude residue purified by M.V.J. Villa - 2009    135 
flash column chromatography (silica gel with 20 30% EtOAc in 40 60 petroleum ether)) to 
generate the desired aldehyde (154) as clear yellow oil (9.14g, 72%). 
Spectral data matches those of literature reportings Org. Biomol. Chem 2007, 5, 97 102.   
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(E) Ethyl 4 (4 methoxybenzyloxy) 2 methylbut 2 enoate, (156).   
A solution of 2 (4 methoxybenzyloxy)acetaldehyde (154) (9.14g, 0.05mol) in toluene (300 mL) 
was treated with (carbethoxyethylidene) triphenylphosphorane (36.5g, 0.10 mol) and was refluxed 
overnight. The solvent was evaporated under vacuum, and the crude residue washed with diethyl 
ether. The mixture was then filtered to remove the solid triphenylphosphine oxide, and the filtrate 
was then evaporated under vacuum. Any remaining triphenylphosphine was removed by flash 
column chromatography (silica gel with 20 30% EtOAc in 40 60 petroleum ether)) to give (E) 
ethyl 4 (4 methoxybenzyloxy) 2 methylbut 2 enoate (156) as the single E isomer (9.75g, 73%). 
Spectral data matches those of literature reportings Org. Biomol. Chem 2007, 5, 97 102.  
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(E) 4 (4 Methoxybenzyloxy) 2 methylbut 2 en 1 ol, (157).  
Lithium Aluminium Hydride (24.3 mL, 0.03mol) was added to a solution of (E) ethyl 4 (4 
methoxybenzyloxy) 2 methylbut 2 enoate (156) (6.65g, 0.025mol) in dry ether (80 mL) at 0 
oC, 
and the resulting reaction mixture was stirred at 0 
oC for 1 hr. Water (0.75 mL), NaHCO3 (0.75ml) 
and water (2.5 mL) was added slowly, and the resulting white precipitate stirred for 1 hr at room 
temperature. The crude mixture was purified by flash column chromatography (silica gel with 10 
20% EtOAc in 40 60 petroleum ether to afford (E) 4 (4 methoxybenzyloxy) 2 methylbut 2 en 1 ol 
as a light yellow oil (157) (4.81g, 86%).  M.V.J. Villa - 2009    136 
Spectral data matches those of literature reportings Org. Biomol. Chem 2007, 5, 97 102. 
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((2S,3S) 3 ((4 Methoxybenzyloxy)methyl) 2 methyloxiran 2 yl)methanol, (145).  
Diisopropyl D tartrate (0.11 mL, 0.52 mmol) and titanium (IV) isopropoxide (0.15 mL, 0.49 
mmol) were added to a flask charged with activated powdered 4 A˚ molecular sieves (3 g) in dry 
dichloromethane (2 mL) at −23 
oC. The mixture was stirred while tert butyl hydroperoxide (0.57 
mL, 3.11mmol) in dry dichloromethane (2 mL) was added dropwise, and the resulting solution was 
stirred for 30 min at −23 ◦C. A solution of (E) 4 (4 methoxybenzyloxy) 2 methylbut 2 en 1 ol 
(157) (316mg, 1.42 mmol) in dry dichloromethane (2 mL) was then added slowly, and the resulting 
reaction mixture was stirred for 6 hrs at −23 
oC. The reaction was then quenched with water (11.9 
g; 20 times the weight of the titanium(IV) isopropoxide used) and was stirred for a further 40 min, 
while allowing the suspension to warm to room temperature. To hydrolyse the tartrate, a 30% 
aqueous solution of sodium hydroxide saturated with sodium chloride was added and the biphasic 
mixture was stirred vigorously for 30 min. The mixture was filtered through a pad of silica and 
Celite to break up the emulsion, and the phases were separated. The aqueous phase was extracted 
with DCM (2 × 10 mL), the combined organic extracts were dried over Na2SO4 and the filtrate was 
evaporated under vacuum. The residue was purified by flash chromatography on silica gel eluting 
with (silica gel with 25 40% EtOAc in 40 60 petroleum ether) to give [3 (4 
methoxybenzyloxymethyl) 2 methyloxiranyl] methanol (145) (213mg, 64%, .90% e.e). 
Spectral data matches those of literature reportings Org. Biomol. Chem 2007, 5, 97 
102. 
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(R) 3,3 Dimethyl 1,5 dioxaspiro[5.5]undecane 2 carboxamide, (164).  
p Toluenesulphonic acid (516mg, 0.003mol) was added to a solution of amide (5.0g, 0.03mol) in 
DCM (80 mL). Cyclohexanone diethyl acetal was added (16.1 mL, 0.08mol). The reaction 
mixture was stirred at RT for 4.5hrs. The solvent was removed under vacuum, and the resulting oil 
was purified by flash column chromatography (silica gel with 30 50% EtOAc in 40 60 petroleum 
ether to afford (R) 3,3 dimethyl 1,5 dioxaspiro[5.5]undecane 2 carboxamide (164) as a white solid 
(4.52g, 66%).  
1H NMR (400MHz, CDCl3) δ: 6.47 (1H, bs, NHA, HB), 5.64 (1H, bs, NHA, HB), 4.06 (1H, s, CH(O)), 
3.66 (1H, d, J = 11.7 Hz, CHA, HB), 3.21 (1H, d, J = 11.7 Hz, CHA, HB), 1.81 (2H, m, CH2), 1.63 (2H, 
m, CH2), 1.53 (2H, m, CH2), 1.37 (4H, m, 2x CH2), 1.00 (3H, s, CCH3), 0.97 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 172.8 (NC=O), 99.2 (OCO), 76.5 (CH(O)), 70.7 (OCH2), 38.3 
(CH2), 33.1 (CCH3), 27.3 (CH2), 25.6 (CH2), 22.7 (CH2), 22.4 (CH2), 22.1 (CCH3), 19.1 (CCH3).   
IR νmax(film)/cm
 1 3323 (s), 2978 (s), 1730 (s).   
HRMS calcd for C12H21NO3 (M+H
+): 227.1521 Found 228.1604.   
[α]D  +204.4 (c = 1.0, CHCl3) 
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(R) 3,3 Dimethyl 1,5 dioxaspiro[5.5]undecane 2 carbonitrile, (165). 
A solution of Cyanuric chloride (156mg, 0.085mmol) in t butylmethylether (5 mL) was added to a 
solution of (R) 3,3 dimethyl 1,5 dioxaspiro[5.5]undecane 2 carboxamide (164) (193mg, 
0.85mmol) in DMF (5 mL). The reaction mixture was stirred for 16 hrs. The reaction mixture was 
neutralised with 28% NaOH (8 mL). The crude mixture was extracted with TBME (10 mL) and M.V.J. Villa - 2009    138 
water (10 mL). The organic layers were combined and dried over Na2SO4, and filtered. The solvent 
was removed under vacuum, and the resulting oil was purified by flash column chromatography 
(silica gel with 10 20% EtOAc in 40 60 petroleum ether to afford 3,3 dimethyl 1,5 
dioxaspiro[5.5]undecane 2 carbonitrile as a clear oil (165) (116mg, 65%). 
1H NMR (400MHz, CDCl3) δ: 4.53 (1H, s, CH(O)), 3.66 (1H, d, J = 11.9 Hz, CHA, HB), 3.48 (1H, d, 
J = 11.8 Hz, CHA, HB), 1.84 (2H, m, CH2), 1.74 (2H, m, CH2), 1.60 (2H, m, CH2), 1.46 (4H, m, 2x 
CH2).   
13C NMR (100MHz, CDCl3) δ: 116.7 (C≡N), 100.1 (OCO), 68.7 (OCH2), 68.6 (CH(O)), 42.0 
(CH2), 36.9 (CH2), 33.2 (CCH3), 27.9 (CH2), 25.4 (CH2), 22.3 (CH2), 21.6 (CCH3), 19.9 (CCH3).   
IR νmax(film)/cm
 1 2995(s), 2250 (s).   
HRMS calcd for C12H19NO2 (M+  ): 209.1416. Found 209.1419.   
[α]D  +12.9 (c = 1.3, CHCl3). 
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(R) 3,3 Dimethyl 1,5 dioxaspiro[5.5]undecane 2 carbaldehyde, (166).  
Dibal (0.62 mL, 0.61mmol) was added to a solution of 3,3 dimethyl 1,5 dioxaspiro[5.5]undecane 
2 carbonitrile (165) (116mg, 0.55mmol) in dry ether (5 mL) at 0 
oC, and the resulting reaction 
mixture was stirred at 0 
oC for 1 hr. The reaction mixture was allowed to warm to RT over 16 hrs. 
The reaction was worked up with Rochelles salt (2 mL), and the resulting white precipitate stirred 
for 1 hr at room temperature. The crude mixture was purified by flash column chromatography 
(silica gel with 10 20% EtOAc in 40 60 petroleum ether to afford 3,3 dimethyl 1,5 
dioxaspiro[5.5]undecane 2 carbaldehyde as a clear oil (166) (66mg, 57%). 
1H NMR (400MHz, CDCl3) δ: 9.58 (1H, s, O=CH), 3.96 (1H, s, CH(O)), 3.71 ((1H, d, J = 11.5 Hz, 
CHA, HB), 3.26 (1H, d, J = 11.5 Hz, CHA, HB), 1.86 (2H, m), 1.73 (2H, m), 1.62 (2H, m), 1.44 (4H, m), 
1.12 (3H, s, CCH3), 0.95 (3H, s, CCH3)  M.V.J. Villa - 2009    139 
13C NMR (100MHz, CDCl3) δ: 212.9 (O=CH), 76.5 (OCH2), 75.8 (CH(O)), 69.3 (OCO), 43.9  
(CCH3), 41.9 (CH2), 27.0 (CH2), 24.9 (CH2), 22.9 (CH2), 22.1 (2x CH2), 21.9 (CH3), 18.8 (CH3).  
IR νmax(film)/cm
 1 2982 (s), 2854 (s), 1752 (s).  HRMS calcd for C12H20O3 (M+  ): 212.1412. Found 
212.1417.  [α]D   5.091 (c = 1.1, CHCl3). 
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(4S) Methyl 5,5 dimethyl 2 phenyl 1,3 dioxane 4 carboxylate, (168).   
A solution of pantolactone (19) (1.99g, 0.015mol) and benzaldehyde dimethyl acetal (3.9 mL, 
0.026mol) in dioxane (5 mL) was treated with p toluenesulphonic acid (58mg, 0.3 mmol) and the 
resulting mixture stirred at room temperature for 48hrs. Upon reaction completion as indicated by 
TLC analysis, the reaction was quenched with NaHCO3 (2 mL) and stirred for a further 3hrs. After 
this time the the solution was diluted with Et2O (15 mL), washed with NaHCO3 (5 mL) and H2O 
(10 mL) and brine (5 mL). The organic layer was separated and dried over Na2SO4, filtered, and the 
solvent  was  removed  under  vacuum.    The  crude  residue  was  then  purified  by  flash  column 
chromatography (silica gel, 10% EtOAc in 40 60 petroleum ether) to afford the desired ester (168) 
(1.39g, 37%). 
1H NMR (400MHz, CDCl3) δ: 7.58 (2H, dd, J = 7.6, 1.6 Hz, ArH x2), 7.40 (3H, m, 3x ArH), 5.54 
(1H, s, OCHO), 4.31 (1H, s, CH(O)), 3.81 (3H, s, OCH3), 3.80 (1H, d, J = 11.2 Hz, CHA, HB), 3.73 
(1H, d, J = 11.2 Hz, CHA, HB), 1.25 (3H, s, CCH3), 1.03 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 169.2 (OC=O), 137.7 (ArC q), 129.1 (ArC), 128.3 (2x ArC), 126.4 
(2x ArC), 101.6 (OCO), 83.9 (CH(O)), 78.3 (OCH2), 51.8 (OCH3), 32.9 (CCH3), 21.7 (CCH3), 19.6 
(CCH3).   
IR νmax(film)/cm
 1 2959 (s), 2873 (s), 1735 (s), 1395 (s), 1371 (s).   
HRMS calcd for C14H19O4 (M+H
+): 251.1283. Found 251.1280.   
[α]D   40.2 (c = 1.7, CHCl3). M.V.J. Villa - 2009    140 
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(4S) (5,5 Dimethyl 2 phenyl 1,3 dioxan 4 yl)methanol, (169).   
A solution of ester (168) (1.12g, 4.5mmol) in diethylether (30 mL) was cooled to 0
oC before being 
treated with LiAlH4 (1.0M diethylether) (16 mL, 0.016mol). The mixture was stirred at 0
oC for 
10mins, warmed to room temperature and stirred for a further 2hrs. Upon reaction completion as 
indicated by TLC analysis, the reaction was quenched with the addition of H2O (1 mL), 15% 
NaOH (1 mL), and H2O (3 mL). The organic layer was extracted with ether (2x 20 mL) and the 
solvent  was  removed  under  vacuum.    The  crude  residue  was  then  purified  by  flash  column 
chromatography (silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to generate the desired 
alcohol (169) (652mg, 65%) 
1H NMR (400MHz, CDCl3) δ: 7.41 (2H, dd, J = 7.6, 1.8 Hz, ArH x2), 7.26 (3H, m, 3x ArH), 5.35 
(1H, s, OCHO), 3.48 (5H, m, 2x CH2 and CH(O)), 2.55 (1H, bs, OH), 0.98 (3H, s, CCH3), 0.68 
(3H, s, CCH3). 
13C NMR (100MHz, CDCl3) δ: 138.3 (ArC  q), 129.1 (ArC), 128.4 (2x ArC), 126.3 (2x ArC), 
102.1 (OCO), 85.9 (CH(O)), 78.9 (HOCH2), 61.6 (OCH2), 31.6 (CCH3), 21.4 (CCH3), 19.2 (CCH3)  
IR νmax(film)/cm
 1 3442 (br), 2958 (s), 2850 (s), 1393 (s). 
HRMS calcd for C13H19O3 (M+H
+): 223.1334. Found 223.1333.   
[α]D  +19.3 (c = 1.6, CHCl3). 
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(4S) (5,5 Dimethyl 2 phenyl 1,3 dioxan 4 yl)methyl diethyl phosphate, (171).  
Iodine (145mg, 0.6 mmol) was added to a solution of triethyl phosphite (0.11 mL, 0.67 mmol) in 
dry DCM (2 mL) at 0 
oC, and the solution was stirred for 20 min at 0 
oC and then for 1 hr at room 
temperature. The freshly made phosphorylation agent was then added slowly to a roundbottomed 
flask containing 5,5 dimethyl 2 phenyl 1,3 dioxan 4 yl)methanol (169) (124mg, 0.6 mmol) and 
pyridine (0.18 mL, 2.2 mmol) in dry DCM (3 mL) at −40 
oC. The reaction was allowed to warm up 
to room temperature and stirred for 4 hr. The mixture was then washed with a solution of 3% 
KHSO4 (5 mL), saturated NaHCO3 (5 mL), and brine (5 mL). The organic layer was then extracted 
with DCM (2x 10 mL) dried over Na2SO4 and the solvent was removed under vacuum. The crude 
residue was then purified by flash chromatography on silica gel eluting with 20 30% EtOAc in 40 
60 petroleum ether  to give the expected phosphoric acid 5,5 dimethyl 2 phenyl 1,3 dioxan 4 
yl)methyl diethyl phosphate (171) (215mg, 30%). 
 
1H NMR (400MHz, CDCl3) δ: 7.52 (2H, dd, J = 7.5, 1.9 Hz, ArH x2), 7.37 (3H, m, 3x ArH), 5.52 
(1H, s, OCHO), 4.21 (1H, ddd, J = 11.1, 6.1, 2.7 Hz, (CHC, HD), 4.10 (5H, m, 2 x POCH2CH3 and 
CHC, HD), 3.89 (1H, dd, J = 7.9, 2.6 Hz, CH(O)), 3.72 (1H, d, J = 11.2 Hz, CHA, HB), 3.66 (1H, d, J = 
11.3 Hz, CHA, HB), 1.22 (3H, dt, J = 7.1, 1.0 Hz, POCH2CH3), 1.18 (3H, dt, J = 7.1, 1.0 Hz,  
POCH2CH3), 1.17 (3H, s, CCH3), 0.91 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 138.2 (ArC q), 128.9 (ArC), 128.2 (2x ArC), 126.2 (2x ArC), 101.8 
(OCO), 83.8 (CH(O)), 78.7 (OCH2), 66.7 (OCH2CH3), 66.6 (OCH2CH3), 63.9 (OCH2CH3), 31.7 
(CCH3), 21.5 (CCH3), 18.9 (CCH3), 16.1 (OCH2CH3), 16.0 (OCH2CH3). 
IR νmax(film)/cm
 1 2980 (s), 2910 (s), 2872 (s), 1468 (s).   
HRMS calcd for C17H28O6P (M+H
+): 359.1624. Found 359.1621.   
[α]D  +51.8 (c = 2.0, CHCl3). M.V.J. Villa - 2009    142 
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(4R) Methyl 5,5 dimethyl 2 phenyl 1,3 dioxane 4 carboxylate, (172).   
A solution of pantolactone (19b) (1.03g, 8mmol) and benzaldehyde dimethyl acetal (1.95 mL, 
0.013mmol) in dioxane (5 mL) was treated with p toluenesulphonic acid (30mg, 0.16mmol) and 
the resulting mixture stirred at room temperature for 48hrs. Upon reaction completion as indicated 
by TLC analysis, the reaction was quenched with NaHCO3 (2 mL) and stirred for a further 3hrs. 
After this time the the solution was diluted with Et2O (10 mL), washed with NaHCO3 (5 mL), H2O 
(5 mL) and brine (5 mL). The organic layer was separated and dried over Na2SO4, filtered, and the 
solvent  was  removed  under  vacuum.    The  crude  residue  was  then  purified  by  flash  column 
chromatography (silica gel, 10% EtOAc in 40 60 petroleum ether) to afford the desired ester (172) 
(1.00g, 50%). 
1H NMR (400MHz, CDCl3) δ: 7.55 (2H, dd, J = 7.7, 1.8 Hz, ArH x2), 7.36 (3H, m, 3x ArH), 5.49 
(1H, s, OCHO), 4.27 (1H, s, CH(O)), 3.76 (1H, d, J = 11.3 Hz, CHA, HB), 3.75 (3H, s, OCH3),  3.68 
(1H, d, J = 11.3 Hz, CHA, HB), 1.21 (3H, s, CCH3), 0.99 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 169.2 (OC=O), 137.7 (ArC q), 129.2 (ArC), 128.4 (2x ArC), 126.4 
(2x ArC), 101.7 (OCO), 84.0 (CH(O)), 78.4 (OCH2), 51.9 (OCH3), 33.0 (CCH3), 21.8 (CCH3), 19.7 
(CCH3). 
IR νmax(film)/cm
 1 2959 (s), 2909 (s), 1735 (s), 1458 (s).   
HRMS calcd for C14H19O4 (M+H
+): 251.1283. Found 251.1282.   
[α]D  +21.9 (c = 1.9, CHCl3). 
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(4R) (5,5 Dimethyl 2 phenyl 1,3 dioxan 4 yl)methanol, (173).  
A solution of ester (172) (990mg, 4 mmol) in diethylether (10 mL) was cooled to 0
oC before being 
treated with LiAlH4 (1.0M diethylether) (14 mL, 0.014mol). The mixture was stirred at 0
oC for 
10mins, warmed to room temperature and stirred for a further 2hrs. Upon reaction completion as 
indicated by TLC analysis, the reaction was quenched with the addition of H2O (0.5 mL), 15% 
NaOH (0.5 mL), and H2O (1.5 mL). The organic layer was extracted with ether (2x 12 mL) and the 
solvent  was  removed  under  vacuum.    The  crude  residue  was  then  purified  by  flash  column 
chromatography (silica gel, 10% to 30% EtOAc in 40 60 petroleum ether) to generate the desired 
alcohol (173) (458mg, 52%). 
1H NMR (400MHz, CDCl3) δ: 7.55 (2H, dd, J = 7.6, 1.9 Hz, ArH x2), 7.40 (3H, m, 3x ArH), 5.53 
(1H, s, OCHO), 3.71 (4H, m, OCH2 and CH(O) and CHA, HB), 3.63 (1H, d, J = 11.4 Hz, CHA, HB), 
2.24 (1H, bs, OH), 1.16 (3H, s, CCH3), 0.86 (3H, s, CCH3). 
13C NMR (100MHz, CDCl3) δ: 136.9 (ArC q), 127.7 (ArC), 126.9 (2x ArC), 124.9 (2x ArC), 100.6 
(OCO), 84.5 (CH(O)), 77.4 (HOCH2), 59.9 (OCH2), 30.1 (CCH3), 19.9 (CCH3), 17.7 (CCH3). 
IR νmax(film)/cm
 1 3450 (s), 2958 (s), 2850 (s), 1467 (s), 1393 (s), 1359 (s).   
HRMS calcd for C13H18O3 (M+  ): 222.1256. Found 222.1253.   
[α]D   20.5 (c = 1.6, CHCl3). 
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(4R) (5,5 Dimethyl 2 phenyl 1,3 dioxan 4 yl)methyl diethyl phosphate,  (174).   
Iodine (375mg, 1.5 mmol) was added to a solution of triethyl phosphite (0.3 mL, 1.7 mmol) in dry 
DCM (2 mL) at 0 
oC, and the solution was stirred for 20 min at 0 
oC and then for 1 hr at room 
temperature. The freshly made phosphorylation agent was then added slowly to a roundbottomed 
flask containing 5,5 dimethyl 2 phenyl 1,3 dioxan 4 yl)methanol (173) (322mg, 1.5 mmol) and 
pyridine (0.47 mL, 6 mmol) in dry DCM (8 mL) at −40 
oC. The reaction was allowed to warm up 
to room temperature and stirred for 4 hrs. The mixture was then washed with a solution of 3% 
KHSO4 (10 mL), saturated NaHCO3 (10 mL), and brine (10 mL). The organic layer was then 
extracted with DCM (2x 15 mL), dried over Na2SO4, and the solvent removed under vacuum. The 
crude residue was then purified by flash chromatography on silica gel eluting with 20 30% EtOAc 
in 40 60 petroleum ether  to give the expected phosphoric acid 5,5 dimethyl 2 phenyl 1,3 dioxan 
4 yl)methyl diethyl phosphate (174) (172mg, 32%). 
 
1H NMR (400MHz, CDCl3) δ: 7.43 (2H, dd, J = 7.6, 1.9 Hz, ArH x2), 7.28 (3H, m, 3x ArH ), 5.43 
(1H, s, OCHO ), 4.12 (1H, ddd, J = 11.1, 6.1, 2.6 Hz, CHC, HD), 4.01 (5H, m, CHC, HD and 
POCH2CH3 x2), 3.80 (1H, dd, J = 7.9, 2.6 Hz, CH(O)), 3.62 (1H, d, J = 11.2 Hz, CHA, HB), 3.56 (1H, 
d, J = 11.2 Hz, CHA, HB ), 1.31 (3H, dt, J = 7.1, 1.0 Hz, POCH2CH3), 1.27 (3H, dt, J = 7.1, 1.0 Hz,  
POCH2CH3), 1.08 (3H, s, CCH3), 0.82 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 138.2 (ArC q), 128.9 (ArC), 128.2 (2x ArC), 126.2 (2x ArC), 101.8 
(OCO), 83.8 (CH(O)), 78.7 (OCH2), 66.7 (OCH2CH3), 66.6 (OCH2CH3), 63.8 (OCH2CH3), 
31.7(CCH3), 21.5 (CCH3), 18.9 (CCH3), 16.1 (OCH2CH3), 16.0 (OCH2CH3).   
IR νmax(film)/cm
 1 2980 (s), 2910 (s), 2872 (s), 1468 (s).   
HRMS calcd for C17H28O6P (M+H
+): 359.1624. Found 359.1627.  
[α]D   49.1 (c = 1.1, CHCl3). M.V.J. Villa - 2009    145 
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(4S) 5,5 Dimethyl 2 phenyl 1,3 dioxane 4 carbaldehyde, (175).  DMSO (1.14 mL, 0.016mol) 
was added slowly to oxalyl chloride (7 mL, 0.014mol) at  78
 oC. When addition was complete, the 
activated  oxalyl  chloride  was  stirred  for  5mins  at   78
  oC.  5,5 dimethyl 2 phenyl 1,3 dioxan 4 
yl)methanol (169) (2.35g, 0.011mol) was added as a DCM solution (30 mL) and stirred at  78
 oC. 
After 1hr, Et3N (4.28 mL, 0.031mol) was added, the solution warmed to RT, and stirred for a 
further 1hr. The reaction was worked up by addition of 1N HCl (1 mL), sat. NaHCO3 (1 mL), H2O 
(1 mL) and finally brine (1 mL). The organic layer was extracted with DCM, dried over Na2SO4, 
and  the  solvent  removed  under  vacuum.  The  crude  residue  was  then  purified  by  flash 
chromatography on silica gel eluting with 5 20% EtOAc in 40 60 petroleum to generate the desired 
aldehyde (175) (1.43g, 59%). 
1H NMR (400MHz, CDCl3) δ: 9.59 (1H, d, J = 1.2, O=CH), 7.49 (2H, dd, J = 7.6, 1.7 Hz, ArH x2), 
7.33 (3H, m, 3x ArH), 5.47 (1H, s, OCHO), 3.88 (1H, s, CH(O)), 3.65 (1H, d, J = 11.3 Hz, CHA, HB), 
3.59 (1H, d, J = 11.3 Hz, CHA, HB), 1.17 (3H, s, CCH3), 0.94 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 201.7 (O=CH), 137.6 (ArC q), 129.4 (ArC), 128.5 (ArC x2), 126.3 
(ArC x2), 101.6 (OCO), 87.4 (CH(O)), 78.6 (OCH2), 33.6 (CCH3), 20.9 (CCH3), 19.2 (CCH3).   
IR νmax(film)/cm
 1 3468 (s), 2963 (s), 2856 (m), 1758 (s) 1468 (s), 1393 (s).   
HRMS calcd for C13H17O3 (M+H
+): 221.1178. Found 221.1187.   
[α]D  +108.0 (c = 1.1, CHCl3). 
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(4R) 5,5 Dimethyl 2 phenyl 1,3 dioxane 4 carbaldehyde, (176)  
DMSO (0.05 mL, 0.67mmol) was added slowly to oxalyl chloride (0.3 mL, 0.6mmol) at  78
 oC. 
When addition was complete, the activated oxalyl chloride was stirred for 5mins at  78
 oC. ((4R) 
5,5 dimethyl 2 phenyl 1,3 dioxan 4 yl)methanol (173) (99mg, 0.45mmol) was added as a DCM 
solution (3 mL) and stirred at  78
 oC. After 1hr, Et3N (0.18 mL, 1.3mmol) was added, the solution 
warmed to RT, and stirred for a further 1hr. The reaction was worked up by addition of 1N HCl 
(0.5 mL), sat. NaHCO3 (0.5 mL), H2O (0.5 mL) and finally brine (0.5 mL). The organic layer was 
extracted  with  DCM,  dried  over  Na2SO4,  and  the  solvent  removed  under  vacuum.  The  crude 
residue was then purified by flash chromatography on silica gel eluting with 5 20% EtOAc in 40 
60 petroleum to generate the desired aldehyde (176) (61mg, 62%). 
1H NMR (400MHz, CDCl3) δ: 9.71 (1H, d, J = 1.4 Hz, O=CH), 7.60 (2H, dd, J = 7.5, 1.9 Hz, ArH 
x2), 7.44 (3H, m, 3x ArH), 5.59 (1H, s, OCHO), 3.99 (1H, s, CH(O)), 3.77 (1H, d, J = 11.3 Hz, 
CHA, HB), 3.70 (1H, d, J = 11.4 Hz, CHA, HB), 1.28 (3H, s, CCH3), 1.06 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 201.7(O=CH), 137.6 (ArC q), 129.4 (ArC), 128.5 (2x ArC), 126.3 
(2x ArC), 101.6 (OCO), 87.4 (CH(O)), 78.6 (CH2), 33.6 (CCH3), 20.9 (CCH3), 19.2 (CCH3).   
IR νmax(film)/cm
 1 3468 (s), 2963 (s), 2832 (m), 1758 (s) 1468 (s), 1393 (s).   
HRMS calcd for C13H17O3 (M+H
+): 221.1178. Found 221.1176.   
[α]D   107.1 (c = 1.1, CHCl3). 
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Diethyl (E) 2 ((4R) 5,5 dimethyl 2 phenyl 1,3 dioxan 4 yl)vinylphosphonate,  (177).   
n BuLi (0.38 mL, 0.87mmol) was added slowly to a solution of tetraethylmethylene diphosphonate 
(0.29 mL, 1.2mmol) in THF (5 mL) at  78
 oC, and stirred at  78
 oC for 30mins. 5,5 dimethyl 2 
phenyl 1,3 dioxane 4 carbaldehyde (175) (160mg, 7.3mmol) was then added as THF solution (5 
mL) and continued to stir at  78
 oC for 1hr. The reaction mixture was warmed to RT and stirred for 
a further 1hr. Workup was performed by addition of 10% w/v NH4Cl (1 mL). The organic layer 
was extracted with EtOAc (2x 5 mL), the organic collections combined, dried over Na2SO4 and the 
solvent removed under vacuum. The crude oil was passed over a pad of silica to yield the desired 
phosphonate (177) (151mg, 49%). 
1H NMR (400MHz, CDCl3) δ: 7.44 (2H, dd, J = 7.6, 1.8 Hz, ArH x2), 7.31 (3H, m, 3x ArH), 6.76 
(1H, ddd, J = 23.0, 17.1, 3.5 Hz, HC=CH), 5.97 (1H, ddd, J = 21.1, 17.1, 2.0 Hz, HC=CH), 5.46 
(1H, s, OCHO), 4.14 (1H, dd, J = 5.5, 3.5 Hz, CH(O)), 4.00 (4H, m, 2x OCH2CH3)), 3.68 (1H, d, J 
= 11.1 Hz, CHA, HB), 3.59 (1H, d, J = 11.2 Hz, CHA, HB), 1.24 (6H, dt, J = 7.1, 3.7 Hz, 2x OCH2CH3), 
1.01 (3H, s, CCH3), 0.85 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 146.4 (C=C), 137.2 (ArC q), 127.9 (ArC), 127.2 (2x ArC), 125.2 
(2x ArC), 100.6 (OCO), 82.9 (CH(O)), 82.7 (C=C), 77.3 (OCH2), 60.8 (OCH2CH3), 60.7 
(OCH2CH3), 32.4 (CCH3), 20.3 (CCH3), 18.0 (CCH3), 15.4 (OCH2CH3), 15.3 (OCH2CH3). 
IR νmax(film)/cm
 1 3013 (s), 2973 (s), 2913 (s), 2870 (s), 1635 (s), 1466 (s). 
HRMS calcd for C18H28O5P (M+H
+): 355.1674. Found 355.1675.   
[α]D  27.8 (c = 1.8, CHCl3). 
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[(3S) 3 ([(4 Methoxyphenyl)methoxy]methyl) 2 methyl oxiran 2 yl]methyl phenylcarbamate, 
(181). 
To a solution of ((2S, 3S) 3 ((4 methoxybenzyloxy)methyl) 2 methyloxiran 2 yl)methanol (145) 
(166mg, 0.69mmol) in dry DCM (3 mL), Et3N (6 drops) was added and stirred for 20mins. After 
this time, phenylisocyanate (0.09 mL, 0.83mmol) was added and stirred for 2.5hrs.  At completion 
by TLC analysis, the white precipitate was filtered through Celite, and the filtrate concentrated 
under vacuum. The crude residue was purified by flash column chromatography (silica gel with 10 
20% EtOAc in 40 60 petroleum ether) to give ((2S, 3S) 3 ((4 methoxybenzyloxy)methyl) 2 
methyloxiran 2 yl)methyl phenylcarbamate (181) (179mg, 72%). 
 
1H NMR (400MHz, CDCl3) δ: 7.26 (6H, m, 4x ArH and 2x PMB ArH), 7.01 (1H, t,  J = 7.3 Hz, 
ArH), 6.81 (2H, d, J = 8.6 Hz, 2x PMB ArH), 4.50 (1H, d, J = 11.5 Hz, BnCHA, HB), 4.40 (1H, d, J = 
11.5 Hz, BnCHA, HB), 4.23 (1H, d, J = 11.8 Hz, CHC, HD), 3.99 (1H, d, J = 11.9 Hz, CHC, HD), 3.73 (3H, 
s, OCH3), 3.62 (1H, dd, J = 11.2, 4.6 Hz, CHE, HF), 3.51 (1H, dd, J = 11.2, 6.0 Hz, CHE, HF), 3.13 (1H, 
dd, J = 5.8, 4.8 Hz, CH(O)), 1.24 (3H, s, CCH3).  
13C NMR (100MHz, CDCl3) δ: 204.4 (ArC q), 159.4 (NC=O), 137.5 (ArC q), 129.8 (ArC q), 129.5 
(2x ArC), 129.1 (2x ArC), 123.7 (ArC), 113.9 (2x ArC), 73.0 (CH2), 68.2 (CH2), 67.8 (CH2), 59. 
1(OCH3), 58.1 (CCH3), 55.3 (CH(O)), 14.5 (CCH3).   
IR νmax(film)/cm
 1 3319 (s), 2935 (s), 2857 (s), 1734 (s), 1214 (s).   
HRMS calcd for C20H23NO5 (M+  ): 357.1576. Found 357.1572.   
[a]D +7.1 (c = 1.4, CHCl3). 
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(4R) 4 [(1S) 1 Hydroxy 2 [(4 methoxyphenyl)methoxy]ethyl] 4 methyl 1,3 dioxolan 2 one,  
(182). 
A solution of [(3S) 3 ([(4 methoxyphenyl)methoxy]methyl) 2 methyl oxiran 2 yl]methyl 
phenylcarbamate (181) (110mg, 0.31mmol) in (3:1 Et2O : DCM) (4 mL) was stirred at 0 
oC, before 
adding Et2AlCl (0.92 mL, 0.92mmol) and stirring at 0 
oC for a further 3hrs. After this time 0.5M 
HCl was added and stirred for 10mins. The solution was extracted with DCM (10 mL), washed 
with Brine (4 mL), NaHCO3 (4 mL). The organic layer was separated, dried over Na2SO4, and 
concentrated under vacuum. The crude residue was purified by flash column chromatography 
(silica gel with 10 20% EtOAc in 40 60 petroleum ether) to give (S) 4 ((S) 1 hydroxy 2 (4 
methoxybenzyloxy)ethyl) 4 methyl 1,3 dioxolan 2 one (182) as a clear oil (23mg, 27%). 
1H NMR (400MHz, CDCl3) δ: 7.15 (2H, d, J = 8.6 Hz, 2x ArH)), 6.82 (2H, d, J = 8.6 Hz, 2x ArH), 
4.61 (1H, d, J = 8.8 Hz, CHA, HB), 4.43 (1H, d, J = 11.4 Hz, CHC, HD), 4.33 (1H, d, J = 11.4 Hz, CHC, 
HD), 3.95 (1H, d, J = 8.8 Hz, CHA, HB), 3.84 (1H, bdd, J = 7.2, 4.5 Hz, CH(O)), 3.74 (3H, s, OCH3), 
3.56 (1H, dd, J = 10.3, 2.7 Hz, CHE, HF), 3.45 (1H, dd, J = 10.3, 5.0 Hz, CHE, HF), 2.92 (1H, d, J = 4.6 
Hz, OH), 1.35 (3H, s, CCH3).   
13C NMR (100MHz, CDCl3) δ: 159.5 (ArC q), 154.6 (C=O), 129.7 (ArC q), 129.5 (ArC x2), 114.1 
(ArC x2), 84.5 (CCH3), 73.5 (CH2), 72.9 (CH(O)), 71.9 (CH2), 69.3 (CH2), 55.3 (OCH3), 21.2 
(CH3). 
IR νmax(film)/cm
 1 3397 (s, br), 1770(s), 1600 (s), 1570 (s).   
HRMS calcd for C14H18O6 (M+  ): 282.1103. Found 282.1100.   
[a]D +10.5 (c = 1.2, CHCl3). 
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